<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001555.pub5" GROUP_ID="NEUROMUSC" ID="665299072816432152" MERGED_FROM="" MODIFIED="2015-07-08 10:03:33 +0100" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Can % change MD values be calculated for each trial as for&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-07-07 18:36:47 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" REVIEW_NO="002" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2015-07-07 18:36:12 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2015-06-23 14:05:57 +0100" MODIFIED_BY="Ruth  Brassington">Treatment for inclusion body myositis</TITLE>
<CONTACT>
<PERSON ID="15431" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Rose</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Neurologist, Honorary Senior Lecturer</POSITION>
<EMAIL_1>m.r.rose@kcl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>King's College Hospital NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Academic Neuroscience Centre</ADDRESS_1>
<ADDRESS_2>Denmark Hill</ADDRESS_2>
<CITY>London</CITY>
<ZIP>SE5 9RS</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 203 299 8343</PHONE_1>
<PHONE_2/>
<FAX_1>+44 203 299 8358</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-07-07 18:36:12 +0100" MODIFIED_BY="Ruth Brassington">
<PERSON ID="15431" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Rose</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Neurologist, Honorary Senior Lecturer</POSITION>
<EMAIL_1>m.r.rose@kcl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>King's College Hospital NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Academic Neuroscience Centre</ADDRESS_1>
<ADDRESS_2>Denmark Hill</ADDRESS_2>
<CITY>London</CITY>
<ZIP>SE5 9RS</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 203 299 8343</PHONE_1>
<PHONE_2/>
<FAX_1>+44 203 299 8358</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1403180839163864033234974307503" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Katherine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jones</LAST_NAME>
<SUFFIX>BSc</SUFFIX>
<POSITION>Research Assistant</POSITION>
<EMAIL_1>katherine.jones12@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>King's College Hospital NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>9th floor Ruskin Wing</ADDRESS_1>
<ADDRESS_2>Denmark Hill</ADDRESS_2>
<CITY>London</CITY>
<ZIP>SE5 9RS</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="0D260B8482E26AA200DA2AF3514EA22D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kevin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Leong</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Training Research Fellow</POSITION>
<EMAIL_1>k.leong@imperial.ac.uk</EMAIL_1>
<EMAIL_2>pt.leoni@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>NHLI, Imperial College London</ORGANISATION>
<ADDRESS_1>ICTEM Builiding; 4th Floor</ADDRESS_1>
<ADDRESS_2>Hammersmith Campus</ADDRESS_2>
<CITY>W12 0HS</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="58F74F1582E26AA200D60225DD761036" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maggie</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Walter</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Neurologist</POSITION>
<EMAIL_1>maggie.walter@lrz.uni-muenchen.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology, Friedrich-Baur-Institute, Laboratory for Molecular Myology</DEPARTMENT>
<ORGANISATION>Ludwig-Maximilians-University</ORGANISATION>
<ADDRESS_1>Ziemssenstr.1</ADDRESS_1>
<ADDRESS_2/>
<CITY>Munich</CITY>
<ZIP>80336</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 89 51607400</PHONE_1>
<PHONE_2>+49 89 218078181</PHONE_2>
<FAX_1>+49 89 5160 7402</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9104" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>James</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Miller</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Neurologist</POSITION>
<EMAIL_1>james.miller@nuth.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>c/o Department of Neurology, Newcastle upon Tyne Hospitals Trust</DEPARTMENT>
<ORGANISATION>Royal Victoria Infirmary</ORGANISATION>
<ADDRESS_1>Queen Victoria Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Newcastle Upon Tyne</CITY>
<ZIP>NE1 4LP</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>0191 2824948</PHONE_1>
<PHONE_2/>
<FAX_1>01922 2824800</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6811" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Marinos</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Dalakas</LAST_NAME>
<SUFFIX>M.D, FAAN</SUFFIX>
<POSITION>Professor &amp; Director of the Neuromuscular Disease Division</POSITION>
<EMAIL_1>marinos.dalakas@jefferson.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology, Sidney Kimmel Medical College</DEPARTMENT>
<ORGANISATION>Thomas Jefferson University</ORGANISATION>
<ADDRESS_1>901 Walnut Street</ADDRESS_1>
<ADDRESS_2>4th Floor</ADDRESS_2>
<CITY>Philadelphia</CITY>
<ZIP>19107</ZIP>
<REGION>PA</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>(215) 955 -7865</PHONE_1>
<PHONE_2/>
<FAX_1>(215) 955 -7865</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9D90184382E26AA200C3FEB648B5FC66" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ruth</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brassington</LAST_NAME>
<SUFFIX/>
<POSITION>Managing Editor</POSITION>
<EMAIL_1>cochranenmd@ion.ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT>
<ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION>
<ADDRESS_1>PO Box 114</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1N 3BG</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0)203 448 8134</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0)203 448 4725</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6632" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Robert</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Griggs</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Robert_Griggs@urmc.rochester.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>University of Rochester</ORGANISATION>
<ADDRESS_1>601 Elmwood Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rochester</CITY>
<ZIP>14642</ZIP>
<REGION>NY</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 585 275 2541</PHONE_1>
<PHONE_2/>
<FAX_1>+1 585 244 2529</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-11-21 15:08:02 +0000" MODIFIED_BY="Ruth  Brassington">
<UP_TO_DATE>
<DATE DAY="7" MONTH="10" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="10" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="10" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="6" YEAR="2015"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-07-07 18:28:42 +0100" MODIFIED_BY="Ruth  Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-07-07 18:28:42 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="7" MONTH="7" YEAR="2015"/>
<DESCRIPTION>
<P>Minor typographical corrections</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-07-07 18:28:31 +0100" MODIFIED_BY="Ruth  Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-07-07 18:28:31 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="30" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>Conflict of interest corrected</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="8" MONTH="2" YEAR="1999"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-01-23 15:39:10 +0000" MODIFIED_BY="Katherine Jones">
<INTERNAL_SOURCES MODIFIED="2015-01-23 15:38:56 +0000" MODIFIED_BY="Katherine Jones">
<SOURCE MODIFIED="2015-01-23 15:38:29 +0000" MODIFIED_BY="Katherine Jones">
<NAME>Wissenschaftliches Institut, Private Europäische Medizinische Akademie der Klinik Bavaria in Kreischa GmbH, An derWolfsschlucht 1-2, 01731 Kreischa</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-01-23 15:38:35 +0000" MODIFIED_BY="Katherine Jones">
<NAME>Lehrstuhl Therapiewissenschaften, SRH Fachhochschule für Gesundheit Gera gGmbH, Hermann-Drechsler-Str. 2, 07548 Gera</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-01-23 15:38:41 +0000" MODIFIED_BY="Katherine Jones">
<NAME>Gesundheitswissenschaften/Public Health, Medizinische Fakultät Carl Gustav Carus der TU Dresden, Fetscherstr. 74, 01307 Dresden</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-01-23 15:38:45 +0000" MODIFIED_BY="Katherine Jones">
<NAME>University of Southampton</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-01-23 15:38:56 +0000" MODIFIED_BY="Katherine Jones">
<NAME>University College London Hospital (UCLH) NHS Foundation Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Ruth Brassington is employed as Managing Editor of the Cochrane Neuromuscular Disease Group, which is hosted by UCLH. The National Institute for Health Research (NIHR) is the largest single funder of this Cochrane Review Group.</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-01-23 15:39:10 +0000" MODIFIED_BY="Katherine Jones">
<SOURCE MODIFIED="2015-01-23 15:39:10 +0000" MODIFIED_BY="Katherine Jones">
<NAME>Association Française contre les Myopathies</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION>
<P>Grant: Katherine Jones</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-07-07 18:36:47 +0100" MODIFIED_BY="Ruth  Brassington">
<SUMMARY MODIFIED="2015-07-07 18:05:02 +0100" MODIFIED_BY="Ruth  Brassington">
<TITLE MODIFIED="2008-07-26 01:52:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;edited - for a check&lt;/p&gt;" NOTES_MODIFIED="2008-07-26 01:52:44 +0100" NOTES_MODIFIED_BY="[Empty name]">Therapy for inclusion body myositis</TITLE>
<SUMMARY_BODY MODIFIED="2015-07-07 18:05:02 +0100" MODIFIED_BY="Ruth  Brassington">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence from clinical trials about the effects of drug treatments for inclusion body myositis (IBM). We did not include trials of exercise or management of swallowing difficulties, as these are subjects of other Cochrane reviews.</P>
<P>
<B>Background</B>
</P>
<P>IBM is a disease that mainly affects older people. The main symptoms are increasing muscle wasting and weakness of the arms and legs. Some people experience swallowing difficulties. As yet no therapy has been shown to alter the course of the disease. Treatments that have been tested include agents that suppress or alter the immune response, drugs that promote muscle growth, and antioxidants.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This review included 10 trials (249 participants). One of these trials (24 participants) is completed but has not yet been published. Seven trials compared treatments with placebo (inactive treatment): three of intravenous immunoglobulin (IVIg), two of interferon beta-1a (IFN beta-1a), and one each of oxandrolone, methotrexate (MTX), and arimoclomol (not yet published). A further two trials compared MTX with combined immunosuppressive therapy (MTX with anti-T lymphocyte immunoglobulin (ATG) (an agent that destroys white blood cells) and MTX with azathioprine). In these two trials, participants and investigators knew which treatment participants were receiving, which could have biased the results.</P>
<P>
<B>Results and quality of the evidence</B>
</P>
<P>For our primary outcome, which was muscle strength, we were only able to combine the results for the two trials of IFN beta-1a therapy versus placebo. This treatment did not appear to offer a benefit in terms of muscle strength. MTX also did not stop or retard loss of muscle strength when compared to placebo. We considered the evidence from these trials to be of moderate quality because the trials were too small to rule out a possible benefit for these drugs. For the other trials, the evidence was of very low quality. Three trials compared IVIg (combined in one trial with prednisone) to a placebo, but we were unable to perform meta-analysis because the available data were not suitable. One trial of ATG combined with MTX versus MTX alone provided very low-quality evidence of an effect on muscle strength in favour of MTX plus ATG at 12 months. The other comparisons, of MTX versus placebo, oxandrolone versus placebo, azathioprine combined with MTX versus MTX, and arimoclomol versus placebo were reported in single trials that did not provide enough data for analysis of the effect on muscle strength.</P>
<P>Due to their small size and short duration, the trials we studied were generally unable to give definitive answers as to whether the treatments tested were effective or ineffective. All of the interventions we studied had some adverse effects and are known to cause potentially serious adverse events. We need larger trials of longer duration, using robust ways of measuring the effects of treatments that are meaningful to people with IBM. Agreeing on common trial measurements will also make it easier to compare trial results and assess potential treatments.</P>
<P>The evidence is current to October 2014.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-07-07 18:22:28 +0100" MODIFIED_BY="Ruth  Brassington">
<ABS_BACKGROUND MODIFIED="2015-06-23 21:19:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Inclusion body myositis (IBM) is a late-onset inflammatory muscle disease (myopathy) associated with progressive proximal and distal limb muscle atrophy and weakness. Treatment options have attempted to target inflammatory and atrophic features of this condition (for example with immunosuppressive and immunomodulating drugs, anabolic steroids, and antioxidant treatments), although as yet there is no known effective treatment for reversing or minimising the progression of inclusion body myositis. In this review we have considered the benefits, adverse effects, and costs of treatment in targeting cardinal effects of the condition, namely muscle atrophy, weakness, and functional impairment.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-06-23 21:19:09 +0100" MODIFIED_BY="Ruth  Brassington">
<P>To assess the effects of treatment for IBM.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-06-23 21:19:12 +0100" MODIFIED_BY="Ruth  Brassington">
<P>On 7 October 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, the Cochrane Central Register for Controlled Trials (CENTRAL), MEDLINE, and EMBASE. Additionally in November 2014 we searched clinical trials registries for ongoing or completed but unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-06-23 21:19:14 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We considered randomised or quasi-randomised trials, including cross-over trials, of treatment for IBM in adults compared to placebo or any other treatment for inclusion in the review. We specifically excluded people with familial IBM and hereditary inclusion body myopathy, but we included people who had connective tissue and autoimmune diseases associated with IBM, which may or may not be identified in trials. We did not include studies of exercise therapy or dysphagia management, which are topics of other Cochrane systematic reviews.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-03-02 17:05:06 +0000" MODIFIED_BY="Katherine Jones">
<P>We used standard Cochrane methodological procedures.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-06-26 10:30:37 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The review included 10 trials (249 participants) using different treatment regimens. Seven of the 10 trials assessed single agents, and 3 assessed combined agents. Many of the studies did not present adequate data for the reporting of the primary outcome of the review, which was the percentage change in muscle strength score at six months. Pooled data from two trials of interferon beta-1a (n = 58) identified no important difference in normalised manual muscle strength sum scores from baseline to six months (mean difference (MD) -0.06, 95% CI -0.15 to 0.03) between IFN beta-1a and placebo (moderate-quality evidence). A single trial of methotrexate (MTX) (n = 44) provided moderate-quality evidence that MTX did not arrest or slow disease progression, based on reported percentage change in manual muscle strength sum scores at 12 months. None of the fully published trials were adequately powered to detect a treatment effect.</P>
<P>We assessed six of the nine fully published trials as providing very low-quality evidence in relation to the primary outcome measure. Three trials (n = 78) compared intravenous immunoglobulin (combined in one trial with prednisone) to a placebo, but we were unable to perform meta-analysis because of variations in study analysis and presentation of trial data, with no access to the primary data for re-analysis. Other comparisons were also reported in single trials. An open trial of anti-T lymphocyte immunoglobulin (ATG) combined with MTX versus MTX provided very low-quality evidence in favour of the combined therapy, based on percentage change in quantitative muscle strength sum scores at 12 months (MD 12.50%, 95% CI 2.43 to 22.57). Data from trials of oxandrolone versus placebo, azathioprine (AZA) combined with MTX versus MTX, and arimoclomol versus placebo did not allow us to report either normalised or percentage change in muscle strength sum scores. A complete analysis of the effects of arimoclomol is pending data publication. Studies of simvastatin and bimagrumab (BYM338) are ongoing.</P>
<P>All analysed trials reported adverse events. Only 1 of the 10 trials interpreted these for statistical significance. None of the trials included prespecified criteria for significant adverse events.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-07-07 18:22:28 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Trials of interferon beta-1a and MTX provided moderate-quality evidence of having no effect on the progression of IBM. Overall trial design limitations including risk of bias, low numbers of participants, and short duration make it difficult to say whether or not any of the drug treatments included in this review were effective. An open trial of ATG combined with MTX versus MTX provided very low-quality evidence in favour of the combined therapy based on the percentage change data given. We were unable to draw conclusions from trials of IVIg, oxandrolone, and AZA plus MTX versus MTX. We need more randomised controlled trials that are larger, of longer duration, and that use fully validated, standardised, and responsive outcome measures.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-07-07 18:36:47 +0100" MODIFIED_BY="Ruth  Brassington">
<BACKGROUND MODIFIED="2015-06-23 21:41:38 +0100" MODIFIED_BY="Ruth  Brassington">
<CONDITION MODIFIED="2015-06-23 21:23:58 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Inclusion body myositis (IBM) is a late-onset inflammatory muscle disease (myopathy) with a distinctive pattern of proximal and distal limb atrophy and weakness. IBM is considered to be the most common acquired myopathy in those over age 50. In early published series, IBM has accounted for up to 28% of all idiopathic inflammatory myopathies, although the true proportion could be much higher (<LINK REF="REF-Lotz-1989" TYPE="REFERENCE">Lotz 1989</LINK>). In the Netherlands, prevalence has been estimated at 4.9 per million inhabitants (<LINK REF="REF-Badrising-2000" TYPE="REFERENCE">Badrising 2000</LINK>). Between 2000 and 2008, prevalence in Western Australia rose from 9.3 to 14.9 per million inhabitants, a change attributed to improved case identification (<LINK REF="REF-Needham-2008" TYPE="REFERENCE">Needham 2008</LINK>; <LINK REF="REF-Phillips-2000" TYPE="REFERENCE">Phillips 2000</LINK>). Prevalence adjusted for age over 50 years is higher, up to 51.3 per million population (<LINK REF="REF-Needham-2008" TYPE="REFERENCE">Needham 2008</LINK>).</P>
<P>IBM is usually a sporadic and isolated disorder that can be associated with secondary mitochondrial DNA abnormalities in excess of those seen with normal ageing (<LINK REF="REF-Oldfors-1995" TYPE="REFERENCE">Oldfors 1995</LINK>). In rare instances, typical IBM occurs in families (<LINK REF="REF-Amato-1998" TYPE="REFERENCE">Amato 1998</LINK>; <LINK REF="REF-Tateyama-2003" TYPE="REFERENCE">Tateyama 2003</LINK>); this familial IBM should not be confused with hereditary inclusion body myopathy, which is not usually associated with inflammation and in which there may be mutations in the GNE gene (<LINK REF="REF-Huizing-2009" TYPE="REFERENCE">Huizing 2009</LINK>). IBM is sometimes associated with a variety of connective tissue and autoimmune diseases, including rheumatoid arthritis (<LINK REF="REF-Soden-1994" TYPE="REFERENCE">Soden 1994</LINK>), vitamin B12 deficiency (<LINK REF="REF-Khraishi-1992" TYPE="REFERENCE">Khraishi 1992</LINK>), Sjögren's syndrome (<LINK REF="REF-Gutmann-1985" TYPE="REFERENCE">Gutmann 1985</LINK>; <LINK REF="REF-Khraishi-1992" TYPE="REFERENCE">Khraishi 1992</LINK>), chronic immune thrombocytopenia (<LINK REF="REF-Riggs-1984" TYPE="REFERENCE">Riggs 1984</LINK>), sarcoidosis (<LINK REF="REF-Danon-1986" TYPE="REFERENCE">Danon 1986</LINK>), collagen vascular disease (<LINK REF="REF-Lane-1985" TYPE="REFERENCE">Lane 1985</LINK>), and common variable immune deficiency (<LINK REF="REF-Dalakas-1995" TYPE="REFERENCE">Dalakas 1995</LINK>; <LINK REF="REF-Lindberg-1990" TYPE="REFERENCE">Lindberg 1990</LINK>).</P>
<P>To date, clinicopathologically defined criteria for sporadic IBM, as proposed by <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK> and revised by <LINK REF="REF-Benveniste-2010" TYPE="REFERENCE">Benveniste 2010</LINK> and <LINK REF="REF-Hilton_x002d_Jones-2010" TYPE="REFERENCE">Hilton-Jones 2010</LINK>, have formed the basis for diagnostic criteria. Improved case ascertainment through clinical assessment has supported the application of clinically defined diagnostic criteria. However, for the purpose of reviewing the existing clinical trials, we included those trials using clinicopathologically defined sporadic IBM, as defined by <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK>, <LINK REF="REF-Benveniste-2010" TYPE="REFERENCE">Benveniste 2010</LINK>, or <LINK REF="REF-Hilton_x002d_Jones-2010" TYPE="REFERENCE">Hilton-Jones 2010</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="2">Potential outcome measures</HEADING>
<P>The muscle atrophy and weakness of IBM usually follow a slowly progressive course. In the absence of established effective drug treatment, the mainstay of treatment is supportive. Natural history studies suggest that people with IBM can experience a 3.5% to 5.2% annual decline in compound muscle strength graded manually (<LINK REF="REF-Cortese-2013" TYPE="REFERENCE">Cortese 2013</LINK>; <LINK REF="REF-Cox-2011" TYPE="REFERENCE">Cox 2011</LINK>). Because of its characteristic pattern of muscle involvement, IBM may cause predictable functional difficulties. For example, weakness of the long (extrinsic) finger flexors can impair handgrip, while quadriceps weakness can cause knee instability, making rising from chairs, managing stairs, and walking increasingly difficult. For the purpose of this review, it seemed reasonable to choose those outcome measures assessing the cardinal effects of IBM, namely muscle atrophy, weakness, and functional impairment.</P>
<P>In terms of atrophy, muscle mass can be measured in a number of ways, including:</P>
<OL>
<LI>urinary creatinine excretion under controlled conditions;</LI>
<LI>potassium isotope counting;</LI>
<LI>magnetic resonance imaging (MRI);</LI>
<LI>computerised tomography (CT) muscle imaging; and</LI>
<LI>dual energy X-ray absorptiometry (DEXA).</LI>
</OL>
<P>Muscle strength can be measured manually (referred to as manual muscle testing, or MMT) and is commonly scored using the six-point Medical Research Council (MRC) strength scale or modified MRC scale. Alternatively, the maximal voluntary isometric contraction or isokinetic muscle strength can be measured using a hand-held or fixed myometer (referred to as quantitative muscle testing (QMT)) and the results expressed in units of force (newtons, kilograms, or pounds). However, as with MMT, the selected muscles tested by QMT can vary; QMT sum scores are often expressed as the z-score, which is the sum of the standard deviations from the mean for each muscle tested.</P>
<P>In terms of measuring functional impairment, single-item tests include timed walking tests, stair climb, and rise from chair; we have chosen timed walking tests as appropriate measures for the patient population in this review. There are also questionnaire based, multi-item rating scales, such as the IBM Functional Rating Scale, that provide an overall score across different functional tasks (<LINK REF="REF-Jackson-2008" TYPE="REFERENCE">Jackson 2008</LINK>). In choosing appropriate outcome measures for this review, we also wanted to consider other patient reported outcome measures, including symptom severity and quality of life, as well as adverse events associated with treatment. However, these outcome measures are not consistently applied across different muscle disease centres and trials at present.</P>
<P>We can specify a minimum time period for the primary outcome measure in relation to its sensitivity to change in a slowly progressive condition. Power calculations based upon available natural history data for muscle strength in IBM support a minimum trial length of six months (<LINK REF="REF-Rose-2001" TYPE="REFERENCE">Rose 2001</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2015-06-23 21:41:38 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Interventions included pharmacological agents, dietary supplements, and musculoskeletal surgery. We excluded the management of dysphagia and the role of exercise therapy for muscle disease, which other Cochrane systematic reviews of interventions discuss (<LINK REF="REF-Hill-2004" TYPE="REFERENCE">Hill 2004</LINK>; <LINK REF="REF-Voet-2013" TYPE="REFERENCE">Voet 2013</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2015-06-23 21:24:24 +0100" MODIFIED_BY="Ruth  Brassington">
<P>As the first systematic review of treatment for IBM, this Cochrane review aimed to determine the evidence base for current treatment and to identify dose-responses where possible. Our findings may also be relevant to other neuromuscular and age-related conditions in which muscle weakness, atrophy, and inflammation are prominent symptoms.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-06-23 21:24:19 +0100" MODIFIED_BY="Ruth  Brassington">
<P>To systematically assess the effects of treatment for IBM.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-07-07 18:23:21 +0100" MODIFIED_BY="Ruth  Brassington">
<SELECTION_CRITERIA MODIFIED="2015-07-07 18:23:21 +0100" MODIFIED_BY="Ruth  Brassington">
<CRIT_STUDIES MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We considered for inclusion randomised or quasi-randomised trials, including cross-over trials, of treatment for IBM (except for exercise therapy and dysphagia management). We included comparisons of treatment versus placebo or any other treatment. We included studies reported as full text, those published as abstract only, and unpublished data, with no language restrictions.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-06-23 21:24:36 +0100" MODIFIED_BY="Ruth  Brassington">
<P>All participants were over 18 years of age and had a clinicopathologically defined diagnosis of IBM (<LINK REF="REF-Benveniste-2010" TYPE="REFERENCE">Benveniste 2010</LINK>; <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK>; <LINK REF="REF-Hilton_x002d_Jones-2010" TYPE="REFERENCE">Hilton-Jones 2010</LINK>). We specifically excluded people with familial IBM and hereditary inclusion body myopathy, but we included people who had connective tissue and autoimmune diseases associated with IBM, which may or may not be identified in trials.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We included the following interventions.</P>
<OL>
<LI>Immunosuppressive agents, e.g. prednisolone (and other corticosteroids), cyclophosphamide, chlorambucil, azathioprine, methotrexate (MTX), and ciclosporin.</LI>
<LI>Immunomodulatory interventions, e.g. intravenous immunoglobulin, leukopheresis, plasma exchange, and immune-targeted monoclonal antibodies.</LI>
<LI>Antioxidants, e.g. vitamin E.</LI>
<LI>Mitochondrial substrates, e.g. carnitine and ubiquinone.</LI>
<LI>Anabolic steroids and muscle supplements.</LI>
<LI>Other interventions except for exercise therapy and dysphagia management.</LI>
</OL>
<P>Therapies were administered using various protocols including as single agents, combined therapy, or sequential therapy. We analysed different interventions separately.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-07-07 18:23:21 +0100" MODIFIED_BY="Ruth  Brassington">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-11-05 10:06:07 +0000" MODIFIED_BY="Ruth Brassington">
<P>The primary outcome measure for this review was percentage change in muscle strength (using MMT or QMT) from baseline at six months.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-07-07 18:23:21 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Secondary outcome measures for this review were as follows.</P>
<OL>
<LI>Percentage change from baseline in muscle strength (using MMT or QMT) at 12 months.</LI>
<LI>Percentage change from baseline in handgrip strength at 6 months.</LI>
<LI>Percentage change from baseline in muscle mass (by whatever method, e.g. MRI) at 6 months.</LI>
<LI>Percentage change from baseline in timed walk (e.g. 10-metre or 6-minute walk) at 6 months.</LI>
<LI>Significant adverse events from the intervention.*</LI>
</OL>
<P>We evaluated QMT only when the trial did not use MMT for muscle testing.</P>
<P>Where relevant data were available we considered the costs of interventions in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.</P>
<P>*An `adverse event' is defined as an adverse outcome that occurs during or after the use of a drug or other intervention but is not necessarily caused by it (<LINK REF="REF-Cochrane-2015" TYPE="REFERENCE">Cochrane 2015</LINK>).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-07-07 18:09:27 +0100" MODIFIED_BY="Ruth  Brassington">
<ELECTRONIC_SEARCHES MODIFIED="2015-07-07 18:09:27 +0100" MODIFIED_BY="Ruth  Brassington">
<P>On 7 October 2014, the Trials Search Co-ordinator searched the Cochrane Neuromuscular Disease Group Specialized Register, the Cochrane Central Register for Controlled Trials (CENTRAL, 2014, Issue 9 in the Cochrane Library), MEDLINE (January 1966 to September 2014), and EMBASE (January 1947 to September 2014). Detailed search strategies are in the appendices: Cochrane Neuromuscular Disease Group Specialized Register (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), CENTRAL (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), MEDLINE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), and EMBASE (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
<P>We searched all databases from their inception to the present, and we imposed no restriction on language of publication.</P>
<P>In November 2014, we searched ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">clinicaltrials.gov</A>) and the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">who.int/trialsearch/</A>) for ongoing trials and completed unpublished studies using the search term `inclusion body myositis'.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-06-23 21:25:50 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We checked references in the identified trials and contacted trial authors to identify any additional published or unpublished data. In 1999, the review authors scanned conference abstracts including those of the American Academy of Neurology, the International Conference on Neuromuscular Diseases, the World Muscle Society, and the European Neurological Society for relevant studies but did not update this search.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-07-07 18:10:31 +0100" MODIFIED_BY="Ruth  Brassington">
<P>At least two review authors (from among JM, KJ, KL, MW, MR and RB) extracted data and resolved any discrepancies by discussion. We contacted the authors of the trials to provide missing data where possible.</P>
<STUDY_SELECTION MODIFIED="2015-06-23 21:25:58 +0100" MODIFIED_BY="Ruth  Brassington">
<P>At least two review authors (from among MR, KJ, MW, and JM) examined the papers identified by the search strategy for studies eligible for inclusion. The review authors independently confirmed that studies were randomised or quasi-randomised trials and that diagnostic criteria for IBM had been met.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-06-23 21:26:03 +0100" MODIFIED_BY="Ruth  Brassington">
<P>At least five review authors (from among MR, KJ, KL, MW, JM, and RB) independently performed data extraction using a specially designed data extraction form. The review authors contacted authors of included trials to provide missing data where possible. One or two review authors checked and entered data into the Cochrane authoring and statistical software, Review Manager (RevMan) 5 (MR and KL) (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>); another review author checked the data entry (KJ). A non-conflicted review author performed data extraction independently if any review author had potential conflicts of interest, for example through involvement in an included study.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-07-07 18:10:21 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Two review authors (MR and KJ) independently assessed the risk of bias in included studies using the following criteria: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, and other risk of bias. The review authors identified high, low, or unclear risk of bias for each trial according to criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We used the `unclear' rating when there was insufficient information to reach a judgement or when, despite knowing what occurred in the study, the risk of bias remained unclear. We also examined whether studies included explicit diagnostic criteria, validation of outcome measurements, and power calculations to detect statistical benefit. Where we were uncertain, we contacted trial authors for clarification. The review authors resolved any disagreements over `Risk of bias' assessment by consensus. We conducted the review according to the published protocol (<LINK REF="REF-Rose-2014" TYPE="REFERENCE">Rose 2014</LINK>), reporting any deviations from it in <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We analysed dichotomous data as a risk ratio with a 95% confidence interval (CI). We analysed continuous data as the mean difference, or standardised mean difference with 95% CI when outcomes were conceptually the same but measured in different ways. We calculated a treatment effect through random-effects meta-analysis, using RevMan 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-06-23 21:26:41 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Included studies determined compound muscle strength using different muscle groups, which represented a potential unit of analysis error. The carry-over effect of sequential intervention in cross-over trials was another potential source of unit of analysis error. There was also a possible learning effect in the primary outcome of interest, muscle strength, that we would have considered in particular for cross-over trials if they had provided data suitable for analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-06-23 21:26:45 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We contacted investigators in order to verify key study characteristics and to obtain missing numerical outcome data where possible (such as when a study was only available as an abstract). Where this was not possible, and we thought that missing data introduced serious bias, we explored the impact of including such studies.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-06-23 21:26:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We used the I² statistic to measure heterogeneity among the trials in each analysis. If we identified any substantial unexplained heterogeneity, we planned to report this and to explore the possible causes by prespecified subgroup analysis.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-06-23 21:26:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We were not able to pool enough trials (that is more than 10) to create and examine a funnel plot to explore possible small-study biases.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-07-07 18:10:31 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We used a random-effects model on the assumption that the included studies estimated different but related intervention effects. We applied a fixed-effect model to further consider the presence of any heterogeneity among included studies. As the review included several comparisons that could not be combined in the same analysis, we reported the results for each comparison separately.</P>
<SUBSECTION>
<HEADING LEVEL="3">`Summary of findings' table</HEADING>
<P>We created a `Summary of findings' table using the following outcomes.</P>
<OL>
<LI>Percentage change in muscle strength (using MMT or QMT) from baseline at 6 months.</LI>
<LI>Percentage change from baseline in muscle strength (using MMT or QMT) at 12 months.</LI>
<LI>Percentage change from baseline in muscle mass (by whatever method, e.g. MRI) at 6 months.</LI>
<LI>Percentage change from baseline in handgrip strength at 6 months.</LI>
<LI>Percentage change from baseline in timed walk (e.g. 10-metre or 6-minute walk) at 6 months.</LI>
<LI>Significant adverse events from the intervention.</LI>
</OL>
<P>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence (studies that contribute data for the prespecified outcomes). We employed methods and recommendations described in Chapter 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), using GRADEpro software (<LINK REF="REF-GRADEpro-2014" TYPE="REFERENCE">GRADEpro 2014</LINK>). We justified all decisions to down- or upgrade the quality of studies using footnotes and made comments to aid readers' understanding of the review where necessary. Three review authors (MR, KJ, and RB) completed this evidence grading, which all review authors checked and agreed on.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-06-23 21:27:36 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We were unable to perform subgroup analysis to investigate treatment effects in particular groups of participants because the included studies provided insufficient detail about the different participant groups. We were unable to use meta-regression techniques to investigate heterogeneity.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-06-23 21:27:40 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We would have completed a sensitivity analysis on the basis of risk of bias and to further explore heterogeneity in the results if sufficient data (trials) had been available.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-07-07 18:18:52 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;The number of papers found by the strategies in the appendices which were run on 7 October 2014 are&lt;/p&gt;&lt;p&gt;MEDLINE - 273 papers&lt;/p&gt;&lt;p&gt;EMBASE - 95 papers&lt;/p&gt;&lt;p&gt;Cochrane Neuromuscular Disease Group Specialized Register - 23 papers&lt;/p&gt;&lt;p&gt;CENTRAL - 26&lt;/p&gt;&lt;p&gt;The NMD Group is now following the Cochrane policy of giving the total number of references found by each database, the number of references after deduplication, the number of references selected for further review and the number meeting the inclusion criteria for the review.&lt;/p&gt;&lt;p&gt;The numbers given above are total references retrieved.&lt;/p&gt;&lt;p&gt;The following Database included in the Cochrane Library contained a reference which you may wish to use the results in the discussion section&lt;/p&gt;&lt;p&gt;DARE (Database of Abstracts of Reviews of Effectiveness) - 3 paper&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-07-07 18:18:52 +0100" NOTES_MODIFIED_BY="Ruth  Brassington">
<STUDY_DESCRIPTION MODIFIED="2015-06-24 10:52:29 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The search strategies in the Appendices produced the following results: Cochrane Neuromuscular Disease Group Specialized Register 23 records, CENTRAL 26 records, MEDLINE 273 records, and EMBASE 95 records. In total, the review authors identified 24 studies, with 10 fulfilling the inclusion criteria; see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. We excluded 14 studies (4 ongoing) because they were not randomised controlled trials (RCTs); see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>The interventions used among the 10 trials identified for inclusion were: intravenous immunoglobulin (IVIg) (<LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK>; <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK>; <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK>); interferon beta-1a (IFN beta-1a) (<LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>; <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>); methotrexate (MTX) (<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK>); an anabolic steroid (oxandrolone) (<LINK REF="STD-Rutkove-2002" TYPE="STUDY">Rutkove 2002</LINK>); and arimoclomol (<LINK REF="STD-Machado-2013" TYPE="STUDY">Machado 2013</LINK>). All of these trials compared the intervention, used on its own, to placebo. The remaining two trials compared combination immunosuppressive therapy (MTX and anti-T lymphocyte immunoglobulin (ATG) (<LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>); and MTX and azathioprine (AZA) (<LINK REF="STD-Leff-1993" TYPE="STUDY">Leff 1993</LINK>)) to an MTX treatment regimen.</P>
<P>As a protocol deviation, we included three studies that used clinicopathological diagnostic criteria not specified in <LINK TAG="CRIT_PARTICIPANTS" TYPE="SECTION">Types of participants</LINK> (<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK>; <LINK REF="STD-Leff-1993" TYPE="STUDY">Leff 1993</LINK>; <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK>).</P>
<P>We identified three ongoing studies (one of which had three associated trial registrations) from ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (<LINK REF="STD-EUCTR2007_x002d_004359_x002d_12_x002d_IT" TYPE="STUDY">EUCTR2007-004359-12-IT</LINK>; <LINK REF="STD-NCT00001265" TYPE="STUDY">NCT00001265</LINK>; <LINK REF="STD-NCT01423110" TYPE="STUDY">NCT01423110</LINK>). See <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Intravenous immunoglobulin versus placebo</HEADING>
<P>Three trials compared IVIg with placebo (<LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK>; <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK>; <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK>).</P>
<P>
<LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK> block-randomised 22 participants fulfilling the diagnostic criteria according to <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK> either to placebo (consisting of dextrose in half-normal saline) or to 2 g/kg body weight IVIg monthly for 3 months. After a washout period of at least one month, the participants had the option of crossing over to the alternative treatment for a further three months. Nineteen of the participants were also being treated with prednisone or another immunosuppressant (MTX, AZA) prior to the study; only three participants continued with a low-to-moderate dose of prednisone during the trial. Assessments were made at baseline and at the end of each three-month period, with both investigators and participants blinded to the treatment intervention. The study authors reported baseline mean total Medical Research Council (MRC) scores to be comparable.</P>
<P>
<LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK> block-randomised 22 participants (11 in each group) fulfilling diagnostic criteria similar to <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK>. Participants were randomised to either placebo (1% human albumin in 2.5% glucose) or to IVIg at 2 g/kg body weight given over two to five days per month for six months, before crossing over to the other regimen for another six months. Nineteen of the participants had received various drugs prior to the study, including corticosteroids, AZA, and combined MTX and AZA. Six participants in each group remained on a constant, pretreatment medication, with nine receiving 2.5 mg to 15 mg daily corticosteroids and three receiving 4 mg to 10 mg daily corticosteroids and 100 mg to 150 mg daily AZA. All participants in both groups received physiotherapy once or twice weekly. The trial was double blinded with monthly outcome measurement from baseline to 12 months. Although the groups differed in baseline mean age (67 ± 12 years in the IVIg-placebo group and 51 ± 11 years in the placebo-IVIg group, the MRC sum scores and Neuromuscular Symptom and Disability Functional Scores showed no statistically significant between-group differences at baseline.</P>
<P>
<LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK> block-randomised 37 participants (according to the flow chart in the study report) who fulfilled the diagnostic criteria for IBM according to <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK> either to placebo (consisting of dextrose in half-normal saline) or two daily doses of 1g/kg body weight IVIg (2 g/kg bodyweight IVIg) monthly for three months. In addition, all participants in both groups received prednisone (tapered from 60 mg daily to 60 mg every other day). Assessments were made at baseline and at the end of each month of treatment for three months, with investigators and participants both blinded to intervention. At baseline, age and muscle strength (QMT and MRC sum scores) were comparable between treatment and placebo groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interferon beta-1a versus placebo</HEADING>
<P>Two trials compared the use of IFN beta-1a with placebo.</P>
<P>
<LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK> randomised 30 participants who had definite or probable IBM according to the criteria of <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK> into a double-blinded, parallel-group study. Sample size was chosen "to provide 85% power to detect a difference in tolerability of 95% in the placebo group versus 50% in the IFN beta-1a group". The participants received either IFN beta-1a or a matching placebo (lyophilised powder reconstituted with sterile saline). The dose of IFN beta-1a was 15 &#956;g/week initially and 30 &#956;g/week from 4 weeks, administered by intramuscular injection once weekly for 24 weeks. Participants also received a 650 mg dose of paracetamol at the time of injection and repeated six-hourly with a total of four doses. Trialists made assessments at baseline and at 4, 12, and 24 weeks. Baseline characteristics suggested between-group similarity for age and average motor function; however, trial authors acknowledge a predominance of men in the treatment group.</P>
<P>The second trial performed by the same group recruited 30 participants (<LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>). The study design and outcome measures were consistent with <LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>, but the dosage of IFN beta-1a was increased to 60 &#956;g/week. Assessments were reported at baseline and at 4, 12, and 24 weeks; no primary outcome measure was specified. All reported baseline characteristics suggested that the two treatment groups were clinically similar. There was a predominance of men in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methotrexate versus placebo</HEADING>
<P>One double-blinded trial randomised 44 participants to receive either MTX or an identical-looking placebo (<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK>). Sample size was chosen "to detect a difference of 100 Newtons (N) in mean [strength] changes or a clinically important stabilisation". Over a treatment period of 48 weeks, participants started on an initial dose of 5 mg a week that increased by 5 mg every 6 weeks up to 20 mg/week. To enhance blinding, the investigators reduced the dose by 2.5 mg without explanation for three months, and restored doses to 20 mg/week thereafter. The average dose was 14.6 mg/week in those who completed the trial and 14.0 mg/week in all treated participants. Forty-two participants had a diagnosis of definite IBM and two a diagnosis of probable IBM, according to the European Neuromuscular Centre (ENMC) diagnostic criteria for IBM (<LINK REF="REF-Verschuuren-1997" TYPE="REFERENCE">Verschuuren 1997</LINK>), elements of which are similar to those of <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK>. Assessments were made at baseline, 22, and 48 weeks or immediately after withdrawal. The baseline characteristics suggested between-group similarity. The study authors performed both an intention-to-treat analysis, carrying forward the last assessment, and a per protocol analysis of those who completed the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Combined immunosuppressive therapy: methotrexate and anti-T lymphocyte immunoglobulin versus methotrexate</HEADING>
<P>
<LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK> was an open, randomised trial of 11 participants who fulfilled the morphological diagnostic criteria for IBM according to <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK>. This trial compared 12 months' treatment with oral MTX 7.5 mg/week (MTX group, n = 5) with 12 months' MTX treatment preceded by 7 days of intravenous anti-T lymphocyte immunoglobulin treatment (MTX + ATG group, n = 6). ATG doses were fixed for the first two days (5 mg/kg and 4 mg/kg body weight, respectively) and varied thereafter to keep the T lymphocyte counts between 50 x 10<SUP>6</SUP>/L and 150 x 10<SUP>6</SUP>/L. The total amount of ATG given over seven days varied between 24.8 mg/kg and 30.2 mg/kg body weight. Five participants in the MTX + ATG group and four participants in the MTX group also took prednisone (10 mg to 30 mg every second day) during the trial. Participants received methylprednisolone (125 mg injection) before the first ATG infusion. Assessments were made 2 months before commencement of treatment and at 0, 2, 4, 6, 9, and 12 months of treatment. Mean between-group muscle strength was reported to be nearly equal at baseline.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Combined immunosuppressive therapy: methotrexate and azathioprine versus methotrexate (plus leucovorin)</HEADING>
<P>
<LINK REF="STD-Leff-1993" TYPE="STUDY">Leff 1993</LINK> was an open, randomised trial of 11 participants who were diagnosed as having definite myositis by the Bohan and Peters' criteria (<LINK REF="REF-Bohan-1975" TYPE="REFERENCE">Bohan 1975</LINK>), together with light microscopic changes consistent with biopsy-proven IBM.</P>
<P>The trial authors compared six months of intravenous MTX with a combination treatment of oral azathioprine and MTX (AZA + MTX). For the MTX regimen, the investigators infused 0.5 g/m<SUP>2</SUP> intravenously over one hour every two weeks; participants on intravenous MTX also received oral doses of 50 mg/m<SUP>2</SUP> leucovorin rescue. Oral doses of AZA and MTX began at 50 mg/day and 7.5 mg/week, respectively, and gradually increased to a maximum of 150 mg/day and 25 mg/week, respectively, over the course of the first 12 weeks unless adverse events occurred. In addition, both treatment groups received prednisone, which was tapered to a small, alternate-day dose of 0.25 mg/kg after one month. Participants only crossed over regimens if worsening or stabilisation occurred after six months of drug therapy. If improvement occurred after the first six months, the participants continued prednisolone and discontinued the trial therapy; such participants were kept under observation, and only when worsening occurred did they begin the other therapeutic regimen. The trial authors defined change in clinical status by categorical changes in MMT and activities of daily living (ADL) between the start and end of treatment. The trial authors did not report whether participants' baseline characteristics were similar.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oxandrolone versus placebo</HEADING>
<P>One trial compared oxandrolone, an anabolic steroid (a synthetic androgen), with placebo (<LINK REF="STD-Rutkove-2002" TYPE="STUDY">Rutkove 2002</LINK>). This double-blinded study randomised participants to 20 mg/day oxandrolone orally (10 mg twice daily) (n = 10) or placebo (n = 9) for 12 weeks. After a washout period of two to four months, the groups crossed over to the alternate intervention for another 12 weeks. All participants fulfilled the <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK> criteria for definite IBM. Assessments were performed at baseline, at the end of the first intervention period, at the end of the washout period, and at the end of the second 12-week intervention period (with additional serologic evaluation at 6 weeks of each treatment). Only 13 of the 19 participants completed both periods of the study, although the changes reported on oxandrolone were based on the 15 participants who completed active treatment, and the changes reported on placebo were based on the 14 participants who completed a placebo period. Baseline median muscle strength (whole-body maximal voluntary isometric contraction testing and MMT scores) were significantly higher in the group receiving placebo for the first study period (P = 0.03 and P = 0.008, respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Arimoclomol versus placebo</HEADING>
<P>
<LINK REF="STD-Machado-2013" TYPE="STUDY">Machado 2013</LINK> compared the safety and tolerability of arimoclomol with placebo in participants who fulfilled the diagnostic criteria for IBM according to <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK>. This double-blinded trial randomised one group to 100 mg three times daily and the other to placebo for four months, with an eight-month blinded follow-up phase. Available data were insufficient to determine the between-group similarity in baseline characteristics.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-07-07 18:10:52 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We have reported `Risk of bias' assessments for each included study in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> summarises review authors' assessments for each `Risk of bias' domain for all trials. The overall risk of bias in the included studies was unclear in 6 of the 10 trials. The review authors evaluated one trial of MTX as at low risk of bias (<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK>). We judged three other trials to be at high risk of bias: two open studies of multi-agent treatment, <LINK REF="STD-Leff-1993" TYPE="STUDY">Leff 1993</LINK> and <LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>, and <LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK>, due to incomplete outcome data, selective reporting, and breaking of randomisation by elective cross-over.</P>
<P>Insufficient information on blinding procedures was a common source of unclear risk of bias; this finding was particularly important because the primary outcome was a measure of muscle strength performance, likely to be influenced by a lack of blinding. Most studies also did not clearly demonstrate minimisation of the potentially confounding effects of previous or concurrent treatments.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-07-07 18:18:52 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;Arimoclomal - some deletion if Co-ed approves&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-07-07 18:18:52 +0100" NOTES_MODIFIED_BY="Ruth  Brassington">
<SUBSECTION>
<HEADING LEVEL="3">Intravenous immunoglobulin versus placebo</HEADING>
<P>Three studies contributed data for this comparison (<LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK>; <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK>; <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 6 months</HEADING>
<P>In <LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK> (19 analysed participants), the investigators assessed muscle strength change after three months of the intervention (cross-over study). The paper provided no statistical comparison between muscle strength in the IVIg and placebo groups at baseline. Since participants had the option to cross over, only the first period of the trial was randomised. We considered rescaling trial data (0 to 10 scale; maximum sum score = 200) to estimate the percentage change in muscle strength at six months despite an assumption of linear change. However, we were not able to perform secondary analysis because no standard deviation (SD) values were given. Primary data were not available for re-analysis, and we could not accurately regenerate primary data from the graphs and tables. At three months, trial authors found a non-significant gain in mean MRC points with IVIg and a non-significant loss with placebo. The mean change in the IVIg group was 4.2 MRC points (range -16 to 39.8), whereas the mean change in the placebo group was -2.7 MRC points (range -10 to 8). Trial authors reported "the effect of IVIg did not differ significantly compared with placebo in overall muscle strength" using a per protocol analysis.</P>
<P>In <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK> (36 analysed participants; 19 in treatment group), trialists assessed muscle strength change following three months of the intervention (parallel-group study). We considered whether to rescale trial data (0 to 10 scale) to estimate the percentage change in muscle strength at six months. However, the maximum sum score was unclear, as the study authors described 12 muscle group actions but reported 13 muscle groups as assessed. Also, they reported muscle strength change from baseline separately for upper and lower extremities, despite the primary outcome measure being total-body MRC sum scores. At three months, trial authors found no significant difference in mean muscle strength scores with IVIg compared with placebo. Trial authors concluded "the lack of improvement in strength, the primary endpoint of our study, was disappointing" based on a per protocol analysis. We intended to pool the data for upper and lower extremities, but primary data were unavailable for secondary analysis.</P>
<P>In <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK> (20 analysed participants), the investigators assessed muscle strength change following six months of the intervention (cross-over study). They reported comparable baseline muscle strength between IVIg and placebo groups based on MRC sum scores (P = 0.49). In the first period of the trial, there was a mean increase of 2.5 MRC points (0 to 6 scale; maximum sum score = 180) with IVIg from a baseline of 137.4 (± 28.3) to 139.9 (± 30.6); in the placebo group there was a mean increase of 4 MRC points from a baseline of 141.5 (± 33.8) to 145.5 (± 26.6) points. In the second period of intervention following cross-over, there was a mean increase of 4.5 MRC points, from 145.5 (± 26.6) to 150 (± 25.3) with IVIg and 6.8 MRC points with placebo, from 139.9 (±30.6) to 146.7 (± 28.1). The trial publication did not clearly state whether the figures in parentheses are SD. Trial authors also provided the overall comparative data for IVIg-placebo versus placebo-IVIg groups, although this does not measure IVIg efficacy. Trial authors reported "there were no significant changes in MRC scales during IVIg treatment" based on a per protocol analysis of efficacy data. We intended to pool the data for percentage change in muscle strength with IVIg versus placebo, but primary data were unavailable for secondary analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 12 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in handgrip at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle mass at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in timed walk at 6 months</HEADING>
<P>No available data.<B>
<BR/>
</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Significant adverse events from the intervention</HEADING>
<P>In <LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK>, two participants dropped out of the study before completing the first period, and a third completed the first period but refused to continue for reasons not stated. It is not clear if these dropouts were from the treatment or placebo group. In <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK>, there was one dropout from the placebo group due to death following a heart attack after the first infusion. In <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK>, the trial authors recorded two dropouts, but did not provide reasons for their discontinuation.</P>
<P>
<LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK> and <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK> did not report adverse events experienced by participants in sufficient detail for the review authors to analyse the data. In <LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK>, trial authors reported that there were no serious side effects; some participants experienced a mild headache, but without specification of the intervention group. In <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK>, trial authors again noted no serious side effects in the IVIg-randomised participants. <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK> reported no serious adverse events during the trial, although two participants had headaches with raised body temperature (38°C), and two participants developed allergic exanthema of the skin.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interferon beta-1a versus placebo</HEADING>
<P>Two studies contributed data for this comparison (<LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>; <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 6 months</HEADING>
<P>In <LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK> (29 analysed participants but 30 reported with an intention-to-treat (ITT) principle; 14 in treatment group), investigators assessed the muscle strength change following 24 weeks of the intervention (parallel-group study). They tested a total of 34 muscle groups, and the text suggested a maximum MRC sum score of 170 (based on an MRC scale of 0 to 5). Trial authors generated a `composite' score, which is defined in relation to QMT strength scores as "the average number of SD units from predicted normal strength, given age, gender and height of the subject". The mean MMT changes of 0.03 (SD 0.16) increment with placebo and 0.06 (SD 0.15) decline with IFN beta-1a appear to be consistent with a non-significant change in mean number of SD units plus SD, rather than mean muscle strength scores plus SD. The results were in favour of placebo (MD -0.09, 95% CI -0.20 to 0.02) based on an ITT principle with no computation of missing data. However, the formulation of the composite MMT score was not clear. We intended to ascertain the percentage change in muscle strength for IFN beta-1a versus placebo, but primary data were unavailable for secondary analysis.</P>
<P>In <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK> (28 analysed participants including carry-forward of 1 participant's data and no computation of missing data from 2 participants; 15 in treatment group), the trialists assessed muscle strength change similarly following 24 weeks of the intervention (parallel-group study). The dosage of IFN beta-1a was double that used in the earlier trial, but study methodology was otherwise consistent. The mean MMT decreases of 0.08 (SD 0.21) with placebo and 0.08 (SD 0.22) with IFN beta-1a again appeared to be consistent with a non-significant change in mean number of SD units plus SD, although this was not clearly stated. The results were neither in favour of placebo nor IFN beta-1a (MD 0.00, 95% CI -0.16 to 0.16).</P>
<P>As we were unable to ascertain percentage change in muscle strength, we decided to complete a pooled analysis of data from the two trials for change in normalised muscle strength sum scores. Overall, there was no significant benefit of IFN beta-1a over placebo; the combined data (58 participants) produced an MD of -0.06 (95% CI -0.15 to 0.03) in favour of placebo, but non-significant (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The result was not sensitive to the use of a fixed-effect versus a random-effects analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 12 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in handgrip at 6 months</HEADING>
<P>Data were unavailable for secondary analysis of handgrip strength; no baseline data were provided to estimate percentage change in handgrip strength based on the mean change in each participant. However, the mean change in grip strength scores was reported: -0.72 kg (SD 1.99) with IFN beta-1a and -0.72 kg (SD 1.46) with placebo (MD -0.16 kg, 95% CI -1.55 to 1.22) for <LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>. <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK> reported a change in grip strength of +0.23 kg (SD 1.66) with IFN beta-1a and -1.45 kg (SD 1.44) with placebo (MD 1.84 kg, 95% CI 0.46 to 3.21) in favour of IFN beta-1a. In the absence of normalised or percentage change data, we did not perform pooled analysis of the data from these two trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle mass at 6 months</HEADING>
<P>
<LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK> and <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK> measured lean mass as a surrogate for muscle mass.</P>
<P>In <LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>, there was an increase in lean mass of 0.1% with IFN beta-1a and a decrease of 0.85% with placebo. The mean reported change was +0.04 kg (SD 1.10) from a baseline of 40.1 kg (SD 7.5) with IFN beta-1a, and -0.34 kg (SD 1.96) from a baseline of 39.8 kg (SD 9.4) with placebo (MD 0.64 kg, 95% CI -0.71 to 1.99, with MD adjusted for investigator effects in an analysis-of-variance model). When calculated by percentage change, the MD was 0.95%, 95% CI -1.86 to 3.76.</P>
<P>In <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>, there was a decrease in lean mass with IFN beta-1a (-2.18%) and placebo (-1.77%). There was a decrease of 0.94 kg (SD 1.32) from a baseline of 43.2 kg (SD 10.2) in the IFN beta-1a group, and a decrease of 0.82 kg (SD 1.79) from a baseline of 46.3 kg (SD 9.9) in the placebo group (MD -0.10, 95% CI -1.40 to -1.19, with MD adjusted as previously). When calculated by percentage change, the MD was -0.41%, 95% CI -3.02 to 2.20.</P>
<P>Overall, the positive gain in lean mass was negligible in the first study relative to the large SD values and an undefined dual energy X-ray absorptiometry precision error; there was no positive gain of lean mass in the second study. Subsequently, IFN beta-1a did not appear to influence lean mass after six months of treatment, irrespective of the therapeutic dose. The combined percentage change data from these 2 trials (58 participants) produced an MD of 0.22% (95% CI -1.69 to 2.13) in favour of IFN beta-1a; the CI includes the possibility of an effect favouring either IFN beta-1a or placebo (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The result was not sensitive to the use of a fixed-effect versus a random-effects analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in timed walk at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Significant adverse events from the intervention</HEADING>
<P>In <LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>, 1 participant from the IFN beta-1a group withdrew from the study owing to death post-surgery for colon cancer; although 29 people completed the trial, the study authors based subsequent analysis on all 30 participants (16 placebo, 14 IFN beta-1a), carrying forward the results of the deceased. In <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>, three participants dropped out of the trial, two from the IFN beta-1a group and one from the placebo group. The analyses carried forward data from one of the dropouts in the IFN beta-1a group to the endpoint of the study. The reason given for one participant dropping out of the IFN beta-1a group was post-injection flu-like reaction; the reason for the other IFN beta-1a group dropout is not clear from the report.</P>
<P>Adverse events reported with IFN beta-1a included one death post-intervention with cause unlikely to be related to medication, flu-like symptoms, arthralgia/myalgias, skin rash, injection site reaction, diarrhoea, headache, depression, chills/fever, and abdominal pain or classified as other/unspecified. Trial authors reported numbers of participants experiencing each type of adverse event and mean numbers of adverse events per participant. <LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK> recorded a mean of 2.65 (no SD provided) participant-reported adverse events with IFN beta-1a compared with 2.25 (no SD) in the placebo group. In <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>, the trial authors recorded a mean of 4.00 (SD 2.83) participant-reported adverse events with IFN beta-1a, compared with 2.36 (SD 1.98) with placebo. Only <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK> reported the proportion of participants experiencing any type of adverse event following intervention: 79% of participants reported adverse events with placebo, and 81% with IFN beta-1a.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methotrexate versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 6 months</HEADING>
<P>One study contributed data for this comparison (<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK>). No six-month data were available, although ITT and per protocol analyses shown in graphs indicated declines in compound QMT at 22 weeks in both MTX and placebo groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 12 months</HEADING>
<P>
<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK> (44 analysed participants; 21 in the treatment group using ITT analysis) reported mean changes in muscle strength sum scores using percentages, thus we presented the results as reported by trial authors. For the primary outcome measure of the trial, mean QMT sum scores declined in both groups by 48 weeks (-0.2% in MTX and -3.4% in placebo) (MD 3.2%, 95% CI -2.5% to 9.1%). By limiting analysis to only those participants who fully completed the study (per protocol analysis), the trial authors found 0.9% improvement with MTX compared to a decline of 2.7% with placebo (MD 3.6%, 95% CI -3.3% to 10.7% in favour of placebo).</P>
<P>Mean MMT sum scores also declined in MTX and placebo groups: -0.5% for MTX and -2.0% for placebo (MD 1.5%, 95% CI -1.0% to 3.9%). Using the per protocol analysis, MMT sum score changes were -2.2% for MTX and -3.8% for placebo (MD 1.6%, 95% CI -2.3% to 5.4%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in handgrip at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle mass at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in timed walk at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Significant adverse events from the intervention</HEADING>
<P>Eight of the 21 participants in the MTX group dropped out, compared with 1 of 23 in the placebo group (risk ratio (RR) 8.76, 95% CI 1.19 to 64.28, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The significantly higher dropout rate reported with MTX was due to nausea (n = 3), hair loss (n = 2), arthralgia (n = 2), and progressive muscle weakness (n = 1). One participant on placebo treatment discontinued trial medication because of progressive muscle weakness. Both cases of dropout for progressive muscle weakness could have been the result of disease progression, but trial authors classified them as adverse events. Trial authors also reported that four participants in the MTX group and one participant in the placebo group required dose reductions, although it is not clear whether these were the same people who discontinued with the trial.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Combined immunosuppressive therapy: methotrexate and anti-T lymphocyte immunoglobulin versus methotrexate</HEADING>
<P>One study contributed data for this comparison (<LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 12 months</HEADING>
<P>At 12 months, the MTX + ATG group showed a change of 1.4% (SD 9.8%) in compound QMT compared with -11.1% (SD 7.2%) in the MTX group (P = 0.021). In the MTX + ATG group, mean strength increased from 90.3 N (SD 15.3) to 91.6 N (SD 18.2), as compared to the MTX group, in which there was a decrease from 78.4 N (SD 33.3) to 71.4 N (SD 34.5). The MD was 12.50% (95% CI 2.43 to 22.57) in favour of MTX (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in handgrip at 6 months</HEADING>
<P>No available data. The review authors opted not to rescale trial data from 12 to 6 months due to the uncertainty of assuming a linear change between these time points.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle mass at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in timed walk at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Significant adverse events from the intervention</HEADING>
<P>Ten participants completed the trial, but the trial authors based the analysis on 11 participants by carrying forward the data taken from the last assessment of the 1 person who dropped out. The use of ATG in this trial was not complicated by any serum sickness or anaphylaxis. However, one participant in the MTX group developed severe pneumonia after 118 days of treatment and was withdrawn from the study.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Combined immunosuppressive therapy: methotrexate and azathioprine versus methotrexate (plus leucovorin)</HEADING>
<P>One study contributed data for this comparison (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1411211456225159968434083476192&amp;format=REVMAN#STD-Leff-1993">Leff 1993</A>). The trial authors measured change in muscle strength based on MMT but presented results categorically (improved, stabilised, or worse), which prevented any data extraction.</P>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 12 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in handgrip at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle mass at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in timed walk at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Significant adverse events from the intervention</HEADING>
<P>Two of 11 participants discontinued combined AZA and MTX treatment due to side effects that were described as transient, reversible, and mainly gastrointestinal; these participants both underwent cholecystectomies for acute cholecystitis and were unable to resume drug treatment. A third participant did not cross over to MTX (plus leucovorin) due to pneumonitis. Another complication reported during the trial was a flareup of pre-existing gout in one participant during MTX (plus leucovorin) treatment. Trial authors reported that most participants received the full six months of each regimen. Insufficient data were available to give actual numbers of participants from each group who experienced significant adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oxandrolone versus placebo</HEADING>
<P>One study contributed data for this comparison (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1411211456225159968434083476192&amp;format=REVMAN#STD-Rutkove-2002">Rutkove 2002</A>). This was a cross-over trial that reported the effects of 12 weeks' treatment with oxandrolone versus placebo. Overall changes were reported at the end of the trial for 15 participants who completed the oxandrolone phase and 14 participants who completed the placebo phase. The trial authors reported median values and interquartile ranges "because of concerns about the normality of the data". The trial authors expressed results as GEE (generalised estimating equation) estimates and standard errors, with the result that the available data were insufficient to calculate percentage change in outcome measures.</P>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 6 months</HEADING>
<P>Insufficient data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle strength at 12 months</HEADING>
<P>Insufficient data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in handgrip at 6 months</HEADING>
<P>No available data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Percentage change from baseline in muscle mass at 6 months</HEADING>
<P>Insufficient data.</P>
<P>The analyses only excluded those participants who dropped out prior to completion of the first treatment period.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Arimoclomol versus placebo</HEADING>
<P>One trial investigated the use of arimoclomol for treating IBM (<LINK REF="STD-Machado-2013" TYPE="STUDY">Machado 2013</LINK>). However, only the abstract was available at the time of this review. In the pilot study, 16 participants used arimoclomol (100 mg 3 times daily) and 8 participants received a placebo for 4 months. The abstract did not report numerical data suitable for inclusion in this review.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-07-07 18:36:47 +0100" MODIFIED_BY="Ruth  Brassington">
<SUBSECTION>
<HEADING LEVEL="2">Intravenous immunoglobulin versus placebo</HEADING>
<P>We planned to perform a meta-analysis of the IVIg trials using data reported for our primary outcome, muscle strength, albeit at different time points. However, none of the IVIg studies reported data in a form that could be combined at 3, 6, or 12 months. <LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK> presented change in MRC sum scores for participants at three months in graphical form; we did not feel confident to accurately convert the graphical data to numerical values for meta-analysis. Additionally, we expected the need to extrapolate three-month data to six months to amplify any existing inaccuracies. In order to perform our analysis, we would have needed to rescale the original three-month trial data to six months, assuming a linear rate of change in strength over time. <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK> provided summary data for upper and lower limbs, but calculation of a percentage change from these summary scores and extrapolation to six months would again be subject to large assumptions in terms of the effect size. The <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK> cross-over trial similarly did not provide data in a form suitable for meta-analysis.</P>
<P>
<LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK> included 2 groups of 11 participants of different mean ages (67 years and 51 years); in theory, the cross-over design of the trial should negate any baseline differences seen between the two groups. However, we were unable to perform subgroup analysis with respect to age because of insufficient data. Subsequently, we cannot rule out the influence of faster disease progression in the older subgroup in relation to sarcopenia and enhanced mitochondrial dysfunction, as proposed previously (<LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK>; <LINK REF="REF-Santorelli-1996" TYPE="REFERENCE">Santorelli 1996</LINK>). Exploring the relationship between inflammation, mitochondrial dysfunction, and muscle atrophy and determining the rate of IBM progression could be essential for understanding any clinically relevant change with treatment (<LINK REF="REF-Rygiel-2014" TYPE="REFERENCE">Rygiel 2014</LINK>); additionally, we may need to consider the sexual dimorphic effect of ageing in relation to muscle protein synthesis in IBM, as postulated in the study of older adults (<LINK REF="REF-Smith-2012" TYPE="REFERENCE">Smith 2012</LINK>). While an ageing effect on our reviewed outcomes cannot be confirmed, the small, non-significant improvements in muscle strength with both IVIg and placebo may indicate a general learning effect in strength measurement as a proxy measure for disease progression; Neuromuscular Symptom and Disability Functional Score changes showed statistically significant improvement with IVIg only. We planned to perform subgroup meta-analyses for factors such as age and carry-over effect, but insufficient data were available.</P>
<P>In terms of the intervention, <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK>, unlike the other two trials, provided the IVIg and non-IVIg groups with equal doses of prednisone. The supplementation with prednisone was provided on the basis that the combination of steroid with IVIg might have a synergistic effect in improving muscle strength, based on studies in dermatomyositis and Guillain-Barré syndrome (<LINK REF="REF-Dalakas-1993" TYPE="REFERENCE">Dalakas 1993</LINK>; <LINK REF="REF-Dutch-GBS-1994" TYPE="REFERENCE">Dutch GBS 1994</LINK>). However, unlike for IBM, for dermatomyositis and Guillain-Barré syndrome, IVIg alone is known to be effective. For the purposes of meta-analysis, we would have to assume that prednisone did not contribute any effect for either the IVIg or non-IVIg treatment group.</P>
<P>In terms of study design, the three trials used two different MRC scales, and they did not assess the same muscle groups or muscle group actions. <LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK> involved elective cross-over in the second phase of the trial, such that we could consider only the first phase of intervention for meta-analysis (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). The inconsistency in methodology between trials is particularly important because IBM affects different muscles to a variable extent. As a result of the variable muscle involvement in IBM, IVIg might be beneficial for some muscles more than others at any given time point in the disease.</P>
<P>When summarising our findings, we assessed the quality of evidence for the effects of IVIg on muscle strength at six months as very low due to selective reporting and other issues of trial design (high risk of bias in one of the trials and an unclear overall risk of bias in the other two trials).</P>
<P>In conclusion, while marginal increments in muscle strength were identified in two of three trials of IVIg (<LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK>; <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK>), we could not determine an overall effect of IVIg versus placebo due to inconsistencies in trial methodology and reporting (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>None of the IVIg trials included a statistical analysis of the incidence of significant adverse events with intervention to facilitate full evaluation of treatment effect. According to <I>Meyler's Side Effects of Drugs</I> (<LINK REF="REF-Chalker-2000" TYPE="REFERENCE">Chalker 2000</LINK>; <LINK REF="REF-Dukes-2000" TYPE="REFERENCE">Dukes 2000</LINK>), current Ig preparations cause about 3% to 4% of people to experience adverse reactions. Other adverse events associated with IVIg include mild influenza-like illness, sweating, hypotension, chills, fever, nausea, and vasomotor reactions. More serious adverse effects include anaphylactic reactions; however, these are very rare and may occur in as few as 1 in 6000 people (<LINK REF="REF-Aronson-2006" TYPE="REFERENCE">Aronson 2006</LINK>). Stroke and myocardial infarction have been reported after high-dose IVIg, as a result of increased plasma viscosity. At high doses, neutropenia and disseminated intravascular coagulation have also been reported, and very rarely, acute renal failure (<LINK REF="REF-Aronson-2006" TYPE="REFERENCE">Aronson 2006</LINK>). <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK> reported some participants developing headache or raised body temperature, and two participants developed an allergic reaction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Interferon beta-1a versus placebo</HEADING>
<P>Neither of the IFN beta-1a studies showed a significantly greater benefit with IFN beta-1a over placebo. We were able to perform a meta-analysis of parallel-group trials comparing different doses of IFN beta-1a with placebo. The standardised trial procedures and reporting across both trials made pooling of data from <LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK> and <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK> possible. The pooled analysis for normalised muscle strength change from baseline produced a MD in compound MMT in favour of placebo (moderate-quality evidence), but with CIs including the possibility of an effect in either direction (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The forest plot for lean mass, as surrogate for muscle mass (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), also did not show an effect in favour of IFN beta-1a (moderate-quality evidence).</P>
<P>Despite some reported improvement in grip strength with IFN beta-1a treatment, we could not assess the quality of this evidence because the available data were incomplete.</P>
<P>Neither of the IFN beta-1a trials included a statistical analysis of the incidence of significant adverse events to facilitate full evaluation of the treatment effect. Among the participants who took 30 µg doses of IFN beta-1a, 84% reported adverse events (<LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>); this figure was approximately 81% in participants who took 60 µg doses of IFN beta-1a (<LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>). Flu-like reactions following injection were the most commonly specified complaint with high-dose treatment, while diarrhoea was the most commonly specified adverse event with low-dose treatment (<LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>; <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>). Rarer adverse events associated with IFN beta-1a can include mood and personality changes, suicide attempts, hepatitis, and thyroid dysfunction (<LINK REF="REF-Aronson-2006" TYPE="REFERENCE">Aronson 2006</LINK>). Such an adverse event profile and the large percentage of users experiencing more minor adverse events may give rise to problems with compliance over a longer period. However, despite the high frequency of adverse events seen in these two trials, none was assessed as significant enough to require dose reduction (<LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>; <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Methotrexate versus placebo</HEADING>
<P>A single RCT provided moderate-quality evidence of no significant effect of MTX on muscle strength at 12 months; the trial was insufficiently powered to exclude a possible benefit from MTX (see <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). Approximately 38% of participants who were on MTX reported adverse events (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), and there was a statistically significant dropout rate in the MTX treatment group (moderate-quality evidence). A larger or longer trial of MTX could be problematic in terms of compliance (<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK>). The most common adverse events caused by MTX are nausea, vomiting, alopecia, oral mucositis, or effects of myelosuppression (<LINK REF="REF-Aronson-2006" TYPE="REFERENCE">Aronson 2006</LINK>). While there are pharmacological agents to reduce or alleviate common adverse events, polypharmacy may also affect compliance.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Combination therapy in the treatment of IBM</HEADING>
<P>The benefit of combination therapy with MTX and ATG, <LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>, or MTX and AZA, <LINK REF="STD-Leff-1993" TYPE="STUDY">Leff 1993</LINK>, remains unclear in the treatment of IBM. Combined MTX and ATG appeared to show some benefit, but the evidence, based on a small, open-label trial, is very low quality and should be interpreted with caution (see <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>) (<LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>). Aside from risk of bias issues, any positive effect of ATG combined with MTX versus MTX alone could either be due to the effects of ATG alone or to its effects when combined with MTX. Adverse effects known to be associated with ATG include "leukopenia and thrombocytopenia, fever, arthralgia, rash, urticaria, hepatotoxicity, hyperglycaemia, hypertension, and diarrhoea" (<LINK REF="REF-Aronson-2006" TYPE="REFERENCE">Aronson 2006</LINK>). Serum sickness can also occur later. However, none of these potential adverse effects was reported in the trial; only a single case of pneumonia was reported.</P>
<P>In the only trial that looked at AZA and MTX in combination (<LINK REF="STD-Leff-1993" TYPE="STUDY">Leff 1993</LINK>), we could obtain no quantitative data (see <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>). Similar to <LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>, this trial was open label and had a small number of participants (very low-quality evidence). As a combination therapy, there was a risk of exposure to the effects of both drugs in the combination. Adverse events on the regimen that included AZA were gastrointestinal symptoms, acute cholecystitis, and a case of pneumonitis. In the MTX alone group, the authors reported only a flareup of pre-existing gout; other adverse events known to occur with AZA alone include fever, nausea, leukopenia, thrombocytopenia, and anaemia (<LINK REF="REF-Aronson-2006" TYPE="REFERENCE">Aronson 2006</LINK>). Neither <LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK> nor <LINK REF="STD-Leff-1993" TYPE="STUDY">Leff 1993</LINK> provided a statistical analysis of the incidence of significant adverse events with the intervention to facilitate a full evaluation of the treatment effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Oxandrolone versus placebo</HEADING>
<P>In comparing oxandrolone with placebo, the trial authors highlighted that small numbers of participants and a relatively short trial duration restricted the interpretation of results (<LINK REF="STD-Rutkove-2002" TYPE="STUDY">Rutkove 2002</LINK>). The trial authors also considered that between-group differences in baseline characteristics may have had some confounding effects. The trial authors reported a close-to-significant treatment effect for improving whole body strength with oxandrolone at 12 weeks. However, we noted that the methods of analysis (generalised estimating equation) were unusual for this trial design, and the power of the test for carry-over effects was low. Taking into account these and the other study limitations, results should be interpreted with caution (very low-quality evidence).</P>
<P>In terms of adverse events, anabolic steroids have some androgenic activity that can give rise to acne and other signs of virilisation and may affect lipoprotein profiles. As the associated androgenic activity is weak, these adverse events are not common. However, gynaecomastia has occurred with the long-term use of anabolic steroids as a growth promoter in boys (<LINK REF="REF-Aronson-2006" TYPE="REFERENCE">Aronson 2006</LINK>). Withdrawal of high doses of anabolic steroids can give rise to menopause-like symptoms (<LINK REF="REF-Chalker-2000" TYPE="REFERENCE">Chalker 2000</LINK>; <LINK REF="REF-Dukes-2000" TYPE="REFERENCE">Dukes 2000</LINK>). <LINK REF="STD-Rutkove-2002" TYPE="STUDY">Rutkove 2002</LINK> reported no significant adverse events, which was perhaps related to the low doses used over a relative short period of time but, as with all other analysed trials, the investigators included no definition of what constituted an adverse event in order to evaluate treatment effect. If anabolic steroids are associated with few or no significant adverse events in practice, possible therapeutic potential might justify further trials to explore their use in treating IBM. Conversely, more adverse events and issues with compliance may be anticipated in a longer trial of anabolic steroids.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Arimoclomol versus placebo</HEADING>
<P>At the time of review, we did not attempt to evaluate the effects of arimoclomol for treating IBM because the relevant data were not available for systematic review. The trial was only available in abstract (<LINK REF="STD-Machado-2013" TYPE="STUDY">Machado 2013</LINK>), and it was powered to assess safety and tolerability, not treatment effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">The lessons from these trials</HEADING>
<P>This systematic review of treatment for IBM identified nine analysable RCTs and one RCT published in an abstract only. In terms of determining a treatment effect, only 2 of the included trials reported power calculations, and we evaluated all 10 trials as underpowered to detect a statistically significant effect. One trial that included power calculations was primarily a safety and tolerability study, rather than an efficacy study (<LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>). The other trial indicated multiple reasons for the lower-than-expected power for their study, including rate of decline in the placebo group; variability in QMT strength measures; and a higher-than-expected participant dropout rate (<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK>). The largest included RCT had only 22 participants in the treatment group (<LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK>). The largest analysed treatment group included only 21 participants, using an intention-to-treat analysis (<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK>), and 20 participants with a per protocol analysis of the primary outcome measure (<LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK>). <LINK REF="REF-Rose-2001" TYPE="REFERENCE">Rose 2001</LINK> calculated that each group of a placebo-controlled trial needed 94 participantsto have 90% power to detect a 4% difference in mean change in muscle strength between two groups over a 6-month period. This 4% larger difference over placebo was determined to be equivalent to arresting disease progression with the drug on trial. Based on trial experience, <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK> calculated that a 2-arm, 6-month intervention would require 208 participants per group to detect the arrest of disease progression using QMT with 90% power, a 2-tailed t-test, and significance level of 5%.</P>
<P>Multicentre recruitment, pooling of trial results, or both, might allow for the accumulation of sufficient data for a more robust answer as to the efficacy of treatment for IBM. However, we still expect differences in both methodologies and the type of intervention to affect treatment effect estimates and the validity of results. Across the studies included in this review, meta-analysis was compromised by the fact that outcome measurement was not standardised to measure the cardinal effects of interest, namely muscle weakness, atrophy, and functional impairment. Additionally, some studies used normalised MDs for assessing change in muscle strength.</P>
<P>For muscle strength testing, it would be helpful to standardise appropriate test methodology (for example, manual or quantitative measurements (or both), specification and number of muscles or muscle actions tested, and the detection of a minimal clinically important difference) for use in research trials. The potential for harm resulting from treatment also needs to be carefully considered; none of the included studies defined what constituted an adverse effect, although drug treatments were associated with adverse effects of variable severity. Most of the studies also did not specify the methods used to monitor adverse effects. Analysis of treatment effect can risk bias towards a focus on favourable outcome measures in the absence of sufficient information on conduct and reporting of adverse events (<LINK REF="REF-Loke-2007" TYPE="REFERENCE">Loke 2007</LINK>).</P>
<P>None of the completed trials made reference to responsiveness or a minimal clinically important difference for any outcome measure in relation to disease progression. The validation of trial outcome measures, where reported, was also not performed specifically in an IBM population.</P>
<P>In terms of comparing future clinical trials in IBM, it will be important to minimise the differences in inclusion and exclusion criteria applied; this review found that trials used a range of criteria regarding comorbidity and concomitant treatment that could have a fundamental impact on study outcomes. Some have argued that insistence on pathological criteria for the inclusion of IBM in clinical trials may result in such trials attempting to treat participants who have more advanced, and therefore inherently less treatable, disease. Currently proposed diagnostic criteria reduce the emphasis on pathological criteria with the aim of allowing recruitment of participants earlier in the course of their disease. However, this strategy is subject to verification, and currently there are no trials that apply these newer criteria for IBM.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Costs</HEADING>
<P>UK costs for treatment with the interventions used in the included studies would be:</P>
<UL>
<LI>Interferon beta-1a (Avonex): injection, 60 &#956;g (12 million units)/mL, net price 0.5 mL (30 &#956;g, 6 million-unit) prefilled syringe = GBP 163.50 (<LINK REF="REF-BNF-2014" TYPE="REFERENCE">BNF 2014</LINK>).</LI>
<LI>Methotrexate: tablets, 2.5 mg, net price 24-tablet pack = GBP 2.22; 10 mg, net price 100-tablet pack = GBP 37.06 (<LINK REF="REF-BNF-2014" TYPE="REFERENCE">BNF 2014</LINK>).</LI>
<LI>Azathioprine: tablets, 50 mg, 56-tablet pack = GBP 3.42 (<LINK REF="REF-BNF-2014" TYPE="REFERENCE">BNF 2014</LINK>).</LI>
<LI>Intravenous immunoglobulin: based on 2 g/kg in 70 kg man = GBP 3906 to 4900 (<LINK REF="REF-DH-2011" TYPE="REFERENCE">DH 2011</LINK>).</LI>
<LI>Oxandrolone: a price from 2000 of USD 4 per 2.5 mg tablet (<LINK REF="REF-Beaston_x002d_Blaakman-2007" TYPE="REFERENCE">Beaston-Blaakman 2007</LINK>). In the UK, injection, nandrolone decanoate 50 mg/L, net price 1 mL ampoule = GBP 3.17 by deep intramuscular injection, 50 mg every 3 weeks (<LINK REF="REF-BNF-2014" TYPE="REFERENCE">BNF 2014</LINK>).</LI>
</UL>
<P>Intervention treatment costs per person over a six-month period were estimated to be greatest for IVIg (approximately GBP 15,000) followed by IFN beta-1a therapy, and with markedly lower costs for oxandrolone by intramuscular injection, AZA, and MTX treatment.</P>
</SUBSECTION>
<POTENTIAL_BIASES MODIFIED="2015-06-23 21:37:58 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We chose to express the primary outcome as the percentage change in compound MMT over time because it is a widely used approach to muscle strength assessment in clinical research. However, percentage change calculation was rarely feasible using the available data, and two trials reported normalised data instead. Our percentage figures related to group-level changes, but these are likely to be different from those calculated using absolute data from individuals. We expected the data to be subject to uncertainty in relation to clinical and statistical heterogeneity and significance. Using absolute changes would be preferable, but these were not retrievable across all trials in the review. Also, to calculate mean change in absolute MMT scores might have required that only those muscles tested by all studies and scaled to the same MRC grading were included in analysis.</P>
<P>Another potential bias in the review process was in the type of selected outcome measures. Our selected functional impairment outcome measures were restricted to specific single-item tasks, while inflammatory and pathological biomarkers were not analysed at all. Nevertheless, our data extraction did suggest that included trials inconsistently assessed or reported those additional functional, inflammatory, and pathological outcomes.</P>
<P>Some of the review authors were investigators in included trials. A non-conflicted review author performed independent data extraction if any review author had potential conflicts of interest, for example through involvement in an included study.</P>
<P>A further limitation of the review was that the review methods were unlikely to adequately detect serious, rare adverse events. We therefore discussed adverse events described in other sources in the Discussion.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-07-07 18:36:47 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The results of this systematic review confirmed previous observational study and review findings that there are no established, evidence-based treatments for IBM as yet (<LINK REF="REF-Benveniste-2011" TYPE="REFERENCE">Benveniste 2011</LINK>; <LINK REF="REF-Breithaupt-2013" TYPE="REFERENCE">Breithaupt 2013</LINK>; <LINK REF="REF-Machado-2013b" TYPE="REFERENCE">Machado 2013b</LINK>). The small sample sizes and short duration of clinical trials are recognised as major limitations in the evaluation of treatment efficacy in this muscle condition (<LINK REF="REF-Breithaupt-2013" TYPE="REFERENCE">Breithaupt 2013</LINK>; <LINK REF="REF-Fergusson-2005" TYPE="REFERENCE">Fergusson 2005</LINK>). In terms of assessment, MMT scores of muscle strength are widely used in research and clinical practice, but further development of sensitive outcome measures is advocated (<LINK REF="REF-Breithaupt-2013" TYPE="REFERENCE">Breithaupt 2013</LINK>; <LINK REF="STD-Machado-2013" TYPE="STUDY">Machado 2013</LINK>). Studies included in this review used different methodological and analytical approaches to assess muscle strength and applied a range of secondary outcome measures. Such variations in methods and outcome measures hindered the pooling of trial data to contribute to the evidence base. As part of a systematic review in neurological conditions, <LINK REF="REF-Fergusson-2005" TYPE="REFERENCE">Fergusson 2005</LINK> analysed the same three IVIg trials for IBM as in our review; like us, they were unable to come to a conclusion about the efficacy of IVIg from the available data. <LINK REF="REF-Fergusson-2005" TYPE="REFERENCE">Fergusson 2005</LINK> similarly elected not to perform pooled analysis due to between-trial differences in methodology. Interestingly, the benefit of IVIg in chronic inflammatory demyelinating polyneuropathy (CIDP) was identified using a disability scale, as was the benefit <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK> showed for IVIg in IBM, using the Neuromuscular Symptom and Disability Functional Score. Such evidence perhaps argues for the use of disability scales in future IBM trials. However, <LINK REF="REF-Fergusson-2005" TYPE="REFERENCE">Fergusson 2005</LINK> also emphasised that evidence of benefit still does not necessarily support IVIg as a first-line treatment owing to other factors, including adverse events and cost.</P>
<P>Evidence of mitochondrial abnormalities in IBM that are in excess of those seen with normal ageing may suggest another range of therapeutic options, but there are currently no known effective treatments for primary mitochondrial disease (<LINK REF="REF-Pfeffer-2012" TYPE="REFERENCE">Pfeffer 2012</LINK>). Similarly, currently there are no drugs with the therapeutic potential to arrest or slow down the degenerative pathology seen in IBM (<LINK REF="REF-Breithaupt-2013" TYPE="REFERENCE">Breithaupt 2013</LINK>). A common issue highlighted across Cochrane intervention reviews in muscle disease is the quality of study design and paucity of RCTs, emphasising ongoing problems with sample size and risk of bias (<LINK REF="REF-Hill-2004" TYPE="REFERENCE">Hill 2004</LINK>; <LINK REF="REF-Pfeffer-2012" TYPE="REFERENCE">Pfeffer 2012</LINK>; <LINK REF="REF-Voet-2013" TYPE="REFERENCE">Voet 2013</LINK>). The validity of the evidence base also appears to be limited by a lack of standardisation in the collection, evaluation, and reporting of data. This systematic review identified specific quality issues in clinical trials of people with IBM, which should encourage investigators to validate outcome measures and ensure standardisation of trial procedures.</P>
<P>Only one of the studies included in this review measured swallowing function, which we did not include as a predefined outcome measure. In the future a Cochrane review of treatment for swallowing difficulties in chronic muscle disease will include IBM (<LINK REF="REF-Hill-2004" TYPE="REFERENCE">Hill 2004</LINK>). In terms of ongoing drug trials for IBM, we identified an RCT of bimagrumab (BYM338), which has been developed to target molecular pathways involved in muscle growth, and which we may include in a future review. An RCT of simvastatin is also pending completion.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-06-26 10:30:37 +0100" MODIFIED_BY="Ruth  Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2015-06-26 10:30:37 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Trials of interferon beta-1a and methotrexate provided moderate-quality evidence of having no effect on the progression of sporadic inclusion body myositis although we cannot exclude clinically relevant effects. An open trial of anti T-lymphocyte immunoglobulin combined with methotrexate versus methotrexate provided very low-quality evidence in favour of the combined therapy, based on the percentage change data given. We were unable to draw conclusions from trials of intravenous immunoglobulin, oxandrolone, and azathioprine plus methotrexate versus methotrexate. Overall trial design limitations and selective reporting made it difficult to say whether or not any of the drug treatments were effective in arresting or slowing disease progression. Any decision to prescribe these treatment regimens in the absence of evidence for or against benefit will need to consider the potential adverse effects and the cost of medication.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-06-23 21:40:25 +0100" MODIFIED_BY="Ruth  Brassington">
<P>More randomised controlled trials are needed on which to base treatment decisions. Such trials will need to recruit larger numbers and be of longer duration than has hitherto been the case, in order to derive definite conclusions as to the benefit or otherwise of any intervention. Standardisation of the trial protocols using agreed diagnostic criteria and validated, responsive outcome measures for such trials is also necessary. Finally, we recommend a cost-utility analysis to assist decision-making in the treatment of IBM.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-06-23 15:05:59 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Angela Gunn, the Trials Search Co-ordinator of the Cochrane Neuromuscular Disease Group conducted database searches.</P>
<P>This project was supported by the National Institute for Health Research via Cochrane Infrastructure funding to the Cochrane Neuromuscular Disease Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health. The Cochrane Neuromuscular Disease Group is also supported by the MRC Centre for Neuromuscular Disease.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-06-30 18:01:31 +0100" MODIFIED_BY="Ruth  Brassington">
<P>MR is a member of the Muscle Study Group that published the two trials of IFN beta-1a for IBM. These trials were grant funded with a proportion of those funds paid to my institution for the conduct of the trial only and with no personal financial benefit ensuing. For these trials the drug (Avonex) and matching placebo were supplied free of charge by the manufacturer Biogen. The trial protocols, data entry, data analysis, and publications were in the hands of the investigators with no input from Biogen.</P>
<P>KJ's research contribution has been paid for by a grant from the Association Française contre les Myopathies.</P>
<P>KL has no known financial conflicts of interest.</P>
<P>MW has published one randomised trial of IVIg in IBM. She contributed to the Novartis EU Local Advisory Board Meeting (IBM BYM338 trial) on 15 April 2013.</P>
<P>JM has been a member of advisory boards for CSL Behring, Octapharma, and Grifols, companies that produce IVIg. He received meeting expenses to attend Peripheral Nerve Society meetings in 2011, 2012, and 2013 from Baxter and CSL Behring, which produce IVIg products. He is a local principal investigator for the RESILIENT study, an ongoing study of bimagrumab in sporadic IBM sponsored by Novartis.</P>
<P>MD has published three randomised trials of IVIg in IBM. He has accepted institutional grants unrelated to the present review from: CSL, Genesis, Merck, Novartis, and Genzyme. He has also received personal compensation for lectures or consultancies from Novartis, Dysimmune Diseases Foundation, Therapath, Genzyme, Octapharma, and Baxter.</P>
<P>RB has no known financial conflicts of interest. She is Managing Editor of the Cochrane Neuromuscular Disease Group.</P>
<P>RG is a member of the Muscle Study Group that published two trials of IFN beta-1a for IBM. He has no other known conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-07-07 18:11:05 +0100" MODIFIED_BY="Ruth  Brassington">
<P>For the protocol: MR and KL drafted earlier versions of the protocol with input from co-authors (<LINK REF="REF-Rose-1999" TYPE="REFERENCE">Rose 1999</LINK>; <LINK REF="REF-Rose-2007" TYPE="REFERENCE">Rose 2007</LINK>). KJ updated the protocol in 2014. All review authors reviewed drafts and agreed on the final text.</P>
<P>For the review stage:</P>
<UL>
<LI>MR, KJ, MW, and JM assessed studies for inclusion.</LI>
<LI>MR, KJ, KL, MW, and JM extracted data.</LI>
<LI>MR and KL entered data; KJ checked data entry.</LI>
<LI>MR and KJ assessed the risk of bias in included studies.</LI>
<LI>RB assisted with analyses and drafted `Summary of findings' tables.</LI>
<LI>MR, KJ, and RB drafted text.</LI>
<LI>All review authors reviewed drafts and agreed on the final text.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-07-07 18:11:20 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We used The Cochrane `Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We commented on the use of explicit diagnostic criteria, the quality of outcome measures, and the power of the study to detect benefit where appropriate in the text.</P>
<P>We searched clinical trials registries for ongoing trials but did not carry out an up-to-date handsearch of conference abstracts.</P>
<P>We referred to <LINK REF="REF-Griggs-1995" TYPE="REFERENCE">Griggs 1995</LINK>, <LINK REF="REF-Benveniste-2010" TYPE="REFERENCE">Benveniste 2010</LINK>, and <LINK REF="REF-Hilton_x002d_Jones-2010" TYPE="REFERENCE">Hilton-Jones 2010</LINK> for clinicopathologically defined IBM, but two trials referred to clinicopathologically defined criteria using alternative references.</P>
<P>We renamed our outcome `significant side-effects' as `significant adverse events'.</P>
<P>We defined significant adverse events as the incidence of withdrawals.</P>
<P>We clarified significant adverse events as the incidence of participant withdrawal from trials, with reasons explained where possible. In line with the definition of an adverse event, we accepted that withdrawal might occur for reasons unspecified or unrelated to the intervention.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-07-07 18:21:32 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDIES MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington">
<INCLUDED_STUDIES MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Badrising-2002" MODIFIED="2012-05-29 17:46:47 +0100" MODIFIED_BY="[Empty name]" NAME="Badrising 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-05-29 17:46:47 +0100" MODIFIED_BY="[Empty name]" NOTES="UI - 21888200" NOTES_MODIFIED="2012-05-29 17:46:47 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, et al</AU>
<TI>Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo</TI>
<SO>Annals of Neurology</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>3</NO>
<PG>369-72</PG>
<IDENTIFIERS MODIFIED="2012-05-29 17:46:47 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 17:46:47 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11891832"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalakas-1997" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Dalakas 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NOTES="Article abstract-We randomized 19 patients with inclusion-body myositis (IBM) to a double-blind, placebo-controlled, crossover study using monthly infusions of 2 g/kg intravenous immunoglobulin (IVIg) or placebo for 3 months. Patients crossed over to the alternate treatment after a washout period. We evaluated responses at baseline and at the end of each treatment period using expanded (0-10) MRC scales, the Maximum Voluntary Isometric Contraction (MVIC) method, symptom and disability scores, and quantitative swallowing studies. We calculated the differences in scores between IVIg and placebo from baseline to end of treatment. Of the 19 patients, 9 (mean age, 61.2 years; mean disease duration, 5.6 years) were randomized to IVIg and 10 (mean age, 66.1 years; mean disease duration, 7.4 years) to placebo. During IVIg the patients gained a mean of 4.2 (-16 to +39.8) MRC points, and during placebo lost 2.7 (-10 to +8) points (p &amp;lt; 0.1). These gains were not significant. Similar results were obtained with the MRC and MVIC scores when the patients crossed to the alternate treatment. Six patients had a functionally important improvement by more than 10 MRC points that declined when crossed over to placebo. Limb-by-limb analysis demonstrated that during IVIg the muscle strength in 39% of the lower extremity limbs significantly increased compared with placebo (p &amp;lt; 0.05), while a simultaneous decrease in 28% of other limbs was detected. The clinical importance of these minor gains is unclear. The duration of swallowing functions measured in seconds with ultrasound improved statistically in the IVIg-randomized patients (p &amp;lt; 0.05) compared with placebo. Although the study did not establish efficacy of IVIg, possibly because of the small sample size, the drug induced functionally important improvement in 6 (28%) of the 19 patients. Whether the modest gains noted in certain muscle groups justify the high cost of trying IVIg in IBM patients at a given stage of the disease remains unclear." NOTES_MODIFIED="2014-11-13 17:51:23 +0000" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K</AU>
<TI>Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48</VL>
<NO>3</NO>
<PG>712-6</PG>
<IDENTIFIERS MODIFIED="2012-08-09 14:04:24 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-08-09 14:04:24 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="9065553"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;Abstract&lt;/p&gt;&lt;p&gt;Need to check details&lt;/p&gt;" NOTES_MODIFIED="2015-06-05 15:15:02 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujii M, Koffman B, Sivakumar K, Dalakas MC</AU>
<TI>Histologic characteristics in repeated muscle biopsies of patients with inclusion body myositis treated in a control trial with high-dose intravenous immunoglobulin and prednisone</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48 Suppl 2</VL>
<PG>A332-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalakas-2001" MODIFIED="2012-05-29 17:50:59 +0100" MODIFIED_BY="[Empty name]" NAME="Dalakas 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-05-29 17:50:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E</AU>
<TI>A controlled study of intravenous immunoglobulin combined with prednisolone in the treatment of IBM</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>3</NO>
<PG>323-7</PG>
<IDENTIFIERS MODIFIED="2012-05-29 17:50:59 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 17:50:59 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11171896"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leff-1993" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Leff 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH</AU>
<TI>The treatment of inclusion body myositis: a retrospective review and a randomised prospective trial of immunosuppressive therapy</TI>
<SO>Medicine</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>4</NO>
<PG>225-35</PG>
<IDENTIFIERS MODIFIED="2012-05-29 17:55:35 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 17:55:35 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8393509"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindberg-2003" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Lindberg 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="UI - 22756920" NOTES_MODIFIED="2015-06-05 15:15:02 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindberg C, Trysberg E, Tarkowski A, Oldfors A</AU>
<TI>Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61</VL>
<NO>2</NO>
<PG>260-2</PG>
<IDENTIFIERS MODIFIED="2012-05-29 17:57:35 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 17:57:35 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="12874415"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Machado-2013" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Machado 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Machado P, Miller A, Herbelin L, He J, Noel J, Wang Y, et al</AU>
<TI>Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, phase IIA proof-of-concept trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2013</YR>
<VL>72</VL>
<NO>Suppl 3</NO>
<PG>A164</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>Machado P, Miller A, Herbelin L, He J, Wang Y, McVey AL, et al</AU>
<TI>Arimoclomol study in IBM: [personal communication]</TI>
<SO>Email to P Machado</SO>
<YR>4 November 2014</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muscle-Study-Group-2001" MODIFIED="2015-03-04 16:25:07 +0000" MODIFIED_BY="Ruth Brassington" NAME="Muscle Study Group 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-03-04 16:25:07 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Muscle Study Group</AU>
<TI>Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>9</NO>
<PG>1566-70</PG>
<IDENTIFIERS MODIFIED="2015-03-04 16:25:07 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2015-03-04 16:25:07 +0000" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="11706093"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muscle-Study-Group-2004" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Muscle Study Group 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NOTES="DA - 20040824" NOTES_MODIFIED="2014-11-13 17:51:23 +0000" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Muscle Study Group</AU>
<TI>Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>4</NO>
<PG>718-20</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:06:11 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:06:11 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="15326251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rutkove-2002" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Rutkove 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NOTES="UI - 21938576" NOTES_MODIFIED="2014-11-13 17:51:23 +0000" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM</AU>
<TI>A pilot randomized trial of oxandrolone in inclusion body myositis</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>58</VL>
<NO>7</NO>
<PG>1081-7</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:01:31 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:01:31 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11940697"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walter-2000" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Walter 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;Need to check on volume number&lt;/p&gt;" NOTES_MODIFIED="2015-06-05 15:15:02 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pongratz D, Lochmuller H, Toepfer M, Schlotter B, Schroder M, Muller-Felber W, et al</AU>
<TI>High dose intravenous immunoglobulin (IVIG) in the treatment of inclusion body myositis - a double-blind placebo-controlled study</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>Suppl 7</NO>
<PG>S131</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-02 17:34:48 +0000" MODIFIED_BY="Katherine Jones" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, et al</AU>
<TI>High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double blind, placebo-controlled study</TI>
<SO>Journal of Neurology</SO>
<YR>2000</YR>
<VL>247</VL>
<NO>1</NO>
<PG>22-8</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:04:19 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:04:19 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="10701893"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12614000082606" MODIFIED="2015-01-23 15:32:07 +0000" MODIFIED_BY="Katherine Jones" NAME="ACTRN12614000082606" YEAR="2606">
<REFERENCE MODIFIED="2015-01-23 15:32:07 +0000" MODIFIED_BY="Katherine Jones" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12614000082606</AU>
<TI>Pilot study of the treatment of patients with sporadic inclusion body myositis with the anaplerotic medication Triheptanoin</TI>
<SO>https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365625</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amato-1994" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Amato 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT</AU>
<TI>Inclusion body myositis: treatment with intravenous immunoglobulin</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>8</NO>
<PG>1516-8</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:09:27 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:09:27 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8058161"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnardottir--2003" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Arnardottir  2003" YEAR="35(1)">
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;(1) Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: Pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. Journal of Rehabilitation Medicine Vol 35(1)()(pp 31-35), 2003 2003;(1):31-5.&lt;/p&gt;" NOTES_MODIFIED="2015-06-05 15:15:02 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnardottir S, Alexanderson H, Lundberg IE, Borg K</AU>
<TI>Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction</TI>
<SO>Journal of Rehabilitation Medicine</SO>
<YR>2003</YR>
<VL>35</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:18:33 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:18:33 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="12610846 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danon-1982" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Danon 1982" YEAR="39(12">
<REFERENCE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Danon MJ, Reyes MG, Perurena OH, Masdeu JC, Manaligod JR</AU>
<TI>Inclusion body myositis. A corticosteroid-resistant idiopathic inflammatory myopathy</TI>
<SO>Archives of Neurology</SO>
<YR>1982</YR>
<VL>39</VL>
<NO>12</NO>
<PG>760-4</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:12:16 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:12:16 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="6291495"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heikkill_x00e4_-2001" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Heikkillä 2001" YEAR="87(6)">
<REFERENCE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;(3) Heikkila S, Viitanen JV, Kautiainen H, Rajamaki T, Mantyvuo P, Harju T. Rehabilitation in Myositis. Physiotherapy Vol 87(6)()(pp 301-309), 2001 2001;(6):301-9.&lt;/p&gt;" NOTES_MODIFIED="2015-06-23 21:42:51 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heikkillä S, Viitanen JV, Kautiainen H, Rajamäki T, Mäntyvuo P, Harju T</AU>
<TI>Rehabilitation in myositis: preliminary study</TI>
<SO>Physiotherapy</SO>
<YR>2001</YR>
<VL>87</VL>
<NO>6</NO>
<PG>301-9</PG>
<IDENTIFIERS MODIFIED="2012-05-29 19:53:00 +0100" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-03-16 14:48:13 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joffe-1993" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Joffe 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al</AU>
<TI>Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy</TI>
<SO>American Journal of Medicine</SO>
<YR>1993</YR>
<VL>94</VL>
<NO>4</NO>
<PG>379-87</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:23:33 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:23:33 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8386437"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosmidis-2013" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Kosmidis 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC</AU>
<TI>The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2013</YR>
<VL>334</VL>
<NO>1-2</NO>
<PG>1235</PG>
<IDENTIFIERS MODIFIED="2014-11-05 11:48:55 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01165008</AU>
<TI>Anakinra in myositis</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01165008</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindberg-1994" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Lindberg 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindberg C, Persson LI, Bjorkander J, Oldfors A</AU>
<TI>Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>2</NO>
<PG>123-31</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:25:49 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:25:49 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8191875"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mastaglia-1998" MODIFIED="2012-05-29 18:28:09 +0100" MODIFIED_BY="Kate Jewitt" NAME="Mastaglia 1998" YEAR="65(1)">
<REFERENCE MODIFIED="2012-05-29 18:28:09 +0100" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;(4) Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry Vol 65(1)()(pp 107-110), 1998 1998;(1):107-10.&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:28:09 +0100" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mastaglia FL, Phillips BA, Zilko PJ</AU>
<TI>Immunoglobulin therapy in inflammatory myopathies</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>1</NO>
<PG>107-10</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:28:09 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:28:09 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="9667570"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mowzoon-2001" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Mowzoon 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;Check this reference&lt;/p&gt;" NOTES_MODIFIED="2015-06-23 21:42:51 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mowzoon N, Sussman A, Bradley WG</AU>
<TI>Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>185</VL>
<NO>2</NO>
<PG>119-22</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:29:44 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:29:44 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11311292"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00079768" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="NCT00079768" YEAR="2004">
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00079768</AU>
<TI>Alemtuzumab to treat sporadic inclusion body myositis</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00079768</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-05-03 15:40:56 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2013-05-03 15:40:56 +0100" MODIFIED_BY="Ruth Brassington" TYPE="OTHER" VALUE="NCT00079768"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00917956" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="NCT00917956" YEAR="2009">
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00917956</AU>
<TI>Lithium in inclusion body myositis (IBM) (Li-IBM)</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00917956</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS MODIFIED="2014-11-13 23:50:39 +0000" MODIFIED_BY="Ruth  Brassington"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-05-03 15:42:14 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2013-05-03 15:42:14 +0100" MODIFIED_BY="Ruth Brassington" TYPE="OTHER" VALUE="NCT00917956"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01519349" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="NCT01519349" YEAR="">
<REFERENCE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01519349</AU>
<TI>Follistatin gene transfer to patients with Becker muscular dystrophy and sporadic inclusion body myositis</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01519349</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soueidan-1993" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Soueidan 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soueidan SA, Dalakas M</AU>
<TI>Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>5</NO>
<PG>876-9</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:32:00 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:32:00 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8492940"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-02-05 16:00:32 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-EUCTR2007_x002d_004359_x002d_12_x002d_IT" MODIFIED="2014-11-14 00:05:08 +0000" MODIFIED_BY="Ruth  Brassington" NAME="EUCTR2007-004359-12-IT" YEAR="">
<REFERENCE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>EUCTR2007-004359-12-IT</AU>
<TI>Simvastatin treatment in inclusion body myositis (IBM) - ND</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2007-004359-12-IT</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS MODIFIED="2013-05-03 10:32:13 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2013-05-03 10:32:13 +0100" MODIFIED_BY="Ruth Brassington" TYPE="OTHER" VALUE="EUCTR2007-004359-12-IT"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-14 00:05:08 +0000" MODIFIED_BY="Ruth  Brassington"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00001265" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="NCT00001265" YEAR="1265">
<REFERENCE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00001265</AU>
<TI>Study and treatment of inflammatory muscle diseases</TI>
<SO>http://www.clinicaltrials.gov/show/NCT00001265</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01423110" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="NCT01423110" YEAR="2011">
<REFERENCE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01423110</AU>
<TI>Efficacy and safety of bimagrumab/BYM338 at 52 weeks on physical function, muscle strength, mobility in sIBM patients</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01423110</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;yes&lt;/p&gt;" NOTES_MODIFIED="2015-06-05 15:15:02 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01423110</AU>
<TI>Efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositis</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01423110</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02250443</AU>
<TI>Study of long-term safety, efficacy tolerability of BYM338 in patients with sporadic inclusion body myositis</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT02250443</SO>
<YR>(accessed 6 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-14 00:05:01 +0000" MODIFIED_BY="Ruth  Brassington"/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-07-07 18:21:32 +0100" MODIFIED_BY="Ruth  Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2015-07-07 18:21:32 +0100" MODIFIED_BY="Ruth  Brassington">
<REFERENCE ID="REF-Amato-1998" MODIFIED="2014-11-13 21:24:27 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Amato 1998" TYPE="JOURNAL_ARTICLE">
<AU>Amato AA, Shebert RT</AU>
<TI>Inclusion body myositis in twins</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>2</NO>
<PG>598-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aronson-2006" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Aronson 2006" TYPE="BOOK">
<AU>Aronson JK (editor)</AU>
<TI>Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions</TI>
<SO>Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions</SO>
<YR>2006</YR>
<EN>15th</EN>
<PB>Elsevier BV</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Badrising-2000" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Badrising 2000" TYPE="JOURNAL_ARTICLE">
<AU>Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, et al</AU>
<TI>Epidemiology of inclusion body myositis in the Netherlands: a nationwide study</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>9</NO>
<PG>1385-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beaston_x002d_Blaakman-2007" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Beaston-Blaakman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Beaston-Blaakman A, Shepard DS, Stone N, Shevitz AH</AU>
<TI>Cost-effectiveness of clinical interventions for AIDS wasting</TI>
<SO>AIDS Care</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>8</NO>
<PG>996-1001</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benveniste-2010" MODIFIED="2014-11-13 21:24:54 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Benveniste 2010" TYPE="JOURNAL_ARTICLE">
<AU>Benveniste O, Hilton-Jones D</AU>
<TI>International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>6</NO>
<PG>414-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benveniste-2011" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Benveniste 2011" TYPE="JOURNAL_ARTICLE">
<AU>Benveniste O, Guiget M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al</AU>
<TI>Long-term observational study of sporadic inclusion body myositis</TI>
<SO>Brain</SO>
<YR>2011</YR>
<VL>134</VL>
<NO>Pt 1</NO>
<PG>3176-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2014" MODIFIED="2015-03-04 12:19:42 +0000" MODIFIED_BY="Ruth  Brassington" NAME="BNF 2014" TYPE="BOOK">
<AU>Joint Formulary Committee</AU>
<SO>British National Formulary</SO>
<YR>2014</YR>
<VL>68</VL>
<PB>British Medical Association and Royal Pharmaceutical Society of Great Britain</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bohan-1975" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Bohan 1975" TYPE="JOURNAL_ARTICLE">
<AU>Bohan A, Peter JB</AU>
<TI>Polymyositis and dermatomyositis (first of two parts)</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1975</YR>
<VL>292</VL>
<NO>7</NO>
<PG>344-7</PG>
<IDENTIFIERS MODIFIED="2012-05-29 19:19:08 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 19:19:08 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="1090839"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Breithaupt-2013" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Breithaupt 2013" TYPE="JOURNAL_ARTICLE">
<AU>Breithaupt M, Schmidt J</AU>
<TI>Update on treatment of inclusion body myositis</TI>
<SO>Current Rheumatology Reports</SO>
<YR>2013</YR>
<VL>15</VL>
<NO>5</NO>
<PG>329</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brooke-1983" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Brooke 1983" TYPE="JOURNAL_ARTICLE">
<AU>Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP, et al</AU>
<TI>Clinical investigation in Duchenne dystrophy 2: determination of the "power" of therapeutic trials based on the natural history</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>2</NO>
<PG>91-103</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:38:57 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:38:57 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="6343858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chalker-2000" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Chalker 2000" TYPE="BOOK">
<AU>Chalker J, Leuwer M, Lunde PKM, McInnes GT, Thelle D, Velo GP, et al</AU>
<SO>Meyler's Side Effects of Drugs</SO>
<YR>2000</YR>
<EN>14th Revised</EN>
<PB>Elsevier Science B.V.</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-2015" MODIFIED="2015-01-27 14:43:39 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Cochrane 2015" TYPE="OTHER">
<AU>The Cochrane Collaboration</AU>
<TI>Cochrane glossary</TI>
<SO>http://www.cochrane.org/glossary</SO>
<YR>(accessed 27 January 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Convery-1977" MODIFIED="2012-08-08 13:58:59 +0100" MODIFIED_BY="Ruth Brassington" NAME="Convery 1977" TYPE="JOURNAL_ARTICLE">
<AU>Convery FR, Minteer MA, Amiel D, Connett KL</AU>
<TI>Polyarticular disability: a functional assessment</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1977</YR>
<VL>58</VL>
<NO>11</NO>
<PG>494-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cortese-2013" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Cortese 2013" TYPE="JOURNAL_ARTICLE">
<AU>Cortese A, Machado P, Morrow J, Dewar L, Hiscock A, Miller A, et al</AU>
<TI>Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2013</YR>
<VL>23</VL>
<NO>5</NO>
<PG>404-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cox-2011" MODIFIED="2014-11-13 21:24:46 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Cox 2011" TYPE="JOURNAL_ARTICLE">
<AU>Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA</AU>
<TI>A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities</TI>
<SO>Brain</SO>
<YR>2011</YR>
<VL>134</VL>
<NO>Pt 11</NO>
<PG>3167-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dalakas-1993" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Dalakas 1993" TYPE="JOURNAL_ARTICLE">
<AU>Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al</AU>
<TI>A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>27</NO>
<PG>1993-2000</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:47:43 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:47:43 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8247075"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dalakas-1995" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Dalakas 1995" TYPE="JOURNAL_ARTICLE">
<AU>Dalakas MC, Illa I</AU>
<TI>Common variable immunodeficiency and inclusion body myositis - a distinct myopathy mediated by natural killer cells</TI>
<SO>Annals of Neurology</SO>
<YR>1995</YR>
<VL>37</VL>
<NO>6</NO>
<PG>806-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danon-1986" MODIFIED="2015-03-04 16:16:00 +0000" MODIFIED_BY="Ruth Brassington" NAME="Danon 1986" TYPE="JOURNAL_ARTICLE">
<AU>Danon MJ, Perurena OH, Ronan S, Manaligod JR</AU>
<TI>Inclusion body myositis associated with systemic sarcoidosis</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1986</YR>
<VL>13</VL>
<NO>4</NO>
<PG>334-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DH-2011" MODIFIED="2015-06-22 08:32:25 +0100" MODIFIED_BY="[Empty name]" NAME="DH 2011" TYPE="OTHER">
<AU>Department of Health</AU>
<TI>Clinical guidelines for immunoglobulin use: update to second edition</TI>
<SO>http://www.ivig.nhs.uk/documents/dh_129666.pdf (accessed 27 January 2015)</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dukes-2000" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Dukes 2000" NOTES="&lt;p&gt;?Chalker&lt;/p&gt;" NOTES_MODIFIED="2015-06-05 15:15:02 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" TYPE="BOOK">
<AU>Dukes MNG, Aaronson JK</AU>
<SO>Meyler's Side Effects of Drugs</SO>
<YR>2000</YR>
<EN>14th</EN>
<PB>Elsevier</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dutch-GBS-1994" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Dutch GBS 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dutch Guillain-Barre Syndrome Study Group</AU>
<TI>Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study</TI>
<SO>Annals of Neurology</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>6</NO>
<PG>749-52</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:50:07 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:50:07 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8210234"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2015-01-23 15:33:35 +0000" MODIFIED_BY="Katherine Jones" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fergusson-2005" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Fergusson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fergusson D, Hutton B, Sharma M, Tinmouth A, Wilson K, Cameron DW, et al</AU>
<TI>Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review</TI>
<SO>Transfusion</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>10</NO>
<PG>1640-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2014" MODIFIED="2014-11-13 23:51:03 +0000" MODIFIED_BY="Ruth  Brassington" NAME="GRADEpro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<YR>2014. www.gradepro.org</YR>
<PB>McMaster University</PB>
<CY>Hamilton, Ontario</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griggs-1995" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Griggs 1995" TYPE="JOURNAL_ARTICLE">
<AU>Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al</AU>
<TI>Inclusion body myositis and myopathies</TI>
<SO>Annals of Neurology</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>5</NO>
<PG>705-13</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:51:59 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:51:59 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="7486861"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gutmann-1985" MODIFIED="2015-07-07 18:21:32 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Gutmann 1985" TYPE="JOURNAL_ARTICLE">
<AU>Gutmann L, Govindan S, Riggs JE, Schochet SSJ</AU>
<TI>Inclusion body myositis and Sjogren's syndrome</TI>
<SO>Archives of Neurology</SO>
<YR>1985</YR>
<VL>42</VL>
<NO>10</NO>
<PG>1021-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-2004" MODIFIED="2014-11-13 23:39:53 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Hill 2004" TYPE="COCHRANE_REVIEW">
<AU>Hill M, Hughes T, Milford C</AU>
<TI>Treatment for swallowing difficulties (dysphagia) in chronic muscle disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-11-13 23:39:53 +0000" MODIFIED_BY="Ruth  Brassington">
<IDENTIFIER MODIFIED="2014-11-13 23:39:53 +0000" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD004303.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hilton_x002d_Jones-2010" MODIFIED="2012-08-08 13:53:46 +0100" MODIFIED_BY="Ruth Brassington" NAME="Hilton-Jones 2010" TYPE="JOURNAL_ARTICLE">
<AU>Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG</AU>
<TI>Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>2</NO>
<PG>142-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huizing-2009" MODIFIED="2015-03-04 16:16:19 +0000" MODIFIED_BY="Ruth Brassington" NAME="Huizing 2009" TYPE="JOURNAL_ARTICLE">
<AU>Huizing M, Krasnewich DM</AU>
<TI>Hereditary inclusion body myopathy: a decade of progress</TI>
<SO>Biochimica et Biophysica Acta</SO>
<YR>2009</YR>
<VL>1792</VL>
<NO>9</NO>
<PG>881-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-2008" MODIFIED="2014-11-13 21:33:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Jackson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L</AU>
<TI>Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2008</YR>
<VL>37</VL>
<NO>4</NO>
<PG>473&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khraishi-1992" MODIFIED="2015-03-04 16:16:22 +0000" MODIFIED_BY="Ruth Brassington" NAME="Khraishi 1992" TYPE="JOURNAL_ARTICLE">
<AU>Khraishi MM, Jay V, Keystone EC</AU>
<TI>Inclusion body myositis in association with vitamin B12 deficiency and Sjögren's syndrome</TI>
<SO>Journal of Rheumatology</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>2</NO>
<PG>306-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lane-1985" MODIFIED="2015-03-04 16:16:29 +0000" MODIFIED_BY="Ruth Brassington" NAME="Lane 1985" TYPE="JOURNAL_ARTICLE">
<AU>Lane RJ, Fulthorpe JJ, Hudgson P</AU>
<TI>Inclusion body myositis: a case with associated collagen vascular disease responding to treatment</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1985</YR>
<VL>48</VL>
<NO>3</NO>
<PG>270-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindberg-1990" MODIFIED="2014-11-13 21:31:43 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Lindberg 1990" TYPE="JOURNAL_ARTICLE">
<AU>Lindberg C, Persson L, Oldfors A, Soderstrom T, Hedstrom A, Bjorkander J</AU>
<TI>Inclusion body myositis: association with immunodeficiency</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1990</YR>
<VL>98 (Suppl)</VL>
<PG>178</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loke-2007" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Loke 2007" TYPE="JOURNAL_ARTICLE">
<AU>Loke YK, Price D, Herxheimer A; Cochrane Adverse Events Methods Group</AU>
<TI>Systematic reviews of adverse effects: framework for a structured approach</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>32</PG>
<IDENTIFIERS MODIFIED="2015-01-27 15:07:32 +0000" MODIFIED_BY="Ruth  Brassington">
<IDENTIFIER MODIFIED="2015-01-27 15:07:32 +0000" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1186/1471-2288-7-32"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lotz-1989" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Lotz 1989" TYPE="JOURNAL_ARTICLE">
<AU>Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ</AU>
<TI>Inclusion body myositis. Observations in 40 patients</TI>
<SO>Brain</SO>
<YR>1989</YR>
<VL>112</VL>
<NO>Pt 3</NO>
<PG>727-47</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:55:30 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:55:30 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="2543478"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Machado-2013b" MODIFIED="2014-11-13 23:32:57 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Machado 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Machado P, Brady S, Hanna MG</AU>
<TI>Update in inclusion body myositis</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2013</YR>
<VL>25</VL>
<NO>6</NO>
<PG>763&#8211;71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Needham-2008" MODIFIED="2014-11-13 23:51:48 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Needham 2008" TYPE="JOURNAL_ARTICLE">
<AU>Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia F</AU>
<TI>Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis</TI>
<SO>Journal of Clinical Neuroscience</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>12</NO>
<PG>1350-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oldfors-1995" MODIFIED="2015-03-04 16:16:41 +0000" MODIFIED_BY="Ruth Brassington" NAME="Oldfors 1995" TYPE="JOURNAL_ARTICLE">
<AU>Oldfors A, Moslemi AR, Fyhr IM, Holme E, Larsson NG, Lindberg C</AU>
<TI>Mitochondrial DNA deletions in muscle fibers in inclusion body myositis</TI>
<SO>Journal of Neuropathology &amp; Experimental Neurology</SO>
<YR>1995</YR>
<VL>54</VL>
<NO>4</NO>
<PG>581-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pfeffer-2012" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Pfeffer 2012" TYPE="COCHRANE_REVIEW">
<AU>Pfeffer G, Majamaa K, Turnbull, DM, Thorburn D, Chinnery PF</AU>
<TI>Treatment for mitochondrial disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-11-13 23:31:30 +0000" MODIFIED_BY="Ruth  Brassington">
<IDENTIFIER MODIFIED="2014-11-13 23:31:30 +0000" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD004426.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Phillips-2000" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Phillips 2000" TYPE="JOURNAL_ARTICLE">
<AU>Phillips BA, Zilko PJ, Mastaglia FL</AU>
<TI>Prevalence of sporadic inclusion body myositis in Western Australia</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>6</NO>
<PG>970-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-11-13 23:53:37 +0000" MODIFIED_BY="Ruth  Brassington" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riggs-1984" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Riggs 1984" TYPE="JOURNAL_ARTICLE">
<AU>Riggs JE, Schochet SSJ, Gutmann L, McComas CF, Rogers JS</AU>
<TI>Inclusion body myositis and chronic immune thrombocytopenia</TI>
<SO>Archives of Neurology</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>1</NO>
<PG>93-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rose-2001" MODIFIED="2014-11-13 21:38:56 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Rose 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rose MR, McDermott MP, Thornton CA, Palenski C, Martens WB, Griggs RC</AU>
<TI>A prospective natural history study of inclusion body myositis: implications for clinical trials</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>3</NO>
<PG>548-50</PG>
<IDENTIFIERS MODIFIED="2012-05-29 18:59:50 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2012-05-29 18:59:50 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="11502935"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rygiel-2014" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Rygiel 2014" TYPE="JOURNAL_ARTICLE">
<AU>Rygiel KA, Miller J, Grady, JP, Rocha MC, Taylor RW, Turnbull DM</AU>
<TI>Mitochondrial and inflammatory changes in sporadic inclusion body myositis</TI>
<SO>Neuropathology and Applied Neurobiology</SO>
<YR>2015</YR>
<VL>41</VL>
<NO>3</NO>
<PG>288-303</PG>
<IDENTIFIERS MODIFIED="2015-01-27 15:02:04 +0000" MODIFIED_BY="Ruth  Brassington">
<IDENTIFIER MODIFIED="2015-01-27 15:02:04 +0000" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1111/nan.12149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Santorelli-1996" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Santorelli 1996" TYPE="JOURNAL_ARTICLE">
<AU>Santorelli FM, Sciacco M, Tanji K, Shanske S, Vu TH, Golzi V, et al</AU>
<TI>Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients</TI>
<SO>Annals of Neurology</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>6</NO>
<PG>789-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2012" MODIFIED="2015-01-27 15:00:19 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Smith 2012" TYPE="JOURNAL_ARTICLE">
<AU>Smith GI, Reeds DN, Hall AM, Chambers KT, Finck BN, Mittendorfer B</AU>
<TI>Sexually dimorphic effects of aging on skeletal muscle protein synthesis</TI>
<SO>Biology of Sex Differences</SO>
<YR>2012</YR>
<VL>3</VL>
<NO>1</NO>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soden-1994" MODIFIED="2015-03-04 16:16:54 +0000" MODIFIED_BY="Ruth Brassington" NAME="Soden 1994" TYPE="JOURNAL_ARTICLE">
<AU>Soden M, Boundy K, Burrow D, Blumbergs P, Ahern M</AU>
<TI>Inclusion body myositis in association with rheumatoid arthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>21</VL>
<PG>344-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tateyama-2003" MODIFIED="2014-11-13 21:25:36 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Tateyama 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tateyama M, Saito N, Fujihara K, Shiga Y, Takeda A, Narikawa K, et al</AU>
<TI>Familial inclusion body myositis: a report on two Japanese sisters</TI>
<SO>Internal Medicine (Tokyo, Japan)</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>10</NO>
<PG>1035-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verschuuren-1997" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Verschuuren 1997" TYPE="BOOK_SECTION">
<AU>Verschuuren JJ, Badrising UA, Wintzen AR, van Engelen BGM, van der Hoeven H, et al</AU>
<TI>Inclusion body myositis</TI>
<SO>Diagnostic Criteria for Neuromuscular Disorders</SO>
<YR>1997</YR>
<PG>81&#8211;4</PG>
<ED>Emery AEH</ED>
<PB>Royal Society of Medicine Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Voet-2013" MODIFIED="2014-11-13 21:25:52 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Voet 2013" TYPE="COCHRANE_REVIEW">
<AU>Voet NBM, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BGM, Geurts ACH</AU>
<TI>Strength training and aerobic exercise training for muscle disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>7</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003907.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington">
<REFERENCE ID="REF-Rose-1999" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Rose 1999" TYPE="COCHRANE_PROTOCOL">
<AU>Rose MR, Griggs R, Dalakas M</AU>
<TI>Immunotherapy for inclusion body myositis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-12-20 11:40:40 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2012-12-20 11:40:40 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001555"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rose-2007" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Rose 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Rose MR, Dalakas M, Griggs R, Leong K, Miller J, Walter MC</AU>
<TI>Treatment for inclusion body myositis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-12-20 11:37:18 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2012-12-20 11:37:18 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001555.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rose-2014" MODIFIED="2015-06-05 15:15:02 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Rose 2014" TYPE="COCHRANE_PROTOCOL">
<AU>Rose MR, Dalakas M, Griggs R, Leong K, Miller J, Walter MC, Jones K</AU>
<TI>Treatment for inclusion body myositis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2015-02-25 10:19:28 +0000" MODIFIED_BY="Ruth  Brassington">
<IDENTIFIER MODIFIED="2015-02-25 10:19:28 +0000" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001555.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-11-13 23:46:23 +0000" MODIFIED_BY="Ruth  Brassington"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-07-07 18:17:56 +0100" MODIFIED_BY="Ruth  Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-07-07 18:17:56 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Badrising-2002">
<CHAR_METHODS MODIFIED="2014-12-02 11:29:50 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Randomised, placebo-controlled, parallel-group, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>44 randomised participants (11 female)</P>
<P>Treated group mean age: 68 ± 8 years; mean duration of symptoms: 9 ± 5 years</P>
<P>Placebo group mean age: 69 (± 7) years; mean duration of symptoms: 11 (± 7) years</P>
<P>
<I>Inclusion criteria:</I> diagnostic criteria for definite or probable IBM; sufficient residual muscle strength to evaluate changes; absence of risk factors for MTX-induced toxicity; no use of immunosuppressive therapy for at least 6 weeks before the study; no previous use of MTX; no use of medication interfering with MTX pharmacokinetics or pharmacodynamics; absence of severe dysphagia interfering with oral medication use.</P>
<P>
<I>Exclusion criteria</I>: unspecified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-14 16:22:53 +0000" MODIFIED_BY="Katherine Jones">
<P>MTX versus placebo for 48 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>
<I>Primary outcome measure(s)</I>
</P>
<UL>
<LI>Change in QMT sum scores</LI>
</UL>
<P>14 muscle groups were tested, but the actual muscles tested was not reported.</P>
<P>
<I>Secondary outcome measure(s)</I>
<BR/>
</P>
<UL>
<LI>Change in MMT sum scores</LI>
</UL>
<P>32 muscle groups were tested by MMT using a 5-point MRC scale, but the actual muscles tested was not reported.</P>
<UL>
<LI>Change in level of function, assessed by 3 activity scales: Barthel Index; Rivermead Mobility Index; Brooke's grading system</LI>
<LI>Change in participants&#8217; subjective assessment of muscle strength</LI>
<LI>Change in serum CK activity levels</LI>
<LI>Adverse event</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-02 17:28:41 +0000" MODIFIED_BY="Katherine Jones"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Dalakas-1997">
<CHAR_METHODS MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Randomised, double-blind, placebo-controlled, cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>19 randomised participants (gender unspecified)</P>
<P>IVIg group mean age: 61.2 (42 to 74) years; mean disease duration: 5.6 (3 to 10) years</P>
<P>Placebo group mean age: 66.1 (35 to 76) years; mean disease duration: 7.4 (4 to 16) years</P>
<P>
<I>Inclusion criteria</I>: diagnostic criteria of IBM; active disease characterised by progressive muscle weakness; impaired ability to perform fully the ADL; absence of another systemic illness.</P>
<P>
<I>Exclusion criteria</I>: coronary artery disease; immunoglobulin A deficiency; kidney dysfunction; bedridden patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>IVIg versus placebo for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-22 04:31:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome measure(s)</I>
</P>
<UL>
<LI>Change in compound MMT scores</LI>
</UL>
<P>MMT was completed for 26 muscle groups and muscle group actions bilaterally: deltoid; biceps brachii; triceps brachii; brachioradialis; wrist extensors; wrist flexors; iliopsoas; gluteus maximus; quadriceps femoris; hamstrings; neck, finger and foot extension and flexion. However, analysis was completed on only 10/26 muscle groups as data were not always available. The 10 selected muscle groups were graded using a modified (0 to 10) MRC scale (<LINK REF="REF-Brooke-1983" TYPE="REFERENCE">Brooke 1983</LINK>), with a total maximal MRC score of 200.</P>
<P>
<I>Secondary outcome measure(s)</I>
</P>
<UL>
<LI>Change in QMT sum scores</LI>
<LI>Change in upper and lower limb MRC scores from baseline (limb by limb analysis)</LI>
<LI>Change in participants&#8217; assessment of their response to therapy</LI>
</UL>
<P>Swallowing function was also investigated by ultrasound assessment of the duration of both wet and dry swallowing.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Dalakas-2001">
<CHAR_METHODS MODIFIED="2014-12-02 11:30:06 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Randomised, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>37 randomised participants (gender unspecified)</P>
<P>Treated group mean age: 68.21 (no SD or range) years</P>
<P>Placebo group mean age: 68.35 (no SD or range) years. Duration of symptoms not given.</P>
<P>
<I>Inclusion criteria</I>: diagnostic criteria for sporadic IBM; active disease characterised by progressive muscle weakness that impaired ability to perform independently various activities of daily living such as walking without falls, dressing, buttoning, or climbing up stairs; ambulatory independently or with assistance</P>
<P>
<I>Exclusion criteria</I>: wheelchair-bound patients; coronary artery disease; immunoglobulin A deficiency; kidney dysfunction; any systemic illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-16 13:47:16 +0000" MODIFIED_BY="Katherine Jones">
<P>IVIg and prednisone versus placebo and prednisone for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington">
<P>
<I>Primary outcome measure(s)</I>
</P>
<UL>
<LI>Change in MMT sum scores</LI>
</UL>
<P>MMT was completed for 13 muscle groups and muscle group actions bilaterally (although 12 specified): deltoid; biceps brachii; triceps brachii; brachioradialis; wrist extensors; wrist flexors; iliopsoas; gluteus maximus; quadriceps femoris; hamstrings; foot extension or flexion. Muscle strength was graded on a modified (0 to 10) MRC scale (<LINK REF="REF-Brooke-1983" TYPE="REFERENCE">Brooke 1983</LINK>).</P>
<UL>
<LI>Change in QMT sum scores</LI>
</UL>
<P>QMT was examined for the following muscle group actions: shoulder abduction; forearm flexion and extension; hip flexion; leg extension and flexion; foot extension.</P>
<P>
<I>Secondary outcome measure(s)</I>
</P>
<UL>
<LI>Change in participants&#8217; assessment of their response to therapy, categorised as "felt better and performed more", "felt weaker", or "no change"</LI>
</UL>
<P>Histological features were also assessed in repeated biopsies.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-02 17:29:11 +0000" MODIFIED_BY="Katherine Jones"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Leff-1993">
<CHAR_METHODS MODIFIED="2014-12-02 11:28:25 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Open, randomised, cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington">
<P>11 randomised participants (2 female)</P>
<P>Mean age: 54 ± 8 years (calculated from table). Duration of symptoms not given.</P>
<P>
<I>Inclusion criteria</I>: Bohan and Peter's criteria for definite myositis and biopsy-proven IBM with typical light microscopic changes; signs of active inflammatory muscle disease; progressive weakness refractory to therapy; weak enough to have at least 2 muscle groups graded 3 or less on a scale of 0 to 5 by manual muscle testing; reduction of at least 1 functional level below normal in at least 1 activity group on an assessment of the ADL for functional capabilities.</P>
<P>
<I>Exclusion criteria</I>: severe intercurrent illness; cancer; infection; past history of alcohol abuse; pregnancy; abnormal renal or hepatic function. "Concurrent use of alcohol or nonsteroidal anti-inflammatory drugs was forbidden".</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-25 18:57:46 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Azathioprine and MTX versus MTX for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington">
<UL>
<LI>Categorical change in muscle strength, defined as "improvement", "stabilisation", or "worsening", based on MMT scores</LI>
</UL>
<P>Investigators graded MMT using a 6-point MRC scale. They examined 7 muscle groups or muscle group actions bilaterally: gluteus maximus and medius; iliopsoas; quadriceps; deltoid; trapezius; biceps brachialis; as well as neck flexors and extensors unilaterally. The maximum MRC sum score was reported to be 80. Trial authors defined "improvement" and "worsening" as a change of at least 1 MMT grade in 2 muscle groups and a net change in score of at least 2 points on MMT. They defined "stabilisation" as any result other than "improvement" or "worsening".</P>
<UL>
<LI>Categorical change in level of function, defined as "improvement", "stabilisation", or "worsening", using an ADL score</LI>
</UL>
<P>ADL were assessed using a modified Convery Assessment Scale (<LINK REF="REF-Convery-1977" TYPE="REFERENCE">Convery 1977</LINK>); 4 items relating to feeding, grooming, wheelchair use, and perineal care were deleted from the original questionnaire, and a question about reaching above eye level was added into the scale. "Improvement" was defined as a net increase of at least 1 functional level in at least 1 category in the ADL score. A "worsening" clinical status was defined as similar decreases in ADL scores, and "stabilisation" was any result other than "improvement" or "worsening".</P>
<P>No primary outcome measure was specified. Other pathophysiological measures included laboratory investigations (CK, aldolase, lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase levels), gradings for MRI and inflammatory changes in muscle biopsies.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Single-centre study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-23 21:41:41 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Lindberg-2003">
<CHAR_METHODS MODIFIED="2014-12-02 11:30:25 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Open randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington">
<P>11 randomised participants (3 female)</P>
<P>ATG group mean age: 72 ± 7.0 years; mean duration of disease: 7.2 ± 3.4 years</P>
<P>MTX group mean age: 64.8 ± 4.0 years; mean duration of disease: 9.8 ± 5.0 years</P>
<P>
<I>Inclusion criteria</I>: the morphological criteria of IBM diagnosis included inflammation, rimmed vacuoles and intracellular amyloid deposits or 15 to 20 nm filaments</P>
<P>
<I>Exclusion</I> <I>criteria:</I> unspecified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-23 21:41:41 +0100" MODIFIED_BY="Ruth  Brassington">
<P>MTX and ATG versus MTX (plus leucovorin) for 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-23 21:41:41 +0100" MODIFIED_BY="Ruth  Brassington">
<P>
<I>Primary outcome measure(s)</I>
</P>
<UL>
<LI>Change in muscle strength using QMT and handgrip</LI>
</UL>
<P>The primary outcome measure was the relative change of mean overall muscle strength, expressed as a percentage. Maximal voluntary muscle strength was measured with a handheld myometer and was used to assess the following muscle group actions: elbow flexion and extension; wrist dorsal extension; hip flexion; knee extension. Handgrip mean volumetric contraction was also quantitated using hand-held myometry.</P>
<P>Other outcome measures were blood levels of CK and T lymphocyte subsets. Muscle biopsies were done at the start and end of the trial, and inflammation in the tissue was graded visually.</P>
<P>MVIC was measured using a hand-held myometer.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:30:27 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Machado-2013">
<CHAR_METHODS MODIFIED="2014-12-05 10:27:24 +0000" MODIFIED_BY="Ruth Brassington">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-16 16:40:18 +0000" MODIFIED_BY="Ruth Brassington">
<P>24 participants (7 female) fulfilling Griggs criteria for definite or probable IBM</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-16 13:48:13 +0000" MODIFIED_BY="Katherine Jones">
<P>Arimoclomol versus placebo for 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-05 12:15:52 +0000" MODIFIED_BY="Ruth  Brassington">
<P>
<I>Primary outcome(s)</I>
</P>
<UL>
<LI>Adverse event reporting (safety and tolerability)</LI>
</UL>
<P>
<I>Secondary outcomes(s)</I>
</P>
<UL>
<LI>IBM functional rating scale (IBMFRS)</LI>
<LI>MMT</LI>
<LI>MVICT</LI>
<LI>Fat-free mass percentage (DEXA)</LI>
<LI>HSP70 levels in muscle biopsy tissue (adjusted to myosin content)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-17 11:30:27 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-23 21:41:43 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Muscle-Study-Group-2001">
<CHAR_METHODS MODIFIED="2015-06-23 21:41:43 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Randomised, double-blind, placebo-controlled, parallel-group trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:43 +0100" MODIFIED_BY="Ruth  Brassington">
<P>30 randomised participants (11 female)</P>
<P>IFN beta-1a (Avonex)-treated group: mean age: 65.7 ± 9.3 years; age at onset: 57.0 ± 10.0 years</P>
<P>Placebo-treated group mean age: 65.9 ± 10.3 years; age at onset: 57.3 ± 9.3 years</P>
<P>
<I>Inclusion criteria</I>: diagnostic criteria for definite or probable IBM; able to walk independently 15 feet (cane, walkers, orthoses allowed); age &gt; 30 to &#8804; 80 years; women of childbearing potential must have a reliable method of birth control; must not have received immunosuppressive agents for at least 3 months prior to enrolment; able to give informed consent.</P>
<P>
<I>Exclusion criteria</I>: presence of any one of the following medical conditions: uncontrolled diabetes mellitus; congestive heart disease; symptomatic cardiomyopathy; symptomatic coronary artery disease; cancer other than skin cancer &lt; 5 years previously; multiple sclerosis or other chronic serious medical illness; presence of any of the following on routine blood screening: white blood cell count &lt; 3000, platelets &lt; 100,000, hematocrit &lt; 30%, blood urea nitrogen &gt; 30 mg%, symptomatic liver disease with serum albumin &lt; 3 g/dL, prothrombin time or partial thromboplastin time &gt; upper range of normal; presence of major depression on day of screening or history of attempted suicide; forced vital capacity &lt; 50% of predicted; pregnancy or lactating; history of noncompliance with other therapies; other disease that required immunosuppressive therapy within the last 12 months; coexistence of other neuromuscular disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-02 17:30:57 +0000" MODIFIED_BY="Katherine Jones">
<P>IFN beta-1a versus placebo for 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-23 21:41:43 +0100" MODIFIED_BY="Ruth  Brassington">
<UL>
<LI>Change in muscle strength using QMT, handgrip, and MMT</LI>
</UL>
<P>QMT was performed using the QMA system; 5 muscle groups or muscle group actions were tested on each side: biceps; triceps; quadriceps; hamstrings, and ankle dorsiflexion. These results were expressed as the average number of SD units from predicted normal strength, given the age, gender, and height of the participant. Handgrip MVIC was also quantitated using myometry but with a hand-held device rather than the fixed myometer used for other muscle tests.</P>
<P>MMT tested a total of 34 (unspecified) muscle groups using a 6-point MRC scale.</P>
<UL>
<LI>Change in lean body mass using DEXA</LI>
<LI>Change in level of function, assessed by the following: Purdue pegboard test; time to rise from chair; time to walk 15 feet; ALS-FRS; components of the SF-36</LI>
<LI>Change in participants&#8217; reporting of symptoms on the Beck Depression Inventory</LI>
<LI>Adverse events</LI>
</UL>
<P>Measurements of biologic effects of treatment were also performed: serum neutralising antibodies and serum neopterin levels.</P>
<P>No primary outcome measure was specified.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-30 11:56:47 +0000" MODIFIED_BY="Ruth Brassington"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-22 05:51:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muscle-Study-Group-2004">
<CHAR_METHODS MODIFIED="2015-06-05 15:14:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Randomised, double-blind, placebo-controlled, parallel-group trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-22 05:51:37 +0100" MODIFIED_BY="[Empty name]">
<P>30 randomised participants (11 female)</P>
<P>IFN beta-1a (Avonex)-treated group mean age: 64.9 ± 6.9 years; age at onset: 57.5 ± 8.4 years</P>
<P>Placebo-treated group mean age: 64.9 ± 7.3 years; age at onset: 55.5 ± 7.1 years</P>
<P>
<I>Inclusion</I> and <I>Exclusion criteria</I> as per <LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-02 17:31:18 +0000" MODIFIED_BY="Katherine Jones">
<P>IFN beta-1a versus placebo for 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-05 15:17:41 +0100" MODIFIED_BY="Ruth  Brassington">
<P>As per <LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-30 11:56:55 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Rutkove-2002">
<CHAR_METHODS MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Block-randomised, double-blind, placebo-controlled, cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington">
<P>19 randomised participants, but baseline characteristics provided for 16 participants who completed the trial (2 female). Overall mean age: 68.5 years (no SD or range). Mean duration of disease unspecified.</P>
<P>
<I>Inclusion criteria</I>: pathological criteria for a definite diagnosis of IBM; consistent clinical and laboratory features including prominent weakness of quadriceps, weakness of wrist flexors greater than extensors, age older than 40 years, and elevated serum CK, without evidence of other significant neurologic problems.</P>
<P>
<I>Exclusion criteria</I>: history of prostate or breast cancer; haemodialysis; congestive heart failure; atypical or restricted forms of IBM; a coexisting neuromuscular condition; uncontrolled hypertension; history of substance abuse; currently taking warfarin; IVIg use within 2 months or currently on an immunosuppressive drug regimen including corticosteroids.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-16 13:49:42 +0000" MODIFIED_BY="Katherine Jones">
<P>Oxandrolone versus placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington">
<P>
<I>Primary outcome measure(s)</I>
</P>
<UL>
<LI>Change in QMT sum scores, using MVICT</LI>
</UL>
<P>Using a fixed myometer, whole body MVICT was measured bilaterally for muscle group actions including: shoulder flexion and extension; elbow flexion and extension; knee flexion and extension; foot dorsiflexion. Handgrip strength was also evaluated quantitatively by MVICT but using a hand-held myometer.</P>
<P>
<I>Secondary outcome measure(s)</I>
</P>
<UL>
<LI>Change in MMT sum scores</LI>
</UL>
<P>Whole body MMT was graded using an expanded 1-5 MRC scale. 13 bilateral muscle group actions were assessed: shoulder external rotation and abduction; elbow flexion and extension; wrist flexion and extension; hip flexion, abduction and presumed adduction (written as "abduction" in publication); knee flexion and extension; foot plantar flexion and dorsiflexion. 2 unilateral muscle group actions were also assessed: head flexion and extension. The maximum reported MRC score was 140.</P>
<UL>
<LI>Change in upper and lower extremity MVICT scores</LI>
<LI>Change in upper and lower extremity MMT scores</LI>
<LI>Change in level of function, assessed by the timed get-up-and-go test, 6-minute walk, and stair climb</LI>
<LI>Change in lean body mass (skin fold measurements) and body mass index</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Walter-2000">
<CHAR_METHODS MODIFIED="2015-06-23 21:41:45 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Block-randomised, double-blind, placebo-controlled, cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:45 +0100" MODIFIED_BY="Ruth  Brassington">
<P>22 randomised participants (8 female). Mean age: 59 ± 14 years; disease duration: 1 to 14 years</P>
<P>
<I>Inclusion criteria</I>: clinical and histological criteria for definite sporadic IBM.</P>
<P>
<I>Exclusion criteria</I>: stabilisation or improvement on current immunosuppressive therapy; severe coronary heart disease; renal insufficiency; intolerance to homologous immunoglobulins or human serum proteins; other relevant neuromuscular disorders; those confined to bed or wheelchair for longer than 1 year.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-23 21:41:45 +0100" MODIFIED_BY="Ruth  Brassington">
<P>IVIg versus placebo for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>
<I>Primary outcome measure(s)</I>
</P>
<UL>
<LI>Change in MMT sum scores</LI>
</UL>
<P>MMT was completed for the following muscle groups and muscle group actions bilaterally: deltoid; biceps brachii; triceps brachii; brachioradialis; hand flexion and extension; finger flexion and extension; knee flexion and extension; foot flexion and extension. 2 muscle group actions were tested unilaterally: neck flexion and extension. Muscle strength was graded on a 0-6 MRC scale, with a total maximal score of 180. The change in upper and lower extremity strength was also analysed as a subgroup.</P>
<UL>
<LI>Change in the Neuromuscular Symptom and Disability Functional Score</LI>
</UL>
<P>
<I>Secondary outcome measure(s)</I>
</P>
<UL>
<LI>Change in arm outstretched time</LI>
<LI>Change in participant's assessment of improvement using visual analogue scales for weakness and daily activities</LI>
</UL>
<P>Electromyographic tests to assess graded change in spontaneous activity were also performed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-16 13:50:01 +0000" MODIFIED_BY="Katherine Jones"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL: activities of daily living</P>
<P>ALS-FRS: Amyotrophic Lateral Sclerosis Functional Rating Scale</P>
<P>ATG: anti-T lymphocyte immunoglobulin</P>
<P>CK: creatine kinase</P>
<P>DEXA: dual energy X-ray absorptiometry</P>
<P>HSP70: 70 kilodalton heat shock protein</P>
<P>IFN: interferon</P>
<P>IVIg: intravenous immunoglobulin</P>
<P>MTX: methotrexate</P>
<P>MMT: manual muscle testing</P>
<P>MRC: Medical Research Council</P>
<P>MRI: magnetic resonance imaging</P>
<P>MVICT: maximal voluntary isometric contraction testing</P>
<P>QMA system: Quantitative Muscle Assessment system</P>
<P>QMT: quantitative muscle testing</P>
<P>SD: standard deviation</P>
<P>SF-36: Short Form-36 Health Survey</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:21:54 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-ACTRN12614000082606">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:21:54 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:21:55 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Amato-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:21:55 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-05 15:14:18 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Arnardottir--2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-05 15:14:18 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial. Exercise-based intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:22:03 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Danon-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:22:03 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-05 15:14:19 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Heikkill_x00e4_-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-05 15:14:19 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial. Exercised-based intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:22:09 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Joffe-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:22:09 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:22:09 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Kosmidis-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:22:09 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:22:10 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Lindberg-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:22:10 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:22:11 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Mastaglia-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:22:11 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Non randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Mowzoon-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial (1 participant with IBM)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:22:12 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-NCT00079768">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:22:12 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:22:13 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-NCT00917956">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:22:13 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:22:14 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-NCT01519349">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:22:14 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 16:22:15 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Soueidan-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 16:22:15 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>IBM: inclusion body myositis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-02-05 16:00:32 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-06-23 22:33:14 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-06-23 22:33:14 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-EUCTR2007_x002d_004359_x002d_12_x002d_IT">
<CHAR_STUDY_NAME MODIFIED="2015-06-22 06:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>Simvastatin treatment in inclusion body myositis (IBM)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Randomised, controlled, open, parallel-group trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>People affected by IBM (diagnosis based on clinical, radiological, and pathological data); males and females; aged 18 to 80 years; patients able to give informed consent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-05 15:14:19 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Oral simvastatin </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Main objective: safety and tolerability of simvastatin</P>
<P>Primary endpoint(s): improvement in functional indices<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington">
<P>2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-06-05 15:14:21 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Italian Medical Agency</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-06-23 22:33:14 +0100" MODIFIED_BY="Ruth  Brassington">
<P>-</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-NCT00001265">
<CHAR_STUDY_NAME MODIFIED="2015-03-14 16:29:41 +0000" MODIFIED_BY="Katherine Jones">
<P>Study and treatment of inflammatory muscle diseases</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-03-14 16:29:33 +0000" MODIFIED_BY="Katherine Jones">
<P>Observational study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>People aged 16 and over with known or suspected idiopathic inflammatory myopathies or people with other connective tissue diseases with weakness or myalgia for an inflammatory myopathy or other muscle process</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-16 16:22:55 +0000" MODIFIED_BY="Ruth  Brassington">
<P>None specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-16 16:22:56 +0000" MODIFIED_BY="Ruth  Brassington">
<P>None specified</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-12-17 11:51:13 +0000" MODIFIED_BY="Katherine Jones">
<P>August 1991</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-02 17:32:24 +0000" MODIFIED_BY="Katherine Jones">
<P>National Institutes of Health Clinical Center</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-02 17:32:25 +0000" MODIFIED_BY="Katherine Jones"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-06-23 21:41:47 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-NCT01423110">
<CHAR_STUDY_NAME MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Double-blind, parallel assignment, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-23 21:41:47 +0100" MODIFIED_BY="Ruth  Brassington">
<P>People aged 40 to 80 years old with sporadic IBM<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-16 16:23:01 +0000" MODIFIED_BY="Ruth  Brassington">
<P>BYM338 or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-17 09:43:50 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Primary outcome measures: effect of BYM338 on thigh muscle volume by MRI (after 8 weeks' treatment): change in thigh muscle volume<BR/>Secondary outcome measures: effect of BYM338 on muscle function by timed get-up-and-go test (after 8 weeks' treatment): change in muscle function measured on scale by test results<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington">
<P>August 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Novartis Pharmaceuticals</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Study identifier: CBYM338X2205</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>IBM: inclusion body myositis; MRI: magnetic resonance imaging</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-07-07 18:17:56 +0100" MODIFIED_BY="Ruth  Brassington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-05 15:13:35 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Badrising-2002">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process: "Patients were randomly assigned, using a computer-generated schedule...The randomization schedule used random numbers in permuted blocks of 4".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-05 15:13:40 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Dalakas-1997">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process: "The patients were assigned to receive IVIg or placebo by a block-randomization procedure".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-05 15:13:45 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Dalakas-2001">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process: "The patients were assigned to receive IVIg or placebo by a block-randomization procedure".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Leff-1993">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:41 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Machado-2013">
<DESCRIPTION>
<P>Stated to be randomised. No further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-16 16:20:13 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Muscle-Study-Group-2001">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process: "a computer-generated randomization plan developed by the Biostatistics Centre at the University of Rochester (NY). The randomization was stratified by center and included blocking"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-17 11:32:24 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Muscle-Study-Group-2004">
<DESCRIPTION>
<P>The investigators reference a random component in the sequence generation process: "Randomization procedures were identical to those used in our previous trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-17 09:43:03 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Rutkove-2002">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process: "...a four-person block-randomization procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Walter-2000">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process: "block-randomization procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-05 15:13:36 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Badrising-2002">
<DESCRIPTION>
<P>Central allocation: "The code was concealed by the pharmacy and broken after assessment of all patients".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-05 15:13:41 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Dalakas-1997">
<DESCRIPTION>
<P>Central allocation: "Randomization was performed at the pharmacy".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-05 15:13:45 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Dalakas-2001">
<DESCRIPTION>
<P>Central allocation: "Randomization was performed at the pharmacy".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Leff-1993">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:41 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Machado-2013">
<DESCRIPTION>
<P>Abstract only. Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-17 09:42:12 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Muscle-Study-Group-2001">
<DESCRIPTION>
<P>Central allocation: "Only the biostatistics programmer and the pharmacist at each site...had access to the treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-17 11:32:25 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Muscle-Study-Group-2004">
<DESCRIPTION>
<P>Central allocation: "...only the biostatistics programmer and site pharmacists had access to the treatment assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-16 16:21:10 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Rutkove-2002">
<DESCRIPTION>
<P>Central allocation: pharmacy-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Walter-2000">
<DESCRIPTION>
<P>Method of allocation concealment not described, but "the randomization code was not broken until all patients completed the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-01-30 19:12:30 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" NO="12">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-12.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2015-06-05 15:13:36 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Badrising-2002">
<DESCRIPTION>
<P>Blinding procedures undertaken following allocation concealment: "To enhance blinding, all patients were requested to decrease their 20mg dosage by 2.5mg without explanation after routine laboratory evaluations for 3 months. After blood assessments, the dosage was restored to 20mg per week".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2015-06-05 15:13:41 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Dalakas-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement: "The principal investigator, the physicians, nurses, physical therapists, and statistician were unaware of which treatment was administered" but "Sixteen of the 19 patients correctly identified the period during which they received placebo or IVIg".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Dalakas-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement: "The principal investigator, the physicians, nurses, physical therapists, and statisticians were unaware of which type of the IV infusion was administered" and based on participants' own assessment "no apparent signs to unblind any of the patients were observed." However, only the assessor of QMT and not MMT is confirmed to have remained blinded, suggesting that blinding of key personnel could have been broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Leff-1993">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Machado-2013">
<DESCRIPTION>
<P>"Double-blind, placebo-controlled". No further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2015-06-23 21:41:43 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Muscle-Study-Group-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement: active injections may have been more likely to cause local reactions; all participants treated with non-steroidal anti-inflammatory drug to mask systemic reactions from active compound.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Muscle-Study-Group-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement: active treatment injections may have been more likely to cause local reactions; all participants treated with non-steroidal anti-inflammatory drug to mask systemic reactions from active compound.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Rutkove-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement: blinding not described fully following allocation concealment: "the principal investigator, coinvestigators, nurses and physical therapists were blinded to the treatment assignments...and the randomization code was maintained in the hospital research pharmacy", but 8/13 participants "...correctly reported that they were on drug..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Walter-2000">
<DESCRIPTION>
<P>Insufficient information to permit judgement: blinding not described fully following allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" NO="13">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2015-06-05 15:13:37 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Badrising-2002">
<DESCRIPTION>
<P>Blinding of outcome assessment described following allocation concealment: "A blinded assessor (JV) monitored patients with regard to treatment schedules...Another blinded assessor (UB) evaluated the QMT and MMT measurements and patients' opinions concerning the state of muscle weakness".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-11-13 17:51:23 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Dalakas-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement: blinding not described fully following allocation concealment, as above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2015-06-05 15:13:46 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Dalakas-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement: as above, only the assessor of QMT is confirmed to have "remained blinded".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Leff-1993">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Machado-2013">
<DESCRIPTION>
<P>"Double-blind, placebo-controlled". No further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2015-06-23 21:41:43 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Muscle-Study-Group-2001">
<DESCRIPTION>
<P>Insufficent information to permit judgement: blinding of assessors not described fully following allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Muscle-Study-Group-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement: blinding of assessors not described fully following allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2015-03-17 09:43:04 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Rutkove-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement: possible unblinding of outcome assessment following allocation concealment indicated, as above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Walter-2000">
<DESCRIPTION>
<P>Insufficient information to permit judgement: blinding not described fully following allocation concealment, although authors retrospectively state that assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-07-07 18:17:56 +0100" MODIFIED_BY="Ruth  Brassington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-05 15:13:37 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Badrising-2002">
<DESCRIPTION>
<P>Number of participants randomised and reasons for missing data stated; all subjects including dropouts analysed with average values and data variance clearly specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Dalakas-1997">
<DESCRIPTION>
<P>No SD values included to assess for a clinically relevant bias in observed effect size. No statistical analysis for the incidence of adverse events was completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-05 15:13:46 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Dalakas-2001">
<DESCRIPTION>
<P>Number of participants randomised and reasons for missing data stated; 1 dropout (died from myocardial infarction on placebo infusion) not analysed. No statistical analysis for the incidence of adverse events was completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-07 18:17:56 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Leff-1993">
<DESCRIPTION>
<P>Reason for missing outcome data likely to be related to true outcome: "All patients received 6 months of each regime unless: a) worsening was noted after 3 months; b) after 3 months of the second (or cross-over) therapy no improvement was noted; or c) unacceptable side effects occurred". While "most patients received the full 6 months of each regime" this is not quantified; there is also evidence of adverse effects leading to exclusion that might have been underestimated in seriousness and without intention-to-treat analysis: "...2 patients underwent cholecystectomies during the study for acute cholecystitis and subsequently were unable to continue because they experienced gastrointestinal intolerance and/or abnormal liver function tests when they resumed treatment with the drugs". No statistical analysis for the incidence of adverse events was completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>Number of participants randomised and reasons for missing data stated; last data carried forward with average values and variance clearly specified. No statistical analysis for the incidence of adverse events was completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Machado-2013">
<DESCRIPTION>
<P>Abstract only. Unable to assess.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-23 21:41:43 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Muscle-Study-Group-2001">
<DESCRIPTION>
<P>Number of participants randomised and reasons for missing data stated; intention-to-treat principle stated with no computation of missing data from 1 dropout. No statistical analysis for the incidence of adverse events was completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Muscle-Study-Group-2004">
<DESCRIPTION>
<P>Number of participants randomised and reasons for missing data stated; intention-to-treat principle stated, although data from only 1 of 3 dropouts were carried forward for analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Rutkove-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement: baseline characteristics not available for all randomised participants, although reasons for missing data given. Also, non-parametric data are reported due to concerns about the normality of the data, but no normality test results are given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Walter-2000">
<DESCRIPTION>
<P>Insufficient information to permit judgement: reasons not given for missing data from 2 dropouts; all participant data carried forward for safety analysis, but only completed data used for efficacy analysis; also non-parametric statistical analyses performed, although both mean and median data are reported in results and without specification of SD or interquartile range.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-06-23 21:42:18 +0100" MODIFIED_BY="Ruth  Brassington" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:39 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Badrising-2002">
<DESCRIPTION>
<P>The study protocol is not available, but outcomes prespecified in the methods are all reported in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-05 15:13:43 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Dalakas-1997">
<DESCRIPTION>
<P>Data largely presented graphically and with discrepancies between data points and figures reported elsewhere. No study protocol available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Dalakas-2001">
<DESCRIPTION>
<P>The study protocol is not available, but outcomes prespecified in the methods are all reported in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Leff-1993">
<DESCRIPTION>
<P>Insufficient information to permit judgement: numerical strength scale interpreted only by subjective improvement, stabilisation, or worsening.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>Insufficient information to permit judgement: percentage change in muscle strength data given but no actual scores.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Machado-2013">
<DESCRIPTION>
<P>No protocol. Unable to assess.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Muscle-Study-Group-2001">
<DESCRIPTION>
<P>The study protocol is not available, but outcomes prespecified in the methods are all reported in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Muscle-Study-Group-2004">
<DESCRIPTION>
<P>The study protocol is not available, but outcomes prespecified in the methods are all reported in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:45 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Rutkove-2002">
<DESCRIPTION>
<P>The study protocol is not available, but outcomes prespecified in the methods are all reported in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:42:18 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Walter-2000">
<DESCRIPTION>
<P>Insufficient information to permit judgement: the primary outcomes specified in the methods are not fully reported in the results; authors do not compare IVIg versus placebo periods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-05 15:13:38 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Badrising-2002">
<DESCRIPTION>
<P>Minimisation of other treatment effects clearly specified: "no use of immunosuppressive therapy for at least 6 weeks before the study, no previous use of MTX, no use of medication interfering with MTX pharmacokinetics or pharmacodynamics, and absence of severe dysphagia interfering with oral medication use".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-25 18:57:11 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Dalakas-1997">
<DESCRIPTION>
<P>Randomisation was broken by giving participants the option to cross over intervention. There was also a potential carry-over effect of previous treatment(s): "Nineteen of the patients had been treated previously with high-dose prednisone or therapeutic doses of another immunosuppressant (methotrexate, azathioprine) for at least 4 to 6 months." There was also a minimum washout period of 1 month, which may not be long enough to exclude a carry-over effect.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:40 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Dalakas-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement, but potential carry-over effect of previous treatment(s): "Several patients had been treated previously with high-dose prednisone or therapeutic doses of another immunosuppressant (methotrexate, azathioprine), but they had not been taking any such medicine up to 3 months before enrollment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-17 11:30:06 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Leff-1993">
<DESCRIPTION>
<P>After the first treatment period, participants were observed for worsening before beginning the second period, breaking randomisation. There was also a potential carry-over effect of previous treatment(s): "For 2 weeks before protocol entry, the prednisone dose was held stable, and apheresis or immunosuppressive therapy was not given"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>Insufficient information to permit judgement, but potential carry-over effect of previous treatment(s).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:42 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Machado-2013">
<DESCRIPTION>
<P>None identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Muscle-Study-Group-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement, but potential carry-over effect of previous treatment(s), although inclusion criteria state that participants "must not have received immunosuppressive agents for at least 3 months prior to enrollment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:44 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Muscle-Study-Group-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement, but potential carry-over effect of previous treatment(s), although inclusion criteria as per their previous study specified that participants must not have received immunosuppressive agents for at least 3 months prior to enrolment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:45 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Rutkove-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgement, but potential carry-over of previous treatment(s), although "Patients were...excluded if they had received IVIg within 2 months or were currently on an immunosuppressive drug regimen including corticosteroids"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-23 21:41:46 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Walter-2000">
<DESCRIPTION>
<P>Insufficient information to permit judgement, but potential carry-over effect from previous treatment(s): "Of the 22 patients 19 patients had previously been treated with various drugs". Also, "Physiotherapy was administered to all patients in both groups once or twice per week throughout the entire trial" but was not assessed as part of the therapeutic intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-07-07 18:16:39 +0100" MODIFIED_BY="Ruth  Brassington">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-06-23 21:41:47 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-11-20 10:44:50 +0000" MODIFIED_BY="Ruth  Brassington">Intravenous immunoglobulin versus placebo for inclusion body myositis</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>Intravenous immunoglobulin versus placebo for inclusion body myositis</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with inclusion body myositis<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> intravenous immunoglobulin<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Intravenous immunoglobulin</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle strength at 6 months (%)</B>
<BR/>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
<P/>
<P>
<BR/>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>78<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment<BR/>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2 of the 3 studies assessed change in muscle strength at 3 months and the other at 6 months. Data were not suitable for meta-analysis.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in muscle strength at 12 months (%) </B>- not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle mass at 6 months (%)</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in handgrip strength at 6 months (%)</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in timed walk at 6 months (%)</B>
</P>
<P>e.g. 10-metre or 6-minute walk test at 6 months - not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Significant adverse events </B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>78 (3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Dalakas-1997" TYPE="STUDY">Dalakas 1997</LINK>: unclear whether dropouts from treatment or placebo group. <LINK REF="STD-Dalakas-2001" TYPE="STUDY">Dalakas 2001</LINK>: treatment group withdrawals = 0; placebo group withdrawals = 1. <LINK REF="STD-Walter-2000" TYPE="STUDY">Walter 2000</LINK>: 2 withdrawals but unspecified whether from treatment or placebo group</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-07-07 18:16:39 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington">Interferon beta-1a compared to placebo for inclusion body myositis</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Interferon beta-1a (IFN beta-1a) compared to placebo for inclusion body myositis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with inclusion body myositis<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> IFN beta-1a<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>IFN beta-1a</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle strength at 6 months (normalised MMT score</B> - see Characteristics of Studies table<B>)</B>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>The mean changes in normalised muscle strength in the control groups was<BR/>
<B>-0.03 and -0.08</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>The mean change in normalised muscle strength in the intervention groups was<BR/>
<B>0.06 lower</B>
<BR/>(0.15 lower to 0.03 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in muscle strength at 12 months (%) </B>- not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle mass at 6 months (%)</B>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>The mean change in muscle mass (%) in the control groups was <B>-0.85 and -1.77.</B>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>The mean change in muscle mass (%) in the intervention groups was<BR/>
<B>0.22 higher </B>(1.69 lower to 2.13 higher)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in handgrip strength at 6 months (%)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58 (2 studies)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Baseline measurements were not reported, so % change was not calculable. There was a non-significant difference in handgrip strength (kg) between IFN beta-1a and placebo in 1 trial (MD -0.16, 95% CI -1.55 to 1.22). In the other the MD was 1.84 kg with a 95% CI of 0.46 to 3.21 in favour of IFN beta-1a</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in timed walk at 6 months (%)</B>
</P>
<P>e.g. 10-metre or 6-minute walk test at 6 months - not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Significant adverse events </B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58 (2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Muscle-Study-Group-2001" TYPE="STUDY">Muscle Study Group 2001</LINK>: treatment group withdrawals = 1; placebo group withdrawals = 0. <LINK REF="STD-Muscle-Study-Group-2004" TYPE="STUDY">Muscle Study Group 2004</LINK>: treatment group withdrawals = 2; placebo group withdrawals = 1</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>MD:</B> mean difference; <B>MMT:</B> manual muscle testing</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The CI includes the possibility of an effect favouring either IFN beta-1a or placebo when data from the two trials are combined.<BR/>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2015-06-23 21:41:47 +0100" MODIFIED_BY="Ruth  Brassington" NO="3" READONLY="YES">
<TITLE MODIFIED="2014-11-20 10:24:54 +0000" MODIFIED_BY="Grade Profiler">Methotrexate compared to placebo for inclusion body myositis</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Methotrexate compared to placebo for inclusion body myositis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with inclusion body myositis<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> methotrexate<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Methotrexate</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle strength at 6 months (%)</B>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44 (1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Data collected at 12 months only</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in muscle strength at 12 months (%)</B> <B>- MMT</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in muscle strength (%) in the control group was <B>-2.0%</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in muscle strength (%) in the intervention group was</P>
<P>
<B>1.5% higher</B>
</P>
<P>(1.0 lower to 3.9 higher)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44 (1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MD in mean change based on intention-to-treat data. Per protocol: MD 1.6%, 95% CI -2.3 to 5.4. This study was assessed as having a low overall risk of bias.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle mass at 6 months (%)</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in handgrip strength at 6 months (%)</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in timed walk at 6 months (%)</B>
</P>
<P>e.g. 10-metre or 6-minute walk test at 6 months - not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Significant adverse events </B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>43 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>381 per 1000 (52 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 8.76</B> (1.19 to 64.28)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44 (1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Badrising-2002" TYPE="STUDY">Badrising 2002</LINK>: treatment group withdrawals = 8/21; placebo group withdrawals = 1/23</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>MMT:</B> manual muscle testing; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded for imprecision. The single randomised controlled trial of methotrexate was insufficiently powered to exclude a possible benefit from methotrexate.</P>
<P>
<SUP>2</SUP> Downgraded for imprecision.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NO="4" READONLY="YES">
<TITLE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington">Methotrexate and anti-T lymphocyte immunoglobulin compared to methotrexate for inclusion body myositis</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Methotrexate (MTX) and anti-T lymphocyte immunoglobulin (ATG) compared to MTX for </B>inclusion body myositis</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with inclusion body myositis<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> methotrexate and anti-T lymphocyte immunoglobulin<BR/>
<B>Comparison: </B>methotrexate</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>MTX</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>MTX and ATG</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle strength at 6 months (%)</B>
<BR/>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>11<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment<BR/>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Data collected at 12 months only</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in muscle strength at 12 months (%) - QMT</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in muscle strength (%) in the control group was <B>-11.1%</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in muscle strength (%) in the intervention groups was</P>
<P>
<B>12.50 higher </B>
</P>
<P>(2.43 to 22.57 higher)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle mass at 12 months (%)</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in handgrip strength at 6 months (%)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>11<BR/>(1 study)<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Data collected at 12 months only; rescaling of data not performed due to uncertainty in the assumption of linear change</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in timed walk at 6 months (%)</B>
</P>
<P>e.g. 10-metre or 6-minute walk test at 6 months - not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Significant adverse events</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>11<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>: combined ATG and MTX group withdrawals = 0; MTX group withdrawals = 1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>MD:</B> mean difference; <B>QMT:</B> quantitative muscle testing; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded for study design: as an open-label study, there is a high risk of bias.<BR/>
<SUP>2</SUP> Downgraded twice for imprecision: 11 participants. The minimum clinically important difference is not known, and the MD has wide CI.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington" NO="5" READONLY="YES">
<TITLE MODIFIED="2015-06-23 21:42:51 +0100" MODIFIED_BY="Ruth  Brassington">Methotrexate and azathioprine compared to methotrexate (plus leucovorin) for inclusion body myositis</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Methotrexate (MTX) and azathioprine (AZA) compared to MTX (plus leucovorin) for inclusion body myositis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with inclusion body myositis<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> methotrexate and azathioprine (plus leucovorin)<BR/>
<B>Comparison: </B>methotrexate</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Methotrexate</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Methotrexate and azathioprine </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle strength at 6 months (%)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>11<BR/>(1 study)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Categorical change in MMT only reported. This study was graded as having a high risk of bias.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in muscle strength at 12 months (%)</B> (using MMT or QMT) at 12 months - not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle mass at 6 months (%)</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in handgrip strength at 6 months (%) </B>- not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in timed walk at 6 months (%)</B>
</P>
<P>e.g. 10-metre or 6-minute walk test at 6 months - not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Significant adverse events</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>11<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Leff-1993" TYPE="STUDY">Leff 1993</LINK>: Combined AZA and MTX = 3 withdrawals; MTX (plus leucovorin) = 0 withdrawals</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>MMT:</B> manual muscle testing; <B>QMT:</B> quantitative muscle testing</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2015-06-23 21:41:47 +0100" MODIFIED_BY="Ruth  Brassington" NO="6" READONLY="YES">
<TITLE MODIFIED="2014-11-20 10:25:42 +0000" MODIFIED_BY="Grade Profiler">Oxandrolone compared to placebo for inclusion body myositis</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Oxandrolone compared to placebo for inclusion body myositis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with inclusion body myositis<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> oxandrolone<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Oxandrolone</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle strength at 6 months (%)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>16 (1 study)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Data collected at 12 months only; re-scaling of data not performed due to uncertainty in the assumption of linear change. There were also insufficient data to calculate percentage change in muscle strength. This study was graded as having an unclear risk of bias</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in muscle strength at 12 months (%)</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in muscle mass at 6 months (%)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>16 (1 study)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Data collected at 12 months only; rescaling of data not performed due to uncertainty in the assumption of linear change.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in handgrip strength at 6 months (%)</B> - not measured</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Change in timed walk at 6 months (%)</B>
</P>
<P>e.g. 10-metre or 6-minute walk test at 6 months - not measured</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Significant adverse events</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Rutkove-2002" TYPE="STUDY">Rutkove 2002</LINK>: treatment group withdrawals = 1; placebo group withdrawals = 2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-11-30 12:29:17 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-06-23 21:41:48 +0100" MODIFIED_BY="Ruth  Brassington">
<COMPARISON ID="CMP-001" MODIFIED="2015-06-23 15:40:47 +0100" MODIFIED_BY="Ruth  Brassington" NO="1">
<NAME>Interferon beta-1a versus placebo</NAME>
<CONT_OUTCOME CHI2="0.824333744636593" CI_END="0.030473650776224992" CI_START="-0.15172351564260111" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06062493243318806" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2015-06-23 15:39:46 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="0.36391618438639817" P_Q="0.36391618438639817" P_Z="0.19212083232371954" Q="0.824333744636593" RANDOM="YES" SCALE="0.84" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="1.3043307584825876">
<NAME>Normalised change in muscle strength over baseline at 6 months</NAME>
<GROUP_LABEL_1>IFN beta-1a</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours beta IFN</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.020995978385694627" CI_START="-0.2009959783856946" DF="0" EFFECT_SIZE="-0.09" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2015-03-16 16:28:05 +0000" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="1.0" P_Z="0.112011281969488" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="16" WEIGHT="67.36103603687563" Z="1.589217566024349">
<NAME>MSG 2001</NAME>
<CONT_DATA CI_END="0.020995978385694627" CI_START="-0.2009959783856946" EFFECT_SIZE="-0.09" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="0.03" MODIFIED="2015-03-16 16:28:05 +0000" MODIFIED_BY="Ruth  Brassington" ORDER="12" SD_1="0.15" SD_2="0.16" SE="0.05663164183689942" STUDY_ID="STD-Muscle-Study-Group-2001" TOTAL_1="14" TOTAL_2="16" WEIGHT="67.36103603687563"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.15945694539665026" CI_START="-0.15945694539665026" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2014-12-12 09:43:26 +0000" MODIFIED_BY="Ruth  Brassington" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="32.63896396312437" Z="0.0">
<NAME>MSG 2004</NAME>
<CONT_DATA CI_END="0.15945694539665026" CI_START="-0.15945694539665026" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="-0.08" MODIFIED="2014-12-12 09:43:26 +0000" MODIFIED_BY="Ruth  Brassington" ORDER="13" SD_1="0.22" SD_2="0.21" SE="0.0813570793414707" STUDY_ID="STD-Muscle-Study-Group-2004" TOTAL_1="15" TOTAL_2="13" WEIGHT="32.63896396312437"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4834966039047054" CI_END="2.133345214468051" CI_START="-1.6903459783481947" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.22149961805992824" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2015-06-23 15:40:47 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" P_CHI2="0.48684279566148847" P_Q="0.48684279566148847" P_Z="0.820365856665066" Q="0.4834966039047054" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.22707444304208488">
<NAME>Percentage change over baseline in muscle mass at 6 months</NAME>
<GROUP_LABEL_1>IFN beta-1a</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours beta IFN</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.755664409977955" CI_START="-1.855664409977955" DF="0" EFFECT_SIZE="0.95" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2014-12-12 09:52:21 +0000" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="1.0" P_Z="0.5069174096605464" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="16" WEIGHT="46.433795445582966" Z="0.6636452238162303">
<NAME>MSG 2001</NAME>
<CONT_DATA CI_END="3.755664409977955" CI_START="-1.855664409977955" EFFECT_SIZE="0.95" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="-0.85" MODIFIED="2014-12-12 09:52:21 +0000" MODIFIED_BY="Ruth  Brassington" ORDER="16" SD_1="2.74" SD_2="4.92" SE="1.4314877375853217" STUDY_ID="STD-Muscle-Study-Group-2001" TOTAL_1="14" TOTAL_2="16" WEIGHT="46.433795445582966"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2022057275067097" CI_START="-3.02220572750671" DF="0" EFFECT_SIZE="-0.41000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2010-04-27 15:12:11 +0100" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="1.0" P_Z="0.7583661085203991" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="53.566204554417034" Z="0.30762708511033937">
<NAME>MSG 2004</NAME>
<CONT_DATA CI_END="2.2022057275067097" CI_START="-3.02220572750671" EFFECT_SIZE="-0.41000000000000014" ESTIMABLE="YES" MEAN_1="-2.18" MEAN_2="-1.77" MODIFIED="2010-04-27 15:12:11 +0100" MODIFIED_BY="Ruth Brassington" ORDER="17" SD_1="3.06" SD_2="3.87" SE="1.3327825144295788" STUDY_ID="STD-Muscle-Study-Group-2004" TOTAL_1="15" TOTAL_2="13" WEIGHT="53.566204554417034"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-03-17 10:08:30 +0000" MODIFIED_BY="Ruth  Brassington" NO="2">
<NAME>Methotrexate versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="64.28487706796366" CI_START="1.1942307204776177" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.761904761904765" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.808108817739046" LOG_CI_START="0.07708823881218833" LOG_EFFECT_SIZE="0.9425985282756173" METHOD="MH" MODIFIED="2015-03-17 10:08:30 +0000" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.032799279931938506" Q="0.0" RANDOM="YES" SCALE="583.1617565273391" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="2.134531720525238">
<NAME>Significant adverse events</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.28487706796366" CI_START="1.1942307204776177" EFFECT_SIZE="8.761904761904763" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.808108817739046" LOG_CI_START="0.07708823881218833" LOG_EFFECT_SIZE="0.9425985282756172" MODIFIED="2010-04-27 15:00:12 +0100" MODIFIED_BY="Ruth Brassington" ORDER="7" O_E="0.0" SE="1.016810056751696" STUDY_ID="STD-Badrising-2002" TOTAL_1="21" TOTAL_2="23" VAR="1.0339026915113871" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-06-23 21:41:48 +0100" MODIFIED_BY="Ruth  Brassington" NO="3">
<NAME>Anti-T lymphocyte + methotrexate versus methotrexate</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="22.565644336530774" CI_START="2.4343556634692263" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2015-03-05 17:05:03 +0000" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.014933931689837279" Q="0.0" RANDOM="NO" SCALE="54.151550027552" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="2.433977298188016">
<NAME>Percentage change from baseline (QMT) at 12 months</NAME>
<GROUP_LABEL_1>ATG+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ATG+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="22.565644336530774" CI_START="2.434355663469228" EFFECT_SIZE="12.5" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="-11.1" MODIFIED="2010-04-27 15:03:20 +0100" MODIFIED_BY="Ruth Brassington" ORDER="10" SD_1="9.8" SD_2="7.2" SE="5.13562719311543" STUDY_ID="STD-Lindberg-2003" TOTAL_1="6" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-07-07 18:17:58 +0100" MODIFIED_BY="Ruth  Brassington">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-07-07 18:17:57 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Red (-) = high risk of bias, yellow (?) = unclear risk of bias and green (+) = low risk of bias.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXcAAAKBCAIAAAAjgXwwAAAl60lEQVR42u3dv04c2bbH8ZYsWQQE
BDyBn4EIISIT8U44JEDCIW+B/AgjPCe0HTmzPNce+Tgg4Nybjeeiut1wdcShq6qruvaurtX781Nr
hHraP4rdu7619r+1ZjMiotyqiIjyCGWICGWICGWIiFCGiFCGiFCGiAhliAhliAhliIhQhgrur/as
owxRpp7a5U1CGaJ1uuna/5dQhohQhmh6QY1+izJEeRFjrIQyRChDKEMoQyhDVNtfIQZliIhQhohQ
hqixvzpkgDJEmTrr0x/0W5QhyksZoEEZIpQhlKHIoNFvUYaICGWICGWIqieLSlayUYaICGWICGWI
VvRXwyWUIcrUWVe+QyhDhDIoQxQENPotyhCl7qZWslGGiAhliAhliAhliIhQhohQhmjt/iojJ8oQ
ZeqsTT8QyhChDMoQoQyhDJGNvyhDRIQyRIQyRC39tfZnQhmixIgBGpQhQhlCGYrbX60xoQwREcoQ
EcoQrRox6booQ5S4s2oElCGKShkhEsoQ5QJN7S3gvkAZKrizJg062h3cGihDRChDFG0s5o5AGdJf
00/Tyo+FMkQ1CEjYb1EGZYjysgBlUIYoOwue3gjuCJQhoDFHizJERChDVHMnOGSAMqS/jrCS7Y5A
GSq3s+Z2NgGMMpQxLkAZlEEZSvytd3mzTNC4I1CGMt6oE+8M5mhRhihkIEMoQ8YIuSjz70UlURLK
UEbEBIoU9FWUIZTJ31lFHChDKBP4TgAvlKHk373hUqUCN8oQ5b75UQZliGoGNWm77lMrdwTKUK6b
ViOYmkEZSj9GcAqZUIbGoEwVZwJYuIEyhDLZr7nlHUIZmihogq5k67ooQ4QyhDIUsb9mmJexxoQy
lDgiiLV2m/va3AIoQ7pp3uV2twDKEFW59865C1CGst+3USKa0RCmh6AMJb5jS04tTihDKAM0KEPB
QRPxeEHyeRnDJZShjPdq4d3Afj+UIUIZlCEaNxBLCwKUQRmi/7jzc5wjN3hEGSJ1F1CGCGUIZahl
jFBmrjwVbFGGsscFRChDKLOB1tA+KEOFgibHiMkeRZShMW7XEN0gX8ThFkAZIuMalCEaHTTJ8/6C
F8pQ3kFT0FFekosXJaEMGX0Ebg2TyijjvgpAmfZry7HYlPDu6vImyhDKuGOnSEaUoSDffSgWGH2g
DImPoj69M2WuqQLWI0cZoox8TH7a2zlylCn3jhqnglq4Sk8ogzJUdFyAMihDIVnQ8k5R91W+eeWn
huZlqKSvPNuIKQdlnJxGGdqGWKbkp7ed0ChDFDWyq2JmPkUZSv8Aj9IHRqvHlNw5x04clKFyxwiB
ZnxGa2drTCiDMrnWmDJtw8lHxkDXjDIUbEpi+vdV0F0tThigDEUaI4QjI6EMZQdN4ScMCGV897OS
1z6yRkmqVqIMxGzDOQBdF2WoLMrkfnrrqChDYpmRrjlrcJR77y/KkJmI4kCz7Jx1V7F5GaLp8mvM
sdj0nVGGjMUi3Ve5z1uUjBiUEWhEigtixV9y4qAMjRQa5Mg7ZyUbZUiUFGYlW202lKExoFCFzWiX
sB26vEkoQ+vcsdFTZ2YKxCIGjyhDKJNlRFZydBAl/kIZlHEKeWw4Zg3oJvg9oozerw+EHOLF62ka
gqb89I5LxtwVaSY+VkIZCnZfBT0HkG9pLMqYF2XgoMqU3TIEZUbY46OiA8pATMZ82nFjmcK/QZSh
SfdRuVpGvnunD0rfFspYya6HIzKiDJXyJByTuYFGeShD+JXl6W3Gepz4C2Uo4x2VY2dqrAqQUSiT
r1IwylDisVL7m4VQJuKMtTUmKndcEzSWiRuTogzhV/pceRCzzBcjJqIwZEzFLxVsUYYCP7pLHn2g
DKFA9pnUWJTJdPYqVpSEMhRvUBPi5KFKKShDlXpMLa0x/VEeylCJcxye3ttBRpShqT9jc2eHi1Ld
JffsSaCYEWWAJt4FZzphECv+QhkKFmznm4wIsac+bmQX4pmBMhTmGRuRMjnMw81/oQxFiuRHyCkR
KGYMFji7NwyaQjiPOYTUQ1CGphtxbEFraGeUoUJ7f6C9c3YPoQzKjDF7UmVOZxcxV54RE5X33cfJ
4ZZ19Src3rlAgRLKUK6nd+7svNPf+5sbBLWtMcFmQRkKQ5mIMx3jzyujDE2l36sA2QLHKBPhKEMk
/qoPwbLSHGVo6k9ClEk+ypt4oIEylO0rzzBiirtDZDTKVHblUcmxjAbJuihWcrYKlKGi46+RA6Uy
c32ijFs346xk8psh0H4Z0SjKQEyuWcmIe39zRBztJiP8CpShaVGmiplrauLXXHtzJaSYeRlCmezz
ndNvjSrmHkWUoYmOEeLeV9abUYZopDshBGJUsKVggUzIp6K8mWIZKhw0dohs5OsTy9DUgwL1TAJV
rVQphTxjs1Cmyp83M9A5ALvyCGVGymIVJf4aIQsyytB0A+8qwzmAWEvCcXcPoQwVOq4JzdxAudbN
y1BxlBnn5I4z2VEJ7q5DmRAndzLNcRDKUKQxQhX2tFGOiGOc6nrTL+SAMlR0/JVv/Jh1V4tdeUSR
5jgi7iREGYo3YlLDoAq14oYyVIXroxokE2JU10MZlCn3GTt+lGQlm4Am8UPbWMzuR5QpfYBQ+Cm+
JhzI9YkyJP6q7MQx+0sCpcAnpytrTChDaVlQBTkojDItTW3ERJMeemS6YwNdc5VhJXuEvb9R5tpR
BmUi5T0Jl7mmUnUXZVCm5LwnIyOmWNCgTNGgCZqoJccdG/FMY5SM6ChD8YCYe/VKHgyUoTBQqIpf
vYo45kUZyhsduGNdM8pQlmmOHNl/A9U2qmJm53XCgMIgJu2URNDakoQyFIYyVf75TqpUfaO48fb0
S0THbecqw+oVyhBlxGKIrmv3I8rQSDgwrpHFCmWo6EFNlX+PT6wanihD5VImXOaaKs9ceNYanihD
5YIm3zmAuPll7JehEscIlVx5hDJUyWI1YlxgLhxlUCbSDt1w5wDcXCiDMsFy5cVtZ5TREAV/95nL
qgYKOhyMQBmikCekRs4ujjJEKVkQaMY6t/mUV8dQxk2brGuOljczxz2ce4/PaMxFGdr+uCAWGXOP
a8bkF8oQykw3VspdQGqciXYjJpr6TRsiLhiNuYQyFOCOnX6dIKBBGdoGylTpch2MXHNazIgyNNE+
6uRhe4hUYK51lNH784YzhfculEEZvT/wZceqM5vjsmUXJ6AJHBdMf15GdnEK8njJfAPkfnSHoAyh
DOWKOALlmkIZlCGUGTu4yzTQS3VezIiJgg2aKpm68zO35CgJZUQcAcY14Z7eI1AmEL9QBmVEHFnG
NVmZGyiFFcq4qSJRRlwQdOSFMkWDJtB8Z9D8WPb+ogzFjjgKH9fY+0soU+7Te4RrNi9DwYZLgXId
xCIjoQxFuqky5eLMPeOjgi3KkKf3eH97iHPkKEMBbgBP7xHa2a48ijf6CBEXbMG4BmWIpkuZ0fKW
hwjrUIaAJjtlqrCVZzMhbOrX6cYwYsq6aoMyOpsGLT3iCFc1KXd2ywIjDpSh7M9q3SBcOxsxkd6v
dzlHjjJGywFrg8Qa16AMypCnd2wyhhjwogyhTNQsVlEy5qGMEVP6HW7hnt7mwlGGMkYcsTJy5nt6
m7FGGUIZGi8aRRmaOmUi7vfzDaIMZR+A5EAM0FSq66EM5XvGJqRM3PNK+ViAMiRKylJbMhMFRstW
UTlhQMUO7OMuME3ZuTLLjjIQUwWvLRli3BQ0J2HCJxDKoIyV7PBf4sT7BsqgTCTKOC3ZPtBDGZri
HRsLMfnu2OTOgc4ZoQxF5Ve+Z2wIyoQeh6Z9AqEMxZgsqJzJjv7U0RA0fcpUAedlqjinjVCGgCZ2
U4SeZTcvQ1PvoCpwV5n3/lY5T0iZl6GpPK9oZMoEcta9DGpoVJoXyC+UQZkw9xWNORZ7+lUaMdG0
QDPybtfpH5hEc5QRyYfZO1c1ZOFLmFwioXPcvb8oQ1MfMY2/dy5HlqwoyXRzfHfJyYgyKBMmkkeZ
lqYWy1BxoBmTX/kqpQSqwTLlGxllykWM+YKNoDzf8YXJRqO6F019VI8yIwcvya8ZZSh2CBbCOdYo
FWVoolHxOE/v0e6rrCPTgQ0+QsyYlowoI5JP3ZnyZ4oMRJnooaKVbCor4gCacb7BXPBy16FM0JJM
E3euMsz4hNtVjDLC4+x556wxFR58oQzl6v0l56CMOxBDGYpHmSrdCYAcY4SR12vyIWzKF4wypQ+U
VIYev8EzsWCyoEEZQUeWXvW0e2nkcZwnOxeOMnp/gBmEfPFX3D0+lSxWhDJB46+szkWPGd115gum
f8cGrWAbcV0/bQ0WlKFI8wXhnAOxYPlvV8OAShyLRaxgm7udVUqhMCOmECwwMkUZChxxUNDxY9ba
uHLlUXGUCZfFKuj4Mcu35q4DmkBjhFhNIYpEGZMFYZ7eQc83R5ylsveXCp2JqCRSaH5CTHm/MspQ
GMoEzWJlKI0yBk1Wsse7aQONmFCGknUjuaZCjx/T7v2VXZwyUqaa/JnsKmYWq6D7ZYyYaKJ9NFzW
642MTKf/nFD1jbKARh/wnDBiotLvqKBZrEJHSUZMVBALtqxZCm0Bd0iZ/T7rE4yCtmpyJqJM0f3+
6QpL1i6bloyZtuQld85HmacXOf1FMZQpnTJZb4McXT/tJrd8zlmnOUZojYR/AsqIZXLBJdONGosy
+fb4oAyVSJl8Ez2hY5nRvkGUIbEMyky9NSrzMpQvhs+XrHvi1xx0J84zq4kfdkUZGgNq2kEf0AmI
CGWICGWIiFCGiFCGiFCGYnypROMKZcqiDGfO03FGGZThzBllSO/njDKEMpw5owzKcOaMMqSPckYZ
2g7K3P19d/7t/OjT0d7ve7PfZrvvdw8+HLz5483tr1vOnJM7o0xxlLn6cbX/j/15B1p+zTvW2z/f
cuac1hllyqLM/KFU24eevuaf4cw5oTPKFESZ+ZNqZTd6fDU9tThz7uu8bZRZO8dX7YfbHdJkQl1K
lDvkzfZrm4+3m4Lh2vD4518/OXMe6LydlFkPBCO3QG2u1oFvrvxzzr+dd+xGLbExZ869nMuiTEtE
sHwDLyfHXv7ny/9kpXn7NScESu2bR5+OanrMo+p60sGHA86cBzoXRJn2G7gpS/N6/7zl/26WMo8L
k9170u77Xc6cBzoXOi8zcISSig7tH+vo02tepr4PPdVSZ+LMeaBzoSOm9eiwcsQ0fcp4xnIWy2xs
xLTeCGU4ZdqZuNKnI7zMF3A2LzMqZZrmUIbwqPusTftX0je26rtkZu2DszWmvPMytSs+TWtMw0dM
7WtMTdfZcWvMyukn+zg42y9TlsZvXntSOdv7WwRZchSfHs4152s4j++MMsVFT/OnVv2awkMwfPH9
gjPntM4oU+IYrSmHSO14mzPngc4oYyaIM+e8ziiDMpw5owzp/ZxRhlCGM2eUQRnOnFGG9FHOKENR
KEM0vlBGLMOZs1iG9FHOKEMow5kzypDezxllCGU4owyhDGfOKEPr96Smc7e3v24n63x/f/evf53/
/Hn0/fvef/3X7Nu33X/+8+Du7s39/XSd/767+3Z+/uno6Pe9vd9ms/e7ux8ODv548+bXbVnOKFMc
Za5+XDWlX5yjoSkT2mad/+d/rr5/358jYPk1R8N///cUnX9cXf1jf782G9T8Bv7zbUHOKFMWZSJm
WpuHFbUUePqaf2ZSzvOH/8rklvPPFOKMMgVRJmLW2HmssRIEj6+muGN853lE0LEcQFN0sE3ORVCm
4ybojiFlwrZqqW3Q/mY5NQzu7++eDmdubmbHx7OdncXr9HT28ePzAc7//u/mnf++u2sadNQOQ/76
uc3OBVGmFybGoUwtTZZ/TlgnO2I1n3/96/zp3f7q1aLR3r2bXV8vfjg87DS6Gdn52/l5n8aoH4Ns
jXOhlKk6F1rq8n97xSDP/uFwyvSqYBuxMuHPn0e1Q5gvXxbeL18+f/+f/9y886ejo1537IeDbXZG
maFFI4fEINXoFWwjVll+XFp+9vr8efb69cL78vL5//r2bfPOjwvA3V/vd7fZGWVWo6fp/64ExxoT
QN3L7K5HmXoKPNVSb9q4c224cXKysDw7q5+p3bjz8j25v6IxttkZZZ7PpHb8vy2Do5XlaLvM/lbd
KuEWG8u8eLEw/vq1BgQDY5kkzmIZlBlpxLT27ElHnzWmqLdpXqbpNXxeZrizeRmUaZu+beFIF8q0
BETJ52XWoMwWrDE9vh7VfQfdyM7WmAqlTMvukuXxSPtopR1SSUZMXdaq1qDMFuyXaWfBkP0yCZ3t
lymRMgXK3t/NOtv7izLlUqZyjmksZ+eYUKZcyjzGHfWrQg/DmYvvFxN0fjg5vdd8cnqKzvPooGnt
Zv7+94uCnFGmOMpUzVlgamdMJuLclAWmdsZkIs5NuVpq5zW22BllSqQMZ85jOqMMynDmjDKk93NG
GUIZzpxRBmU4c0YZ0kc5owxFoQzR+EIZsQxnzmIZ0kc5owyhDGfOKEN6P2eUIZThjDKEMpw5owyt
35OaTk7f/rqdrHPTyen7++k6a2eUKZQyVz+umhJozrtsUy67zTo/ZIHZb84CM0Vn7YwyhVJGrrxx
nLUzyhRKGXl/x3HWzsVRpuMm6I4hZaq26lWuoKn6Qq+L3IIaBjc3s+Pj2c7O4nV6Ovv4MVkNg4TO
2rlQyvTCxAiU6V56qaUeU1/KbEE9plevFn/1u3ez6+vFD4eHyeoxJXTWzihTf7u238wrS6/1ikGa
LqYvevpSZptqS375svB++TJ9bcnhztoZZXrc2EMq2K5RB7KvT7F1sj9/nr1+vfC+vExcJzuJs3ZG
mcbmqL2x+8YR7SYdh06ZKFPfO59qqZtu3Ln2AXtysrA8O6ufm9y4s3ZGmcYxUUsF22f/t2Vw1KuC
7ciU2Zpn7IsXC+OvX2u6/sBYJomzdkaZkUZMXVq/hRo5KLNN8wVNr+HzMsOdtTPKtE3ftnCkC2Va
AqI1IqzklNmCtY/H16O67xkb2Vk7F0qZlv0y/36zZcTUJcBZnq9pGTE1XZL9Ms/0bB9He+8fsl8m
obN2LpEyBcqe1M06a2eUKZcylfM1YzlrZ5QplzKPz8P61YqHMPvi+8UEnR/OCu81nxWeorN2Rply
KVM1ZyepHclPxLkp70ntHMFEnLUzypRLGc6cx3RGGZThzBllSO/njDKEMpw5owzKcOaMMqSPckYZ
ikIZovGFMmIZzpzFMqSPckYZQhnOnFGG9H7OKEMowxllCGU4c0YZWr8nNZ27vb+/nazz33d3387P
Px0d/b6399ts9n5398PBwR9v3vy6LdE5VjujTHGUecghst+cQ+TtBJ1/XF39Y3+/NmfT/Gb4821Z
zuHaGWXKokzEvHPzB+nKFJTzzxTiHLGdUaYgykTMoTt/unZM2t/0pN0m54jtjDJ5J8+e1jboUoSg
ew2D9j3dXfLU39zMjo9nOzuL1+np7OPHZPUAEjr/fXfXFMDXhvR//dxm54jtjDJ5KbOyJO7aVd/W
qzP3rObOq1eLC3j3bnZ9vfjh8DBZbaOEzt/Oz/sUIKqP57fGOWI7o0xKyjQVum2KRKrBtSX7vtlU
P/DLl8XlvXyZvk7jcOdPR0e9ev+Hg212jtjOKJOMMt0r4bZY5aZMbW76z59nr18vOsDlZeKa00mc
HxdTu7/e726zc8R2RpmJUqapYG7t1Ez3i6x9DJ6cLEzOzupnEDfuvNy/9/8zQlz+wBY7R2xnlElJ
meXBUV/KVK2VcDPFMi9eLMy/fq3poANjmSTOYpno7YwyWWKZjrO/Vf9C15nmZZpew+dlhjubl4ne
zigTdV4myRpTe8X1IWtMCZ2tMUVvZ5RZkzJN46NnLbn2iGmc/TLtfXTIfpmEzvbLRG9nlCkr4Krs
/Y3vbO8vTZ0ylXNM8Z2dY6KpU6b6/xO9e80nei8m6Dx/0jatg8zf/35RlnO4dkaZ4ihTNWcnqR3J
T8S5Ke9J7RzB1jvHameUKZEynDmP6YwyKMOZM8qQ3s8ZZQhlOHNGGZThzBllSB/ljDIUhTJE4wtl
xDKcOYtlSB/ljDKEMpw5owzp/ZxRhlCGM8oQynDmjDK0fk9qOtF7f387Weems8K/bqfrfPf33fm3
86NPR3u/781+m+2+3z34cPDmjze3v26L+gZRpjjKPGQn2W/OTvJ2gs4/rq6aUkbO0dCUvW2zzlc/
rvb/sV+bDGoOnbd/vi3nG0SZsigjV944zvOAZWVuy/lnCvkGUaYgysj7O47zPIrpWA2gKaLZpm9w
mykz61n+rumTmRpnYLmC4TUMbm5mx8eznZ3F6/R09vFjshoGCZ0jVhq4+/uuaaBUO3T6+dfPLf4G
S6TMGv88R+MMLL2UpB7Tq1eL7/3du9n19eKHw8Nk9ZgSOkesmnT+7XzWx7p23LQ132DRscy/a8I2
FZ/u+MnlG365snV78+YASq/KhF++LK7z5cv0tSWHO0esAHn06ajm3zeVm/5tdvDhYIu/wdIp01IE
crmcW0citFttljK1We8/f569fr24wsvLxHWykzhHrGb9uGjdnTK773e3+BsUy4zxZtW5HnZfyvSd
l6l9WJ2cLEzOzurn+TbuvHxX7v9nqoHlD2zcuZ4vrdZb/A2izKA3a4vYjkmZJLHMixeL6//6taYb
DXwSJnEWy0T/BlEmzZvdkdF+hZual2l6DR/VD3c2LxP9G0SZKvm8TPtkTfvljbzG1F7LfcgKRUJn
a0zRv8Htp8zyuKbL6GbgGlOLVdO1tXhW2fbLtPekIbstEjrbLxP9G9xyykw8qtrIb7T3dxxne39R
ZuxIalJcc45pHGfnmFCm6Ojp4dztXvO524sJOs/jjqZVofn73y+m6DyPaOrXmx4GShffL8r5BlGm
xDFaUw6R2vH2RJybssDUzphMxLkpv0ztXMwWf4MoYyaIM+e8ziiDMpw5owzp/ZxRhlCGM2eUQRnO
nFGG9FHOKENRKEM0vlBGLMOZs1iG9FHOKEMow5kzypDezxllCGU4owyhDGfOKEPr96Smc7f397ec
OSd3RpniKPOQQ2S/OYfIW86c0zqjTFmUiZhpjXN0Z5QpiDIRs8Zyju68tZRpr0OSb5Ks+7/qVZmg
pQpC98t4lqf+5mZ2fDzb2Vm8Tk9nHz8my4DPmXMplKmtfzIRyvQtgNulPtzKy3hWc+fVq4Xtu3ez
6+vFD4eHyar5cOaMMm1xxLMm61UdqZYOK9u2S4G3jjVw299sqh/45cviIl++TF+ZkDPn7R8xLf+3
6lBVchk661Wk7BjgdPknSShTm5v+8+fZ69eLy768TFxlmTPncimz8g7vOypZr8jsylFSF5T0mpep
fVidnCxMzs7q5/k4cx7oXC5lljNidKdM+78dkzJJYpkXLxZ/yNevNd1o4JOQM2cjpnVimYFvtn8r
uSnTNPZueg0f1XPmvP2UGTLzssYUTK95mV5jtBxrTO0V14esUHDmXDpl2peEOo6Yur/ZMqWy/IEx
98u096Qhuy04cy6CMoXLnlTO9v7SZihTOV/D2Tkmyk2Z6v/P3e41n7u94Mw5rTPKFEeZqjmHSO14
mzPngc4oUyJlOHMe0xllUIYzZ5QhvZ8zyhDKcOaMMijDmTPKkD7KGWUoCmWIxhfKiGU4cxbLkD7K
GWUIZThzRhnS+zmjDKEMZ5QhlOHMGWVo/Z509/fd+bfzo09He7/vzX6b7b7fPfhw8OaPN7e/bifr
3HRW+P5+us7aGWUKpczVj6v9f+zPu+bya95l3/75doLOD3lP9pvznkzRWTujTKGUmT/uanvn09f8
M5NyjpgdTjujTKGUmT8DV3bQx1fT83B854iZbrXzOpTpklU/60RUU8b/tL+oY2XrVCDoVYS711dQ
+7/mI/mmMLs28P7518+NOz/LrX9zMzs+nu3sLF6np7OPH5Nl7U/orJ3Xp0xLUZHclGmqRpSWMuvx
a/gfvl71uJXHRpbfPP923rGDtkTdIzs/qxP06tXir373bnZ9vfjh8DBZBaKEzto5PWVWVnpt9+kS
R9RS5unnO9ZO6lW88dkf+Ky028rKTU8vsiNx+qKnL2WOPh3V9MVH1fXRgw8HG3duqnn45cvC++XL
9NUUhztr50EjpvUKwnYs87jG6KxvHci1S8Su98d2jLnWroTblzKPS57d++ju+92NO9fm0//8efb6
9cL78jJxZegkztp5A5TpHi+0/9uWIGJ4FNASVXUMW/r+RUPM16NMfe98qqVuunHn2gfsycnC8uys
fm5y487aeSTKrBxZ1D75O06+9q1p3Zcy3WdGYlFma56xL14sjL9+ren6A2OZJM7aeTzKdAlw+o4p
towyLdTIQZltmi9oeg2flxnurJ2HrmS3/zDOvEzfa+i4/r2SJt0ngLrMy6wctSWnzBasfbRXiR+y
xpTQWTunp0zL9GqqNaaWeZmVU7wr531rf0s741r+ro5rTE0jRPtlnunZPo723j9kv0xCZ+28JmW2
SaNtupvg32hP6jjO2rloyoz2l06TMpXzNWM5a+eiYxkwnT8P61crHsLsi+8XE3R+OCu813xWeIrO
2hllig7ZmrKT1I7kJ+LclPekdo5gIs7aGWUMDDlzHsMZZVCGM2eUIb2fM8oQynDmjDIow5kzypA+
yhllKApliMYXyohlOHMWy5A+yhllCGU4c0YZ0vs5owyhDGeUIZThzBllaP2e1HSi9/bX7WSdm84K
399P11k7o0yhlLn6cdWU2HHeZZtyrG3W+SHvyX5z3pMpOmtnlCmUMnK4jeOsnVGmUMrIRzuOs3Ze
hzK9EujnmIhqry2Z6hd1LDuXCgQdyxV0ryDe/v4W5Na/uZkdH892dhav09PZx4/JahgkdNbO61Om
qUTJCJRZWY8pyS9aj1/D//AhdbJ7UWYL6gS9erX4k9+9m11fL344PExWjymhs3ZOT5le9ZXWq8dU
S5mnn2/3rOpKSq6soNZUjrI9pOpYj2klNHNQZptqHn75svB++TJ9bcnhztp50IipewXbrLUl1/h1
a1CmO1Kb3uxbn7cXZZpK8bb8xq2p3/z58+z164X35WXiOtlJnLXzBijTPV5o/7ctQUTaOtnPflG+
Otlrm69Hmfre+VRL3XTjzrUP2JOTheXZWf3c5MadtfNIlFk5sqh98necfO0YCq1NmV73+UYoszJK
2u5n7IsXC+OvX2u6/sBYJomzdh6PMl0CnL5jii2jTMuorctwrO/a0zbNFzS9hs/LDHfWzkNXstt/
GGdepu81dFz/XkmT7hNAXeZlVo7aksxYbdnaR3uV+CFrTAmdtXN6yrRMr6ZaY2qZl1k5xbty3rf2
t7QzruXv6rjG1BSM2C/Tvo+jvfcP2S+T0Fk7r0mZbdJom+4m+DfakzqOs3YumjKj/aXTpEzlfM1Y
ztq56FgGTOfPw/rViocw++L7xQSdH84K7zWfFZ6is3ZGmaJDtqbsJLUj+Yk4N+U9qZ0jmIizdkYZ
A0POnMdwRhmU4cwZZUjv54wyhDKcOaMMynDmjDKkj3JGGYpCGaLxhTJiGc6cxTKkj3JGGUIZzpxR
hvR+zihDKMMZZQhlOHNGGVq/JzWd6L39dTtZ56azwvf3rnnq14wyxVHm6sdVU2LHeZdtyrG2WeeH
vCf7zXlPXPOkrxllyqKMHG6uefxrRpmCKCMfrWuW9zfvjTewtlym60n4Zvv3vQW59W9uZsfHs52d
xev0dPbx4xQrDbjmoinTa4CalTJJ6vC2XN621gl69WrRV9+9m11fL344PJxi1STXjDJVl5v2aaTQ
Xt2xnQVrB00DgbL1NQ+/fFl4v3w5xQqQrhllet/eXSphdnln45TZmvrNnz/PXr9eeF9eTrGatWs2
L1Nf0XElZTp+vled7GrdItwrnevRU9s7n2qpm27cufYBe3KysDw7q5+bdM2TuuZyY5mWGrVN1a/X
oEzHvBujUWZrYpkXLxbGX7/WdP3JxgXFXnPRI6a+sUzHoU2vOeNesGv/fGnzMk2vKc9xlHnNKFM/
X7seZTr+3DEw6fW7ylljaq8SP831msKv2ezv7Fkr1BKn+/pR9y0tLTNEXbbGrByObet+mfbeP829
J4Vfc1mUKUr2/rpme39pM5SpnGNyzc4xUW7KPD4P61crHsLsi+8XE3R+OCu813xW2DVP+ppRpjjK
VM3ZSWpH8hNxbsp7UjtH4Jondc0oUyJlOHMe0xllUIYzZ5QhvZ8zyhDKcOaMMijDmTPKkD7KGWUo
CmWIxhfKiGU4cxbLkD7KGWUIZThzRhnS+zmjDKEMZ5QhlOHMGWVo/Z7UdKL39tftZJ2bzgrf33Oe
ujPKFEeZqx9XTYkd52hoyrG2WeeHvCf7zXlPOE/aGWXKooxceZzHd0aZgigj7y9neX83f0OuUfNo
vdbrWK6g15vtl70FNQxubmbHx7OdncXr9HT28eP6ufU5j+OMMs+bpleJ6yGU6V56KWHx7C2ox/Tq
1aKvvns3u75e/HB4uH6dIM7jOKPMCsq0V0r694ef1Ypr+lgvWuWgzDbVlvzyZeH98uX6NQ85j+OM
MvV3b6+StV0+1rEOZG7KbE2d7M+fZ69fL7wvL9ev38x5HGeUWTFQar+B+8Ko+9ApE2XqKfBUSzjY
uHPtA/bkZGF5dlY/N8l5Us4o04Myy0k0an9o+djGKbM1scyLFwvjr19ruv7Apzfn5M4o05Uya4yY
es0fm5fpO1/Q9Bo+E8E5rTPKtDXQykmWgSOm7r/RGlPHKvFDVlU4Z3JGma73/FO+NA2U2teY6hu9
7sP2yzzVs30c7b1/yA4RzpmcUaYgaD7K3l/O9v5SXspUzjFxdo6JclPmMe6oXxV6GM5cfL+YoPPD
WeG95rPCnCftjDLFUaZqzgJTO2MyEeemvCe1cwScJ+WMMiVShjPnMZ1RBmU4c0YZ0vs5owyhDGfO
KIMynDmjDOmjnFGGolCGaHyhDBFt9LGnIYgIZYgIZYiIUIaIUIaIUIaICGWIaFqUISLKp/8Dn1yb
DoLLiEgAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-07-07 18:17:57 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon beta-1a versus placebo, outcome: 1.1 Normalised change in muscle strength over baseline at 6 months.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0wAAAEgCAMAAACw6gONAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-07-07 18:17:58 +0100" MODIFIED_BY="Ruth  Brassington" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Interferon beta-1a versus placebo, outcome: 1.2 Percentage change over baseline in muscle mass at 6 months.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0wAAAEgCAMAAACw6gONAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-06-23 22:33:35 +0100" MODIFIED_BY="Ruth  Brassington">
<APPENDIX ID="APP-01" MODIFIED="2014-11-15 16:07:35 +0000" MODIFIED_BY="Ruth Brassington" NO="1">
<TITLE MODIFIED="2014-11-15 16:06:44 +0000" MODIFIED_BY="Ruth Brassington">Cochrane Neuromuscular Disease Group Specialized Register (CRS) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-15 16:07:35 +0000" MODIFIED_BY="Ruth Brassington">
<P>#1 myositis NEAR "inclusion body" [REFERENCE] [STANDARD]<BR/>#2 (myositis NEAR "inclusion body") AND (INREGISTER) [REFERENCE] [STANDARD] </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-11-13 18:02:55 +0000" MODIFIED_BY="Ruth  Brassington" NO="2">
<TITLE MODIFIED="2012-05-29 17:36:40 +0100" MODIFIED_BY="Angela Gunn">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-30 14:15:52 +0000" MODIFIED_BY="Angela Gunn">
<P>#1 "inclusion body" NEAR myositis<BR/>#2 MeSH descriptor Myositis, Inclusion Body, this term only<BR/>#3 (#1 OR #2)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-11-13 18:03:15 +0000" MODIFIED_BY="Ruth  Brassington" NO="3">
<TITLE MODIFIED="2012-05-29 17:37:21 +0100" MODIFIED_BY="Angela Gunn">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-13 18:03:15 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Database: Ovid MEDLINE(R) &lt;1946 to September Week 4 2014&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (389226)<BR/>2 controlled clinical trial.pt. (89867)<BR/>3 randomized.ab. (285185)<BR/>4 placebo.ab. (151031)<BR/>5 drug therapy.fs. (1748071)<BR/>6 randomly.ab. (201598)<BR/>7 trial.ab. (296312)<BR/>8 groups.ab. (1285103)<BR/>9 or/1-8 (3290339)<BR/>10 exp animals/ not humans.sh. (4016034)<BR/>11 9 not 10 (2802960)<BR/>12 exp Myositis, Inclusion Body/ or inclusion body myositis.tw. (1362)<BR/>13 11 and 12 (285)<BR/>14 remove duplicates from 13 (273)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-11-13 18:03:37 +0000" MODIFIED_BY="Ruth  Brassington" NO="4">
<TITLE MODIFIED="2012-05-29 17:36:16 +0100" MODIFIED_BY="Angela Gunn">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-13 18:03:37 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Database: Embase &lt;1980 to 2014 Week 40&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 crossover-procedure.sh. (40306)<BR/>2 double-blind procedure.sh. (115609)<BR/>3 single-blind procedure.sh. (18869)<BR/>4 randomized controlled trial.sh. (350916)<BR/>5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1065137)<BR/>6 trial.ti. (163276)<BR/>7 or/1-6 (1198699)<BR/>8 (animal/ or nonhuman/ or animal experiment/) and human/ (1290984)<BR/>9 animal/ or nonanimal/ or animal experiment/ (3256545)<BR/>10 9 not 8 (2727334)<BR/>11 7 not 10 (1100982)<BR/>12 limit 11 to embase (913119)<BR/>13 exp Inclusion Body Myositis/ or inclusion body myositis.tw. (1908)<BR/>14 12 and 13 (97)<BR/>15 remove duplicates from 14 (95)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2015-06-23 22:33:35 +0100" MODIFIED_BY="Ruth  Brassington" NO="5">
<TITLE MODIFIED="2015-06-23 22:33:35 +0100" MODIFIED_BY="Ruth  Brassington">Trials registry search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-13 18:04:11 +0000" MODIFIED_BY="Ruth  Brassington">
<P>inclusion body myositis</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>